3hhr › Citations

Human growth hormone and extracellular domain of its receptor: crystal structure of the complex.

de Vos AM, Ultsch M, Kossiakoff AA
Science 255 306-12 (1992)
Cited: 1103 times
EuropePMC logo PMID: 1549776

Abstract

Binding of human growth hormone (hGH) to its receptor is required for regulation of normal human growth and development. Examination of the 2.8 angstrom crystal structure of the complex between the hormone and the extracellular domain of its receptor (hGHbp) showed that the complex consists of one molecule of growth hormone per two molecules of receptor. The hormone is a four-helix bundle with an unusual topology. The binding protein contains two distinct domains, similar in some respects to immunoglobulin domains. The relative orientation of these domains differs from that found between constant and variable domains in immunoglobulin Fab fragments. Both hGHbp domains contribute residues that participate in hGH binding. In the complex both receptors donate essentially the same residues to interact with the hormone, even though the two binding sites on hGH have no structural similarity. Generally, the hormone-receptor interfaces match those identified by previous mutational analyses. In addition to the hormone-receptor interfaces, there is also a substantial contact surface between the carboxyl-terminal domains of the receptors. The relative extents of the contact areas support a sequential mechanism for dimerization that may be crucial for signal transduction.

Reviews - 3hhr mentioned but not cited (3)

  1. Structural Understanding of Interleukin 6 Family Cytokine Signaling and Targeted Therapies: Focus on Interleukin 11. Metcalfe RD, Putoczki TL, Griffin MDW. Front Immunol 11 1424 (2020)
  2. Overview of protein structural and functional folds. Sun PD, Foster CE, Boyington JC. Curr Protoc Protein Sci Chapter 17 Unit 17.1 (2004)
  3. 50 Years of structural immunology. Wilson IA, Stanfield RL. J Biol Chem 296 100745 (2021)

Articles - 3hhr mentioned but not cited (41)

  1. Tools for integrated sequence-structure analysis with UCSF Chimera. Meng EC, Pettersen EF, Couch GS, Huang CC, Ferrin TE. BMC Bioinformatics 7 339 (2006)
  2. Protein-protein docking with a reduced protein model accounting for side-chain flexibility. Zacharias M. Protein Sci 12 1271-1282 (2003)
  3. Conservation and relative importance of residues across protein-protein interfaces. Guharoy M, Chakrabarti P. Proc Natl Acad Sci U S A 102 15447-15452 (2005)
  4. Coarse-grained models for simulations of multiprotein complexes: application to ubiquitin binding. Kim YC, Hummer G. J Mol Biol 375 1416-1433 (2008)
  5. Realistic protein-protein association rates from a simple diffusional model neglecting long-range interactions, free energy barriers, and landscape ruggedness. Schlosshauer M, Baker D. Protein Sci 13 1660-1669 (2004)
  6. Protein-protein docking using region-based 3D Zernike descriptors. Venkatraman V, Yang YD, Sael L, Kihara D. BMC Bioinformatics 10 407 (2009)
  7. Charged residues dominate a unique interlocking topography in the heterodimeric cytokine interleukin-12. Yoon C, Johnston SC, Tang J, Stahl M, Tobin JF, Somers WS. EMBO J 19 3530-3541 (2000)
  8. FiberDock: Flexible induced-fit backbone refinement in molecular docking. Mashiach E, Nussinov R, Wolfson HJ. Proteins 78 1503-1519 (2010)
  9. A script to highlight hydrophobicity and charge on protein surfaces. Hagemans D, van Belzen IA, Morán Luengo T, Rüdiger SG. Front Mol Biosci 2 56 (2015)
  10. Oligomeric protein structure networks: insights into protein-protein interactions. Brinda KV, Vishveshwara S. BMC Bioinformatics 6 296 (2005)
  11. Structural alignment of proteins by a novel TOPOFIT method, as a superimposition of common volumes at a topomax point. Ilyin VA, Abyzov A, Leslin CM. Protein Sci 13 1865-1874 (2004)
  12. Amyloid formation of growth hormone in presence of zinc: Relevance to its storage in secretory granules. Jacob RS, Das S, Ghosh S, Anoop A, Jha NN, Khan T, Singru P, Kumar A, Maji SK. Sci Rep 6 23370 (2016)
  13. Quantitative prediction of protein-protein binding affinity with a potential of mean force considering volume correction. Su Y, Zhou A, Xia X, Li W, Sun Z. Protein Sci 18 2550-2558 (2009)
  14. "Hidden" sequence periodicities and protein architecture. Rackovsky S. Proc Natl Acad Sci U S A 95 8580-8584 (1998)
  15. Spatial chemical conservation of hot spot interactions in protein-protein complexes. Shulman-Peleg A, Shatsky M, Nussinov R, Wolfson HJ. BMC Biol 5 43 (2007)
  16. A simple reference state makes a significant improvement in near-native selections from structurally refined docking decoys. Liang S, Liu S, Zhang C, Zhou Y. Proteins 69 244-253 (2007)
  17. 'Double water exclusion': a hypothesis refining the O-ring theory for the hot spots at protein interfaces. Li J, Liu Q. Bioinformatics 25 743-750 (2009)
  18. Computational stabilization of human growth hormone. Filikov AV, Hayes RJ, Luo P, Stark DM, Chan C, Kundu A, Dahiyat BI. Protein Sci 11 1452-1461 (2002)
  19. Crystal structure of an affinity-matured prolactin complexed to its dimerized receptor reveals the topology of hormone binding site 2. Broutin I, Jomain JB, Tallet E, van Agthoven J, Raynal B, Hoos S, Kragelund BB, Kelly PA, Ducruix A, England P, Goffin V. J Biol Chem 285 8422-8433 (2010)
  20. Statistical analysis of physical-chemical properties and prediction of protein-protein interfaces. Negi SS, Braun W. J Mol Model 13 1157-1167 (2007)
  21. The EM structure of a type I interferon-receptor complex reveals a novel mechanism for cytokine signaling. Li Z, Strunk JJ, Lamken P, Piehler J, Walz T. J Mol Biol 377 715-724 (2008)
  22. Revealing divergent evolution, identifying circular permutations and detecting active-sites by protein structure comparison. Chen L, Wu LY, Wang Y, Zhang S, Zhang XS. BMC Struct Biol 6 18 (2006)
  23. The high- and low-affinity receptor binding sites of growth hormone are allosterically coupled. Walsh ST, Sylvester JE, Kossiakoff AA. Proc Natl Acad Sci U S A 101 17078-17083 (2004)
  24. Identification of hot spot residues at protein-protein interface. Li L, Zhao B, Cui Z, Gan J, Sakharkar MK, Kangueane P. Bioinformation 1 121-126 (2006)
  25. Specific and nonspecific interactions in ultraweak protein-protein associations revealed by solvent paramagnetic relaxation enhancements. Johansson H, Jensen MR, Gesmar H, Meier S, Vinther JM, Keeler C, Hodsdon ME, Led JJ. J Am Chem Soc 136 10277-10286 (2014)
  26. The modular organization of domain structures: insights into protein-protein binding. del Sol A, Carbonell P. PLoS Comput Biol 3 e239 (2007)
  27. A model of the ternary complex of interleukin-10 with its soluble receptors. Pletnev S, Magracheva E, Wlodawer A, Zdanov A. BMC Struct Biol 5 10 (2005)
  28. A common model for cytokine receptor activation: combined scissor-like rotation and self-rotation of receptor dimer induced by class I cytokine. Pang X, Zhou HX. PLoS Comput Biol 8 e1002427 (2012)
  29. Discordant and chameleon sequences: their distribution and implications for amyloidogenicity. Gendoo DM, Harrison PM. Protein Sci 20 567-579 (2011)
  30. Sequence and structure continuity of evolutionary importance improves protein functional site discovery and annotation. Wilkins AD, Lua R, Erdin S, Ward RM, Lichtarge O. Protein Sci 19 1296-1311 (2010)
  31. A computational framework to empower probabilistic protein design. Fromer M, Yanover C. Bioinformatics 24 i214-22 (2008)
  32. Inhibitory GH receptor extracellular domain monoclonal antibodies: three-dimensional epitope mapping. Jiang J, Wan Y, Wang X, Xu J, Harris JM, Lobie PE, Zhang Y, Zinn KR, Waters MJ, Frank SJ. Endocrinology 152 4777-4788 (2011)
  33. Order and disorder-An integrative structure of the full-length human growth hormone receptor. Kassem N, Araya-Secchi R, Bugge K, Barclay A, Steinocher H, Khondker A, Wang Y, Lenard AJ, Bürck J, Sahin C, Ulrich AS, Landreh M, Pedersen MC, Rheinstädter MC, Pedersen PA, Lindorff-Larsen K, Arleth L, Kragelund BB. Sci Adv 7 eabh3805 (2021)
  34. Structural Characterization and Function Prediction of Immunoglobulin-like Fold in Cell Adhesion and Cell Signaling. Chen J, Wang B, Wu Y. J Chem Inf Model 58 532-542 (2018)
  35. Proteomic profiling change during the early development of silicosis disease. Miao R, Ding B, Zhang Y, Xia Q, Li Y, Zhu B. J Thorac Dis 8 329-341 (2016)
  36. Genetic Code Expansion Enables Site-Specific PEGylation of a Human Growth Hormone Receptor Antagonist through Click Chemistry. Tamshen K, Wang Y, Jamieson SMF, Perry JK, Maynard HD. Bioconjug Chem 31 2179-2190 (2020)
  37. GADP-align: A genetic algorithm and dynamic programming-based method for structural alignment of proteins. Mirzaei S, Razmara J, Lotfi S. Bioimpacts 11 271-279 (2021)
  38. Isolation and Characterization of the Arapaima gigas Growth Hormone (ag-GH) cDNA and Three-Dimensional Modeling of This Hormone in Comparison with the Human Hormone (hGH). Lima ER, Freire RP, Suzuki MF, Oliveira JE, Yosidaki VL, Peroni CN, Sevilhano T, Zorzeto M, Torati LS, Soares CRJ, Lima IDM, Kronenberger T, Maltarollo VG, Bartolini P. Biomolecules 13 158 (2023)
  39. Moving Protein PEGylation from an Art to a Data Science. Mao L, Russell AJ, Carmali S. Bioconjug Chem 33 1643-1653 (2022)
  40. Prediction of hot spots towards drug discovery by protein sequence embedding with 1D convolutional neural network. Zhang Y, Yao S, Chen P. PLoS One 18 e0290899 (2023)
  41. research-article Structural modeling of cytokine-receptor-JAK2 signaling complexes using AlphaFold Multimer. Pogozheva ID, Cherepanov S, Park SJ, Raghavan M, Im W, Lomize AL. bioRxiv 2023.06.14.544971 (2023)


Reviews citing this publication (297)

  1. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L. Biochem J 334 ( Pt 2) 297-314 (1998)
  2. Prolactin: structure, function, and regulation of secretion. Freeman ME, Kanyicska B, Lerant A, Nagy G. Physiol Rev 80 1523-1631 (2000)
  3. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Smith CA, Farrah T, Goodwin RG. Cell 76 959-962 (1994)
  4. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Annu Rev Immunol 29 71-109 (2011)
  5. Jaks and STATs: biological implications. Leonard WJ, O'Shea JJ. Annu Rev Immunol 16 293-322 (1998)
  6. The IL-4 receptor: signaling mechanisms and biologic functions. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. Annu Rev Immunol 17 701-738 (1999)
  7. Gp130 and the interleukin-6 family of cytokines. Taga T, Kishimoto T. Annu Rev Immunol 15 797-819 (1997)
  8. Dimerization of cell surface receptors in signal transduction. Heldin CH. Cell 80 213-223 (1995)
  9. Cytokine signal transduction. Kishimoto T, Taga T, Akira S. Cell 76 253-262 (1994)
  10. Interleukin-10 and related cytokines and receptors. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Annu Rev Immunol 22 929-979 (2004)
  11. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Bach EA, Aguet M, Schreiber RD. Annu Rev Immunol 15 563-591 (1997)
  12. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Schlessinger J. Cell 110 669-672 (2002)
  13. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S. Mol Cell 12 541-552 (2003)
  14. Structural symmetry and protein function. Goodsell DS, Olson AJ. Annu Rev Biophys Biomol Struct 29 105-153 (2000)
  15. Atopic dermatitis: new insights and opportunities for therapeutic intervention. Leung DY. J Allergy Clin Immunol 105 860-876 (2000)
  16. Soluble receptors for cytokines and growth factors: generation and biological function. Rose-John S, Heinrich PC. Biochem J 300 ( Pt 2) 281-290 (1994)
  17. Structural basis for fibroblast growth factor receptor activation. Mohammadi M, Olsen SK, Ibrahimi OA. Cytokine Growth Factor Rev 16 107-137 (2005)
  18. Signal transduction via platelet-derived growth factor receptors. Heldin CH, Ostman A, Rönnstrand L. Biochim Biophys Acta 1378 F79-113 (1998)
  19. The molecular details of cytokine signaling via the JAK/STAT pathway. Morris R, Kershaw NJ, Babon JJ. Protein Sci 27 1984-2009 (2018)
  20. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Kenakin T, Miller LJ. Pharmacol Rev 62 265-304 (2010)
  21. Structural biology of insulin and IGF1 receptors: implications for drug design. De Meyts P, Whittaker J. Nat Rev Drug Discov 1 769-783 (2002)
  22. A structural superfamily of growth factors containing a cystine knot motif. McDonald NQ, Hendrickson WA. Cell 73 421-424 (1993)
  23. Regulation of signal transduction and signal diversity by receptor oligomerization. Lemmon MA, Schlessinger J. Trends Biochem Sci 19 459-463 (1994)
  24. Structural biology of shared cytokine receptors. Wang X, Lupardus P, Laporte SL, Garcia KC. Annu Rev Immunol 27 29-60 (2009)
  25. The alphas, betas, and kinases of cytokine receptor complexes. Stahl N, Yancopoulos GD. Cell 74 587-590 (1993)
  26. Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis. Panopoulos AD, Watowich SS. Cytokine 42 277-288 (2008)
  27. Binding in the growth hormone receptor complex. Wells JA. Proc Natl Acad Sci U S A 93 1-6 (1996)
  28. The Immunobiology of the Interleukin-12 Family: Room for Discovery. Tait Wojno ED, Hunter CA, Stumhofer JS. Immunity 50 851-870 (2019)
  29. Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination. Natarajan K, Dimasi N, Wang J, Mariuzza RA, Margulies DH. Annu Rev Immunol 20 853-885 (2002)
  30. Interleukin-6: structure-function relationships. Simpson RJ, Hammacher A, Smith DK, Matthews JM, Ward LD. Protein Sci 6 929-955 (1997)
  31. Structure and distribution of modules in extracellular proteins. Bork P, Downing AK, Kieffer B, Campbell ID. Q Rev Biophys 29 119-167 (1996)
  32. Ciliary neurotrophic factor. Sendtner M, Carroll P, Holtmann B, Hughes RA, Thoenen H. J Neurobiol 25 1436-1453 (1994)
  33. The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Hercus TR, Thomas D, Guthridge MA, Ekert PG, King-Scott J, Parker MW, Lopez AF. Blood 114 1289-1298 (2009)
  34. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Liu J. Immunol Today 14 290-295 (1993)
  35. Dimerization as a regulatory mechanism in signal transduction. Klemm JD, Schreiber SL, Crabtree GR. Annu Rev Immunol 16 569-592 (1998)
  36. The growth hormone receptor: mechanism of activation and clinical implications. Brooks AJ, Waters MJ. Nat Rev Endocrinol 6 515-525 (2010)
  37. Tissue factor encryption. Bach RR. Arterioscler Thromb Vasc Biol 26 456-461 (2006)
  38. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Endocr Rev 23 623-646 (2002)
  39. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Vlodavsky I, Miao HQ, Medalion B, Danagher P, Ron D. Cancer Metastasis Rev 15 177-186 (1996)
  40. Functions of fibroblast growth factors and their receptors. Wilkie AO, Morriss-Kay GM, Jones EY, Heath JK. Curr Biol 5 500-507 (1995)
  41. The type I interferon receptor: structure, function, and evolution of a family business. Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uzé G. J Interferon Cytokine Res 19 1069-1098 (1999)
  42. Biology of somatotropin in growth and lactation of domestic animals. Etherton TD, Bauman DE. Physiol Rev 78 745-761 (1998)
  43. The hematopoietin receptor superfamily. Cosman D. Cytokine 5 95-106 (1993)
  44. Insights into cytokine-receptor interactions from cytokine engineering. Spangler JB, Moraga I, Mendoza JL, Garcia KC. Annu Rev Immunol 33 139-167 (2015)
  45. Oncogenic protein interfaces: small molecules, big challenges. Nero TL, Morton CJ, Holien JK, Wielens J, Parker MW. Nat Rev Cancer 14 248-262 (2014)
  46. Alpha and beta interferons and their receptor and their friends and relations. Uzé G, Lutfalla G, Mogensen KE. J Interferon Cytokine Res 15 3-26 (1995)
  47. The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling. De Meyts P. Diabetologia 37 Suppl 2 S135-48 (1994)
  48. Roles for glycosylation of cell surface receptors involved in cellular immune recognition. Rudd PM, Wormald MR, Stanfield RL, Huang M, Mattsson N, Speir JA, DiGennaro JA, Fetrow JS, Dwek RA, Wilson IA. J Mol Biol 293 351-366 (1999)
  49. Signal transduction via the growth hormone receptor. Zhu T, Goh EL, Graichen R, Ling L, Lobie PE. Cell Signal 13 599-616 (2001)
  50. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Kotenko SV, Pestka S. Oncogene 19 2557-2565 (2000)
  51. Growth hormone in the brain: characteristics of specific brain targets for the hormone and their functional significance. Nyberg F. Front Neuroendocrinol 21 330-348 (2000)
  52. Antagonists of protein-protein interactions. Cochran AG. Chem Biol 7 R85-94 (2000)
  53. Fibronectin structure and assembly. Potts JR, Campbell ID. Curr Opin Cell Biol 6 648-655 (1994)
  54. A glimpse of structural biology through X-ray crystallography. Shi Y. Cell 159 995-1014 (2014)
  55. Structure of gap junction intercellular channels. Yeager M, Nicholson BJ. Curr Opin Struct Biol 6 183-192 (1996)
  56. A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors. Boyington JC, Sun PD. Mol Immunol 38 1007-1021 (2002)
  57. Growth hormone (GH), GH receptor, and signal transduction. Kopchick JJ, Andry JM. Mol Genet Metab 71 293-314 (2000)
  58. Structure and function of fibronectin modules. Potts JR, Campbell ID. Matrix Biol 15 313-20; discussion 321 (1996)
  59. Receptor recognition by gp130 cytokines. Bravo J, Heath JK. EMBO J 19 2399-2411 (2000)
  60. Cytokine receptor signal transduction and the control of hematopoietic cell development. Watowich SS, Wu H, Socolovsky M, Klingmuller U, Constantinescu SN, Lodish HF. Annu Rev Cell Dev Biol 12 91-128 (1996)
  61. Growth hormone - past, present and future. Ranke MB, Wit JM. Nat Rev Endocrinol 14 285-300 (2018)
  62. Signaling from the IL-2 receptor to the nucleus. Lin JX, Leonard WJ. Cytokine Growth Factor Rev 8 313-332 (1997)
  63. The erythropoietin receptor in normal and cancer tissues. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. Crit Rev Oncol Hematol 67 39-61 (2008)
  64. Mechanism of activation of the GM-CSF, IL-3, and IL-5 family of receptors. Guthridge MA, Stomski FC, Thomas D, Woodcock JM, Bagley CJ, Berndt MC, Lopez AF. Stem Cells 16 301-313 (1998)
  65. A structural role for arginine in proteins: multiple hydrogen bonds to backbone carbonyl oxygens. Borders CL, Broadwater JA, Bekeny PA, Salmon JE, Lee AS, Eldridge AM, Pett VB. Protein Sci 3 541-548 (1994)
  66. Structural analysis of receptor tyrosine kinases. Hubbard SR. Prog Biophys Mol Biol 71 343-358 (1999)
  67. The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects. Dehkhoda F, Lee CMM, Medina J, Brooks AJ. Front Endocrinol (Lausanne) 9 35 (2018)
  68. The insulin receptor: a prototype for dimeric, allosteric membrane receptors? De Meyts P. Trends Biochem Sci 33 376-384 (2008)
  69. Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Fontana A, Spolaore B, Mero A, Veronese FM. Adv Drug Deliv Rev 60 13-28 (2008)
  70. Exploring protein-protein interactions with phage display. Sidhu SS, Fairbrother WJ, Deshayes K. Chembiochem 4 14-25 (2003)
  71. Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction. Sebald W, Nickel J, Zhang JL, Mueller TD. Biol Chem 385 697-710 (2004)
  72. Structure-based drug design: progress, results and challenges. Verlinde CL, Hol WG. Structure 2 577-587 (1994)
  73. Bacteriophage display and discovery of peptide leads for drug development. Lowman HB. Annu Rev Biophys Biomol Struct 26 401-424 (1997)
  74. The interferon gamma (IFN-gamma) receptor: a paradigm for the multichain cytokine receptor. Pestka S, Kotenko SV, Muthukumaran G, Izotova LS, Cook JR, Garotta G. Cytokine Growth Factor Rev 8 189-206 (1997)
  75. Signaling through ERBB receptors: multiple layers of diversity and control. Warren CM, Landgraf R. Cell Signal 18 923-933 (2006)
  76. Oxidation of therapeutic proteins and peptides: structural and biological consequences. Torosantucci R, Schöneich C, Jiskoot W. Pharm Res 31 541-553 (2014)
  77. Building proteins with fibronectin type III modules. Campbell ID, Spitzfaden C. Structure 2 333-337 (1994)
  78. Forces and factors that contribute to the structural stability of membrane proteins. Haltia T, Freire E. Biochim Biophys Acta 1228 1-27 (1995)
  79. The molecular basis of IL-10 function: from receptor structure to the onset of signaling. Walter MR. Curr Top Microbiol Immunol 380 191-212 (2014)
  80. The human interferon alpha species and receptors. Pestka S. Biopolymers 55 254-287 (2000)
  81. Ciliary neurotrophic factor and its receptor complex. Ip NY, Yancopoulos GD. Prog Growth Factor Res 4 139-155 (1992)
  82. Molecular mechanisms of prolactin and its receptor. Brooks CL. Endocr Rev 33 504-525 (2012)
  83. Signals and Receptors. Heldin CH, Lu B, Evans R, Gutkind JS. Cold Spring Harb Perspect Biol 8 a005900 (2016)
  84. Emerging themes in structural biology of neurotrophic factors. Ibáñez CF. Trends Neurosci 21 438-444 (1998)
  85. JAK2 activation by growth hormone and other cytokines. Waters MJ, Brooks AJ. Biochem J 466 1-11 (2015)
  86. Transgenic models of growth hormone action. Kopchick JJ, Bellush LL, Coschigano KT. Annu Rev Nutr 19 437-461 (1999)
  87. Alternative processing of growth hormone receptor transcripts. Edens A, Talamantes F. Endocr Rev 19 559-582 (1998)
  88. FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. Liu J. Trends Pharmacol Sci 14 182-188 (1993)
  89. The (Greek) key to structures of neural adhesion molecules. Vaughn DE, Bjorkman PJ. Neuron 16 261-273 (1996)
  90. IL-6 type cytokine receptor complexes: hexamer, tetramer or both? Grötzinger J, Kernebeck T, Kallen KJ, Rose-John S. Biol Chem 380 803-813 (1999)
  91. Mechanistic diversity of cytokine receptor signaling across cell membranes. Stroud RM, Wells JA. Sci STKE 2004 re7 (2004)
  92. Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily. Jones LL, Vignali DA. Immunol Res 51 5-14 (2011)
  93. The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK-Receptor Interactions. Ferrao R, Lupardus PJ. Front Endocrinol (Lausanne) 8 71 (2017)
  94. The prolactin/growth hormone receptor family: structure/function relationships. Goffin V, Kelly PA. J Mammary Gland Biol Neoplasia 2 7-17 (1997)
  95. Overview of the purification of recombinant proteins. Wingfield PT. Curr Protoc Protein Sci 80 6.1.1-6.1.35 (2015)
  96. Signalling by the βc family of cytokines. Hercus TR, Dhagat U, Kan WL, Broughton SE, Nero TL, Perugini M, Sandow JJ, D'Andrea RJ, Ekert PG, Hughes T, Parker MW, Lopez AF. Cytokine Growth Factor Rev 24 189-201 (2013)
  97. Growth Hormone's Links to Cancer. Boguszewski CL, Boguszewski MCDS. Endocr Rev 40 558-574 (2019)
  98. The growth hormone signaling system: Insights into coordinating the anabolic and catabolic actions of growth hormone. Bergan-Roller HE, Sheridan MA. Gen Comp Endocrinol 258 119-133 (2018)
  99. Jaks and Stats in cytokine signaling. Ihle JN, Nosaka T, Thierfelder W, Quelle FW, Shimoda K. Stem Cells 15 Suppl 1 105-11; discussion 112 (1997)
  100. Interactions between scatter factors and their receptors: hints for therapeutic applications. Trusolino L, Pugliese L, Comoglio PM. FASEB J 12 1267-1280 (1998)
  101. The Cation-π Interaction in Small-Molecule Catalysis. Kennedy CR, Lin S, Jacobsen EN. Angew Chem Int Ed Engl 55 12596-12624 (2016)
  102. The metabolic role of growth hormone in humans with particular reference to fasting. Nørrelund H. Growth Horm IGF Res 15 95-122 (2005)
  103. Growth hormone signal transduction. Piwien-Pilipuk G, Huo JS, Schwartz J. J Pediatr Endocrinol Metab 15 771-786 (2002)
  104. Regulation of the extrinsic pathway system in health and disease: the role of factor VIIa and tissue factor pathway inhibitor. Petersen LC, Valentin S, Hedner U. Thromb Res 79 1-47 (1995)
  105. Proximity versus allostery: the role of regulated protein dimerization in biology. Austin DJ, Crabtree GR, Schreiber SL. Chem Biol 1 131-136 (1994)
  106. A model for the interaction of the GM-CSF, IL-3 and IL-5 receptors with their ligands. Goodall GJ, Bagley CJ, Vadas MA, Lopez AF. Growth Factors 8 87-97 (1993)
  107. Genetic control of growth. Mullis PE. Eur J Endocrinol 152 11-31 (2005)
  108. Initiation of blood coagulation: the tissue factor/factor VIIa complex. Kirchhofer D, Nemerson Y. Curr Opin Biotechnol 7 386-391 (1996)
  109. The structure of the T cell antigen receptor. Bentley GA, Mariuzza RA. Annu Rev Immunol 14 563-590 (1996)
  110. Four-helix bundle growth factors and their receptors: protein-protein interactions. Mott HR, Campbell ID. Curr Opin Struct Biol 5 114-121 (1995)
  111. Placental hormones and fetal-placental development. Gootwine E. Anim Reprod Sci 82-83 551-566 (2004)
  112. Erythropoietin as a Neuroprotective Molecule: An Overview of Its Therapeutic Potential in Neurodegenerative Diseases. Rey F, Balsari A, Giallongo T, Ottolenghi S, Di Giulio AM, Samaja M, Carelli S. ASN Neuro 11 1759091419871420 (2019)
  113. Leukemia inhibitory factor: part of a large ingathering family. Taupin JL, Pitard V, Dechanet J, Miossec V, Gualde N, Moreau JF. Int Rev Immunol 16 397-426 (1998)
  114. Minimized proteins. Cunningham BC, Wells JA. Curr Opin Struct Biol 7 457-462 (1997)
  115. Genetic causes and treatment of isolated growth hormone deficiency-an update. Alatzoglou KS, Dattani MT. Nat Rev Endocrinol 6 562-576 (2010)
  116. Structural and functional basis for hormone binding and receptor oligomerization. Wells JA. Curr Opin Cell Biol 6 163-173 (1994)
  117. Structural basis for recognition of MHC and MHC-like ligands by natural killer cell receptors. Deng L, Mariuzza RA. Semin Immunol 18 159-166 (2006)
  118. The βc receptor family - Structural insights and their functional implications. Broughton SE, Nero TL, Dhagat U, Kan WL, Hercus TR, Tvorogov D, Lopez AF, Parker MW. Cytokine 74 247-258 (2015)
  119. Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications. Kopchick JJ, List EO, Kelder B, Gosney ES, Berryman DE. Mol Cell Endocrinol 386 34-45 (2014)
  120. Exercise and the immune system. Natural killer cells, interleukins and related responses. Shephard RJ, Rhind S, Shek PN. Sports Med 18 340-369 (1994)
  121. Function and signal transduction mediated by the interleukin 3 receptor system in hematopoiesis. Hara T, Miyajima A. Stem Cells 14 605-618 (1996)
  122. Ligand-induced dimerization of growth factor receptors: variations on the theme. Heldin CH, Ostman A. Cytokine Growth Factor Rev 7 3-10 (1996)
  123. Structural analysis of cytokines comprising the IL-10 family. Zdanov A. Cytokine Growth Factor Rev 21 325-330 (2010)
  124. Structural, functional and evolutionary implications of the three-dimensional crystal structure of murine interferon-beta. Mitsui Y, Senda T, Shimazu T, Matsuda S, Utsumi J. Pharmacol Ther 58 93-132 (1993)
  125. Luxury accommodations: the expanding role of structural plasticity in protein-protein interactions. Sundberg EJ, Mariuzza RA. Structure 8 R137-42 (2000)
  126. Molecular basis of cytokine receptor activation. Lopez AF, Hercus TR, Ekert P, Littler DR, Guthridge M, Thomas D, Ramshaw HS, Stomski F, Perugini M, D'Andrea R, Grimbaldeston M, Parker MW. IUBMB Life 62 509-518 (2010)
  127. Multifarious determinants of cytokine receptor signaling specificity. Moraga I, Spangler J, Mendoza JL, Garcia KC. Adv Immunol 121 1-39 (2014)
  128. Structural basis for recognition of cellular and viral ligands by NK cell receptors. Li Y, Mariuzza RA. Front Immunol 5 123 (2014)
  129. Growth factor receptors: structure, mechanism, and drug discovery. McInnes C, Sykes BD. Biopolymers 43 339-366 (1997)
  130. Growth hormone signalling and its regulation: preventing too much of a good thing. Frank SJ. Growth Horm IGF Res 11 201-212 (2001)
  131. The structure, organization, activation and plasticity of the erythropoietin receptor. Wilson IA, Jolliffe LK. Curr Opin Struct Biol 9 696-704 (1999)
  132. The three dimensional structure of the type I insulin-like growth factor receptor. Ward CW, Garrett TP, McKern NM, Lou M, Cosgrove LJ, Sparrow LG, Frenkel MJ, Hoyne PA, Elleman TC, Adams TE, Lovrecz GO, Lawrence LJ, Tulloch PA. Mol Pathol 54 125-132 (2001)
  133. Growth hormone and its disorders. Ayuk J, Sheppard MC. Postgrad Med J 82 24-30 (2006)
  134. Comparison of the intermediate complexes of human growth hormone bound to the human growth hormone and prolactin receptors. Kossiakoff AA, Somers W, Ultsch M, Andow K, Muller YA, De Vos AM. Protein Sci 3 1697-1705 (1994)
  135. Natural inhibitors of snake venom hemorrhagic metalloproteinases. Perales J, Neves-Ferreira AG, Valente RH, Domont GB. Toxicon 45 1013-1020 (2005)
  136. Should prolactin be reconsidered as a therapeutic target in human breast cancer? Goffin V, Touraine P, Pichard C, Bernichtein S, Kelly PA. Mol Cell Endocrinol 151 79-87 (1999)
  137. Mecasermin (recombinant human insulin-like growth factor I). Rosenbloom AL. Adv Ther 26 40-54 (2009)
  138. Asymmetric ligand recognition by the activating natural killer cell receptor NKG2D, a symmetric homodimer. Strong RK. Mol Immunol 38 1029-1037 (2002)
  139. Adhesin presentation in bacteria requires molecular chaperones and ushers. Jones CH, Jacob-Dubuisson F, Dodson K, Kuehn M, Slonim L, Striker R, Hultgren SJ. Infect Immun 60 4445-4451 (1992)
  140. Growth Hormone Receptor Mutations Related to Individual Dwarfism. Lin S, Li C, Li C, Zhang X. Int J Mol Sci 19 E1433 (2018)
  141. Building protein structure and function from modular units. Campbell ID, Downing AK. Trends Biotechnol 12 168-172 (1994)
  142. Coagulation factors and their inhibitors. Stubbs MT, Bode W. Curr Opin Struct Biol 4 823-832 (1994)
  143. Genetics of growth hormone deficiency. Mullis PE. Endocrinol Metab Clin North Am 36 17-36 (2007)
  144. Growth hormone receptor modulators. Birzniece V, Sata A, Ho KK. Rev Endocr Metab Disord 10 145-156 (2009)
  145. Mechanism of insulin and IGF-I receptor activation and signal transduction specificity. Receptor dimer cross-linking, bell-shaped curves, and sustained versus transient signaling. De Meyts P, Ursø B, Christoffersen CT, Shymko RM. Ann N Y Acad Sci 766 388-401 (1995)
  146. The defective gene in X-linked severe combined immunodeficiency encodes a shared interleukin receptor subunit: implications for cytokine pleiotropy and redundancy. Leonard WJ. Curr Opin Immunol 6 631-635 (1994)
  147. Identifying structure-function relationships in four-helix bundle cytokines: towards de novo mimetics design. Chaiken IM, Williams WV. Trends Biotechnol 14 369-375 (1996)
  148. Structure and function of the T-cell receptor: insights from X-ray crystallography. Fields BA, Mariuzza RA. Immunol Today 17 330-336 (1996)
  149. Advances in the understanding of cytokine signal transduction: the role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency. O'Shea JJ, Notarangelo LD, Johnston JA, Candotti F. J Clin Immunol 17 431-447 (1997)
  150. Genetic engineering in mice: impact on insulin signalling and action. Lamothe B, Baudry A, Desbois P, Lamotte L, Bucchini D, De Meyts P, Joshi RL. Biochem J 335 ( Pt 2) 193-204 (1998)
  151. Growth hormone secretion in the elderly: ageing and the somatopause. Martin FC, Yeo AL, Sonksen PH. Baillieres Clin Endocrinol Metab 11 223-250 (1997)
  152. Mechanism of ruminant placental lactogen action: molecular and in vivo studies. Gertler A, Djiane J. Mol Genet Metab 75 189-201 (2002)
  153. Growth hormone and aging. Bartke A. Endocrine 8 103-108 (1998)
  154. Role of the time factor in signaling specificity: application to mitogenic and metabolic signaling by the insulin and insulin-like growth factor-I receptor tyrosine kinases. De Meyts P, Christoffersen CT, Ursø B, Wallach B, Grønskov K, Yakushiji F, Shymko RM. Metabolism 44 2-11 (1995)
  155. The ubiquitin-proteasome pathway and the regulation of growth hormone receptor availability. Strous GJ, van Kerkhof P. Mol Cell Endocrinol 197 143-151 (2002)
  156. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics. Clevenger CV, Zheng J, Jablonski EM, Galbaugh TL, Fang F. J Mammary Gland Biol Neoplasia 13 147-156 (2008)
  157. Genetics of isolated growth hormone deficiency. Mullis PE. J Clin Res Pediatr Endocrinol 2 52-62 (2010)
  158. Tissue factor structure and function. Butenas S. Scientifica (Cairo) 2012 964862 (2012)
  159. Circulating growth hormone binding proteins. Baumann G, Shaw MA, Amburn K. J Endocrinol Invest 17 67-81 (1994)
  160. Growth hormone receptor antagonists. van der Lely AJ, Kopchick JJ. Neuroendocrinology 83 264-268 (2006)
  161. IL-12 and IL-23-Close Relatives with Structural Homologies but Distinct Immunological Functions. Floss DM, Moll JM, Scheller J. Cells 9 E2184 (2020)
  162. The molecular basis of growth hormone action. Thomas MJ. Growth Horm IGF Res 8 3-11 (1998)
  163. Where asymmetry in gene expression originates. Barák I, Wilkinson AJ. Mol Microbiol 57 611-620 (2005)
  164. Growth Hormone Receptor Regulation in Cancer and Chronic Diseases. Strous GJ, Almeida ADS, Putters J, Schantl J, Sedek M, Slotman JA, Nespital T, Hassink GC, Mol JA. Front Endocrinol (Lausanne) 11 597573 (2020)
  165. Mechanisms for storage of prolactin and growth hormone in secretory granules. Dannies PS. Mol Genet Metab 76 6-13 (2002)
  166. Physiology and pathophysiology of growth hormone-binding protein: methodological and clinical aspects. Fisker S. Growth Horm IGF Res 16 1-28 (2006)
  167. Structure-function analyses of the kit receptor for the steel factor. Blechman JM, Lev S, Givol D, Yarden Y. Stem Cells 11 Suppl 2 12-21 (1993)
  168. Activating mechanism of CNTF and related cytokines. Inoue M, Nakayama C, Noguchi H. Mol Neurobiol 12 195-209 (1996)
  169. Biological effects of growth hormone and its antagonist. Okada S, Kopchick JJ. Trends Mol Med 7 126-132 (2001)
  170. Dimerization, ubiquitylation and endocytosis go together in growth hormone receptor function. Strous GJ, Gent J. FEBS Lett 529 102-109 (2002)
  171. Loops and secondary structure mimetics: development and applications in basic science and rational drug design. Saragovi HU, Greene MI, Chrusciel RA, Kahn M. Biotechnology (N Y) 10 773-778 (1992)
  172. Trisulfides in proteins. Nielsen RW, Tachibana C, Hansen NE, Winther JR. Antioxid Redox Signal 15 67-75 (2011)
  173. Aging effects on growth hormone receptor binding in the brain. Nyberg F. Exp Gerontol 32 521-528 (1997)
  174. Bacterial chemotaxis: a field in motion. Stock AM, Mowbray SL. Curr Opin Struct Biol 5 744-751 (1995)
  175. Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon. Walter MR, Bordens R, Nagabhushan TL, Williams BR, Williams BR, Herberman RB, Dinarello CA, Borden EC, Trotta PP, Pestka S, Pfeffer LM. Cancer Biother Radiopharm 13 143-154 (1998)
  176. Physiological obstacles after xenotransplantation. Hammer C. Ann N Y Acad Sci 862 19-27 (1998)
  177. Rational design of competitive prolactin/growth hormone receptor antagonists. Tallet E, Rouet V, Jomain JB, Kelly PA, Bernichtein S, Goffin V. J Mammary Gland Biol Neoplasia 13 105-117 (2008)
  178. Structural and mechanistic aspects of Janus kinases: how the two-faced god wields a double-edged sword. Duhé RJ, Farrar WL. J Interferon Cytokine Res 18 1-15 (1998)
  179. Derivatization with fatty acids in peptide and protein drug discovery. Kurtzhals P, Østergaard S, Nishimura E, Kjeldsen T. Nat Rev Drug Discov 22 59-80 (2023)
  180. Implications of atomic-resolution structures for cell adhesion. Leahy DJ. Annu Rev Cell Dev Biol 13 363-393 (1997)
  181. Monoclonal antibodies inducing conformational changes on the antigen molecule. Roguin LP, Retegui LA. Scand J Immunol 58 387-394 (2003)
  182. Tissue factor pathway. McVey JH. Baillieres Clin Haematol 7 469-484 (1994)
  183. Activation of erythropoietin signaling by receptor dimerization. Watowich SS. Int J Biochem Cell Biol 31 1075-1088 (1999)
  184. A new mechanism for growth hormone receptor activation of JAK2, and implications for related cytokine receptors. Waters MJ, Brooks AJ, Chhabra Y. JAKSTAT 3 e29569 (2014)
  185. Growth hormone receptor signalling. Postel-Vinay MC, Kelly PA. Baillieres Clin Endocrinol Metab 10 323-336 (1996)
  186. Molecular heterogeneity of human GH: from basic research to clinical implications. Boguszewski CL. J Endocrinol Invest 26 274-288 (2003)
  187. An unusual host-parasite relationship: the growth hormone-like factor from plerocercoids of spirometrid tapeworms. Phares K. Int J Parasitol 26 575-588 (1996)
  188. Beyond dimerization: a membrane-dependent activation model for interleukin-4 receptor-mediated signalling. Weidemann T, Höfinger S, Müller K, Auer M. J Mol Biol 366 1365-1373 (2007)
  189. Cellular signalling mechanisms in B lymphocytes. Cushley W, Harnett MM. Biochem J 292 ( Pt 2) 313-332 (1993)
  190. Cytokine receptors and signal transduction. Ihle JN, Witthuhn B, Tang B, Yi T, Quelle FW. Baillieres Clin Haematol 7 17-48 (1994)
  191. Genetic studies in idiopathic short stature. Attie KM. Curr Opin Pediatr 12 400-404 (2000)
  192. Growth hormone isoforms and segments/fragments: molecular structure and laboratory measurement. De Palo EF, De Filippis V, Gatti R, Spinella P. Clin Chim Acta 364 67-76 (2006)
  193. Post-Receptor Inhibitors of the GHR-JAK2-STAT Pathway in the Growth Hormone Signal Transduction. Wójcik M, Krawczyńska A, Antushevich H, Herman AP. Int J Mol Sci 19 E1843 (2018)
  194. Receptor signaling: dimerization and beyond. Stock J. Curr Biol 6 825-827 (1996)
  195. Signal transduction in the erythropoietin receptor system. Wojchowski DM, He TC. Stem Cells 11 381-392 (1993)
  196. Studies of the c-Mpl thrombopoietin receptor through gene disruption and activation. Alexander WS, Roberts AW, Maurer AB, Nicola NA, Dunn AR, Metcalf D. Stem Cells 14 Suppl 1 124-132 (1996)
  197. Mechanistic aspects of crosstalk between GH and PRL and ErbB receptor family signaling. Frank SJ. J Mammary Gland Biol Neoplasia 13 119-129 (2008)
  198. Molecular basis of inherited growth hormone resistance in childhood. Amselem S, Sobrier ML, Dastot F, Duquesnoy P, Duriez B, Goossens M. Baillieres Clin Endocrinol Metab 10 353-369 (1996)
  199. Strategies to therapeutically modulate cytokine action. Leonard WJ, Lin JX. Nat Rev Drug Discov 22 827-854 (2023)
  200. CRLF1 and CLCF1 in Development, Health and Disease. Crisponi L, Buers I, Rutsch F. Int J Mol Sci 23 992 (2022)
  201. Predicting the conformation of proteins. Man versus machine. Benner SA, Gerloff DL. FEBS Lett 325 29-33 (1993)
  202. The erythropoietin receptor: its role in hematopoiesis and myeloproliferative diseases. Longmore GD, Watowich SS, Hilton DJ, Lodish HF. J Cell Biol 123 1305-1308 (1993)
  203. Cell surface adhesion receptors. Wagner G, Wyss DF. Curr Opin Struct Biol 4 841-851 (1994)
  204. Granulocyte colony-stimulating factor receptor and its related receptors. Nagata S, Fukunaga R. Growth Factors 8 99-107 (1993)
  205. Growth hormone excess and the development of growth hormone receptor antagonists. Higham CE, Trainer PJ. Exp Physiol 93 1157-1169 (2008)
  206. Molecular recognition events involved in the activation of the growth hormone receptor by growth hormone. Behncken SN, Waters MJ. J Mol Recognit 12 355-362 (1999)
  207. New frontiers in the molecular mechanisms of growth hormone action. Herington AC. Mol Cell Endocrinol 100 39-44 (1994)
  208. New perspectives on the design of cytokines and growth factors. Kallen KJ, Grötzinger J, Rose-John S. Trends Biotechnol 18 455-461 (2000)
  209. The structure and function of membranes--personal memoir. Singer SJ. J Membr Biol 129 3-12 (1992)
  210. Classical and novel GH receptor signaling pathways. Frank SJ. Mol Cell Endocrinol 518 110999 (2020)
  211. Cytokine receptors in congenital hematopoietic disease. D'Andrea AD. N Engl J Med 330 839-846 (1994)
  212. Diagnostic and therapeutic advances in growth hormone insensitivity. David A, Metherell LA, Clark AJ, Camacho-Hübner C, Savage MO. Endocrinol Metab Clin North Am 34 581-95, viii (2005)
  213. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly. Tritos NA, Biller BM. Pituitary 20 129-135 (2017)
  214. A new paradigm for hormone recognition and allosteric receptor activation revealed from structural studies of NPR-C. He XL, Dukkipati A, Wang X, Garcia KC. Peptides 26 1035-1043 (2005)
  215. Hemopoietic growth factor receptor abnormalities in leukemia. Alexander WS, Nicola NA. Leuk Res 22 1097-1111 (1998)
  216. Laboratory assessment of GH. Strasburger CJ. Growth Horm IGF Res 8 Suppl A 41-46 (1998)
  217. The first structure of a receptor tyrosine kinase domain: a further step in understanding the molecular basis of insulin action. McDonald NQ, Murray-Rust J, Blundell TL. Structure 3 1-6 (1995)
  218. The functional basis of granulocyte-macrophage colony stimulating factor, interleukin-3 and interleukin-5 receptor activation, basic and clinical implications. Woodcock JM, Bagley CJ, Lopez AF. Int J Biochem Cell Biol 31 1017-1025 (1999)
  219. Thiyl Radical Reactions in the Chemical Degradation of Pharmaceutical Proteins. Schöneich C. Molecules 24 E4357 (2019)
  220. Coevolution of cytokine receptor families in the immune and nervous systems. Yamamori T, Sarai A. Neurosci Res 15 151-161 (1992)
  221. Conformational changes in MHC class I molecules. Antibody, T-cell receptor, and NK cell recognition in an HLA-B7 model system. Smith KD, Kurago ZB, Lutz CT. Immunol Res 16 243-259 (1997)
  222. Medical management of growth hormone-secreting pituitary adenomas. Racine MS, Barkan AL. Pituitary 5 67-76 (2002)
  223. Nanomedicines in the treatment of acromegaly: focus on pegvisomant. Roelfsema F, Biermasz NR, Pereira AM, Romijn J. Int J Nanomedicine 1 385-398 (2006)
  224. Pharmacological therapy for acromegaly: a critical review. Muller AF, Van Der Lely AJ. Drugs 64 1817-1838 (2004)
  225. Predicting the conformation of proteins from sequences. Progress and future progress. Benner SA. J Mol Recognit 8 9-28 (1995)
  226. Somatostatin analogs in medical treatment of acromegaly. Racine MS, Barkan AL. Endocrine 20 271-278 (2003)
  227. Structural Perspectives on Extracellular Recognition and Conformational Changes of Several Type-I Transmembrane Receptors. Chataigner LMP, Leloup N, Janssen BJC. Front Mol Biosci 7 129 (2020)
  228. The growth hormone receptor in growth. Bougnères P, Goffin V. Endocrinol Metab Clin North Am 36 1-16 (2007)
  229. Interferon-alpha hybrids. Horisberger MA, Di Marco S. Pharmacol Ther 66 507-534 (1995)
  230. Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly. Parkinson C, Trainer PJ. Growth Horm IGF Res 10 Suppl B S119-23 (2000)
  231. Targeting growth factor and cytokine receptors with recombinant peptide libraries. Dower WJ. Curr Opin Chem Biol 2 328-334 (1998)
  232. CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation. Linsley PS, Ledbetter J, Peach R, Bajorath J. Res Immunol 146 130-140 (1995)
  233. Cytokine receptor genes: structure, chromosomal location, and involvement in human disease. Baird PN, D'Andrea RJ, Goodall GJ. Leuk Lymphoma 18 373-383 (1995)
  234. Gender differences in rat hepatic CYP2C gene expression--regulation by growth hormone. Mode A, Ahlgren R, Lahuna O, Gustafsson JA. Growth Horm IGF Res 8 Suppl B 61-67 (1998)
  235. Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms. Gou P, Zhang W, Giraudier S. Int J Mol Sci 23 1013 (2022)
  236. Motifs involved in protein-protein interactions. Slingsby C, Bateman OA, Simpson A. Mol Biol Rep 17 185-195 (1993)
  237. Principal signalling complexes in haematopoiesis: structural aspects and mimetic discovery. Tarasova A, Haylock D, Winkler D. Cytokine Growth Factor Rev 22 231-253 (2011)
  238. Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy. Benedini S, Terruzzi I, Lazzarin A, Luzi L. BioDrugs 22 101-112 (2008)
  239. Signal transduction by interleukin-12 and interleukin-2. A comparison and contrast. Bacon CM, Cho SS, O'Shea JJ. Ann N Y Acad Sci 795 41-59 (1996)
  240. Streptavidin-binding and -dimerizing ligands discovered by phage display, topochemistry, and structure-based design. Katz BA. Biomol Eng 16 57-65 (1999)
  241. The hemopoietic regulators--an embarrassment of riches. Metcalf D. Bioessays 14 799-805 (1992)
  242. The place of pegvisomant in the management of acromegaly. Parkinson C, Trainer PJ. Expert Opin Investig Drugs 10 1725-1735 (2001)
  243. Growth hormone replacement for adult growth hormone deficiency. Shimon I. Expert Opin Pharmacother 4 1977-1983 (2003)
  244. Interferons alpha/beta and their receptors: place in the hierarchy of cytokines. Zav'Yalov VP, Zav'Yalova GA. APMIS 105 161-186 (1997)
  245. Molecular and cellular factors determining the functional pleiotropy of cytokines. McFarlane A, Pohler E, Moraga I. FEBS J 290 2525-2552 (2023)
  246. Pegvisomant: current and potential novel therapeutic applications. Thankamony GN, Dunger DB, Acerini CL. Expert Opin Biol Ther 9 1553-1563 (2009)
  247. Peptidomimetics of the immunoglobulin supergene family--a review. Nakanishi H, Ramurthy S, Raktabutr A, Shen R, Kahn M. Gene 137 51-56 (1993)
  248. Predicting the conformation of proteins from sequences. Progress and future progress. Benner SA, Jenny TF, Cohen MA, Gonnet GH. Adv Enzyme Regul 34 269-353 (1994)
  249. Prolactin receptor antagonists. Kuo CB, Coss D, Walker AM. Endocrine 9 121-131 (1998)
  250. Recognition at the cell surface: recent structural insights. Stuart DI, Jones EY. Curr Opin Struct Biol 5 735-743 (1995)
  251. Recombinant analogues of prolactin, growth hormone, and placental lactogen: correlations between physical structure, binding characteristics, and activity. Gertler A. J Mammary Gland Biol Neoplasia 2 69-80 (1997)
  252. Structural flexibility of small GTPases. Can it explain their functional versatility? Helmreich EJ. Biol Chem 385 1121-1136 (2004)
  253. The Role of Growth Hormone in Mesenchymal Stem Cell Commitment. Bolamperti S, Guidobono F, Rubinacci A, Villa I. Int J Mol Sci 20 E5264 (2019)
  254. The human erythropoietin receptor. Winkelmann JC. Int J Cell Cloning 10 254-261 (1992)
  255. Genetics of GHRH, GHRH-receptor, GH and GH-receptor: its impact on pharmacogenetics. Mullis PE. Best Pract Res Clin Endocrinol Metab 25 25-41 (2011)
  256. Involvement of JAK-family tyrosine kinases in hematopoietin receptor signal transduction. Kirken RA, Rui H, Howard OM, Farrar WL. Prog Growth Factor Res 5 195-211 (1994)
  257. Signal transduction of the growth hormone (GH) receptor, and GH-binding protein. Wojcik J, Postel-Vinay MC. Growth Horm IGF Res 9 Suppl A 51-55 (1999)
  258. The Origination of Growth Hormone/Insulin-Like Growth Factor System: A Story From Ancient Basal Chordate Amphioxus. Li M. Front Endocrinol (Lausanne) 13 825722 (2022)
  259. Biological actions of oncogenes. Smith MR, Matthews NT, Jones KA, Kung HF. Pharmacol Ther 58 211-236 (1993)
  260. Controlling oligomerization of pharmaceutical proteins. Schein CH. Pharm Acta Helv 69 119-126 (1994)
  261. Getting it together: signal transduction in G-protein coupled receptors by association of receptor domains. Underwood DJ, Prendergast K. Chem Biol 4 239-248 (1997)
  262. Growth hormone receptor antagonists therapy for acromegaly. Parkinson C, Trainer PJ. Baillieres Best Pract Res Clin Endocrinol Metab 13 419-430 (1999)
  263. Growth hormone signal transduction. Maharajan P, Maharajan V. Experientia 49 980-987 (1993)
  264. Induction of asymmetry into homodimers. Bardsley B, Cho YR, Westwell MS, Williams DH. Chirality 10 14-23 (1998)
  265. Rational design of peptide agonists of cell-surface receptors. Taylor SI. Trends Pharmacol Sci 21 9-10 (2000)
  266. Structural and functional hot spots in cytokine receptors. Bagley CJ, Woodcock JM, Guthridge MA, Stomski FC, Lopez AF. Int J Hematol 73 299-307 (2001)
  267. Structure of growth hormone and its receptor: an unexpected stoichiometry. de Meyts P. Trends Biochem Sci 17 169-170 (1992)
  268. Analysis of three human interleukin 5 structures suggests a possible receptor binding mechanism. Verschelde JL, Ampe C, Guisez Y, Oefner C, Vandekerckhove J, Tavernier J. FEBS Lett 424 121-126 (1998)
  269. Genetic heterogeneity in Laron syndrome. Francke U, Berg MA. Acta Paediatr Suppl 82 Suppl 391 3-7; discussion 8 (1993)
  270. Growth hormone receptor antagonists: discovery and potential uses. Kopchick JJ, Okada S. Growth Horm IGF Res 11 Suppl A S103-9 (2001)
  271. Production of crystallizable fragments of membrane proteins. Hendrickson WA. J Bioenerg Biomembr 28 35-40 (1996)
  272. Recent progress in structure-function and molecular analyses of the pituitary/placental glycoprotein hormone receptors. Dias JA. Biochim Biophys Acta 1135 287-294 (1992)
  273. Evolution of the IL-6/class IB cytokine receptor family in the immune and nervous systems. Yamamori T, Sarai A. J Physiol Paris 88 165-171 (1994)
  274. Growth hormone proteoformics atlas created to promote predictive, preventive, and personalized approach in overall management of pituitary neuroendocrine tumors. Yang L, Li C, Song T, Zhan X. EPMA J 14 443-456 (2023)
  275. Growth hormone receptor agonists and antagonists: From protein expression and purification to long-acting formulations. Wang Y, Kim M, Buckley C, Maynard HD, Langley RJ, Perry JK. Protein Sci 32 e4727 (2023)
  276. PCR: catching the next wave. Edgington SM. Biotechnology (N Y) 10 137-140 (1992)
  277. Protein hormones and their receptors. Young PR. Curr Opin Biotechnol 3 408-421 (1992)
  278. Regulation of growth hormone-binding protein: clinical implications. Postel-Vinay MC, Léger J, Sotiropoulos A, Delehaye-Zervas MC, Finidori J, Kelly PA. J Pediatr Endocrinol 6 241-244 (1993)
  279. Specificity of signaling by hematopoietic cytokine receptors: instructive versus permissive effects. Skoda RC. J Recept Signal Transduct Res 19 741-772 (1999)
  280. Structural aspects of cytokine/receptor interactions. Nicola NA. Ann N Y Acad Sci 766 253-262 (1995)
  281. The role of growth hormone-receptor antagonism in relation to acromegaly. Ayuk J, Sheppard MC. Expert Opin Pharmacother 5 2279-2285 (2004)
  282. The role of pegvisomant in the treatment of acromegaly. Roelfsema F, Biermasz NR, Pereira AM, Romijn JA. Expert Opin Biol Ther 8 691-704 (2008)
  283. Tissue factor and biotechnology. Martin DM, Wiiger MT, Prydz H. Thromb Res 90 1-25 (1998)
  284. Effects of amino acid sequence changes on antibody-antigen interactions. Colman PM. Res Immunol 145 33-36 (1994)
  285. Exploring unique structures: flexibility is a significant factor in biological activity. Ohkura K. Biol Pharm Bull 30 1025-1036 (2007)
  286. Interaction of lactogenic hormones with prolactin receptors. Gertler A, Grosclaude J, Djiane J. Ann N Y Acad Sci 839 177-181 (1998)
  287. Interleukin 5 interactions with soluble and cell surface forms of its receptor. Li J, Cook R, Chaiken I. J Mol Recognit 9 347-355 (1996)
  288. Putting two and two together: crystal structure of the FGF-receptor complex. Wiesmann C, de Vos AM. Structure 7 R251-5 (1999)
  289. Receptors of the cytokine superfamily: mechanisms of activation and involvement in disease. Woodcock JM, Bagley CJ, Lopez AF. Baillieres Clin Haematol 10 507-524 (1997)
  290. The JAK-STAT pathway: from structural biology to cytokine engineering. Lv Y, Qi J, Babon JJ, Cao L, Fan G, Lang J, Zhang J, Mi P, Kobe B, Wang F. Signal Transduct Target Ther 9 221 (2024)
  291. A rational design approach for developing immunomodulators based on CD4 and CD8. Tretiakova AP, Albert RH, Jameson BA. Biotechnol Genet Eng Rev 19 175-203 (2002)
  292. Growth hormone: new ideas, recurring themes. Reiter EO. Endocrine 15 1-4 (2001)
  293. Immunological manipulation of adiposity. Flint DJ. Proc Nutr Soc 51 433-439 (1992)
  294. Immunological manipulation of growth. Pell JM. Proc Nutr Soc 56 621-630 (1997)
  295. Structural biology and diabetes mellitus: molecular pathogenesis and rational drug design. Blundell T, Hubbard R, Weiss MA. Diabetologia 35 Suppl 2 S69-76 (1992)
  296. Targeting GH-1 splicing as a novel pharmacological strategy for growth hormone deficiency type II. Miletta MC, Flück CE, Mullis PE. Biochem Pharmacol 124 1-9 (2017)
  297. [Ligand recognition mechanism of G-CSF receptor and metabotropic glutamate receptor]. Morikawa K. Yakugaku Zasshi 122 855-868 (2002)

Articles citing this publication (762)

  1. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, Wiley DC. Nature 364 33-39 (1993)
  2. The atomic structure of protein-protein recognition sites. Lo Conte L, Chothia C, Janin J. J Mol Biol 285 2177-2198 (1999)
  3. A hot spot of binding energy in a hormone-receptor interface. Clackson T, Wells JA. Science 267 383-386 (1995)
  4. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD. Cell 87 1161-1169 (1996)
  5. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S. Cell 110 775-787 (2002)
  6. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN. Cell 74 227-236 (1993)
  7. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, Loetscher H, Lesslauer W. Cell 73 431-445 (1993)
  8. Synergistic roles for receptor occupancy and aggregation in integrin transmembrane function. Miyamoto S, Akiyama SK, Yamada KM. Science 267 883-885 (1995)
  9. Letter Leptin receptor missense mutation in the fatty Zucker rat. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CJ, Hess JF. Nat Genet 13 18-19 (1996)
  10. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Zhou Y, Xu BC, Maheshwari HG, He L, Reed M, Lozykowski M, Okada S, Cataldo L, Coschigamo K, Wagner TE, Baumann G, Kopchick JJ. Proc Natl Acad Sci U S A 94 13215-13220 (1997)
  11. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, Jorissen RN, Nice EC, Burgess AW, Ward CW. Cell 110 763-773 (2002)
  12. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA. Mol Cell 11 507-517 (2003)
  13. 2.0 A crystal structure of a four-domain segment of human fibronectin encompassing the RGD loop and synergy region. Leahy DJ, Aukhil I, Erickson HP. Cell 84 155-164 (1996)
  14. CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Ip NY, Nye SH, Boulton TG, Davis S, Taga T, Li Y, Birren SJ, Yasukawa K, Kishimoto T, Anderson DJ. Cell 69 1121-1132 (1992)
  15. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Banner DW, D'Arcy A, Chène C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchhofer D. Nature 380 41-46 (1996)
  16. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, Huang J, Jaye M, Crumley G, Schlessinger J, Lax I. Cell 79 1015-1024 (1994)
  17. Structure of NF-kappa B p50 homodimer bound to a kappa B site. Ghosh G, van Duyne G, Ghosh S, Sigler PB. Nature 373 303-310 (1995)
  18. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Science 283 987-990 (1999)
  19. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. LaPorte SL, Juo ZS, Vaclavikova J, Colf LA, Qi X, Heller NM, Keegan AD, Garcia KC. Cell 132 259-272 (2008)
  20. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, Grötzinger J, Rose-John S. Nat Biotechnol 15 142-145 (1997)
  21. Erythropoietin receptor activation by a ligand-induced conformation change. Remy I, Wilson IA, Michnick SW. Science 283 990-993 (1999)
  22. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chirino AJ, Zhang J, Finer-Moore J, Elliott S, Sitney K, Katz BA, Matthews DJ, Wendoloski JJ, Egrie J, Stroud RM. Nature 395 511-516 (1998)
  23. The fibronectin type III domain as a scaffold for novel binding proteins. Koide A, Bailey CW, Huang X, Koide S. J Mol Biol 284 1141-1151 (1998)
  24. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Naski MC, Wang Q, Xu J, Ornitz DM. Nat Genet 13 233-237 (1996)
  25. Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin. Pandey A, Ozaki K, Baumann H, Levin SD, Puel A, Farr AG, Ziegler SF, Leonard WJ, Lodish HF. Nat Immunol 1 59-64 (2000)
  26. Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Latz E, Verma A, Visintin A, Gong M, Sirois CM, Klein DC, Monks BG, McKnight CJ, Lamphier MS, Duprex WP, Espevik T, Golenbock DT. Nat Immunol 8 772-779 (2007)
  27. The three-dimensional structure of the tenth type III module of fibronectin: an insight into RGD-mediated interactions. Main AL, Harvey TS, Baron M, Boyd J, Campbell ID. Cell 71 671-678 (1992)
  28. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Li P, Morris DL, Willcox BE, Steinle A, Spies T, Strong RK. Nat Immunol 2 443-451 (2001)
  29. The molecular structure of the Toll-like receptor 3 ligand-binding domain. Bell JK, Botos I, Hall PR, Askins J, Shiloach J, Segal DM, Davies DR. Proc Natl Acad Sci U S A 102 10976-10980 (2005)
  30. Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor. Walter MR, Windsor WT, Nagabhushan TL, Lundell DJ, Lunn CA, Zauodny PJ, Narula SK. Nature 376 230-235 (1995)
  31. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Brown RJ, Adams JJ, Pelekanos RA, Wan Y, McKinstry WJ, Palethorpe K, Seeber RM, Monks TA, Eidne KA, Parker MW, Waters MJ. Nat Struct Mol Biol 12 814-821 (2005)
  32. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Brooks AJ, Dai W, O'Mara ML, Abankwa D, Chhabra Y, Pelekanos RA, Gardon O, Tunny KA, Blucher KM, Morton CJ, Parker MW, Sierecki E, Gambin Y, Gomez GA, Alexandrov K, Wilson IA, Doxastakis M, Mark AE, Waters MJ. Science 344 1249783 (2014)
  33. The X-ray structure of a growth hormone-prolactin receptor complex. Somers W, Ultsch M, De Vos AM, Kossiakoff AA. Nature 372 478-481 (1994)
  34. Rapid mapping of protein functional epitopes by combinatorial alanine scanning. Weiss GA, Watanabe CK, Zhong A, Goddard A, Sidhu SS. Proc Natl Acad Sci U S A 97 8950-8954 (2000)
  35. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougnères P. Nat Genet 36 720-724 (2004)
  36. Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Fan QR, Long EO, Wiley DC. Nat Immunol 2 452-460 (2001)
  37. Two EGF molecules contribute additively to stabilization of the EGFR dimer. Lemmon MA, Bu Z, Ladbury JE, Zhou M, Pinchasi D, Lax I, Engelman DM, Schlessinger J. EMBO J 16 281-294 (1997)
  38. cDNA cloning and characterization of the human interleukin 13 receptor alpha chain. Aman MJ, Tayebi N, Obiri NI, Puri RK, Modi WS, Leonard WJ. J Biol Chem 271 29265-29270 (1996)
  39. The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor. Strous GJ, van Kerkhof P, Govers R, Ciechanover A, Schwartz AL. EMBO J 15 3806-3812 (1996)
  40. The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Greenwald J, Groppe J, Gray P, Wiater E, Kwiatkowski W, Vale W, Choe S. Mol Cell 11 605-617 (2003)
  41. Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication. Tan K, Duquette M, Liu JH, Dong Y, Zhang R, Joachimiak A, Lawler J, Wang JH. J Cell Biol 159 373-382 (2002)
  42. Bacterial chitobiase structure provides insight into catalytic mechanism and the basis of Tay-Sachs disease. Tews I, Perrakis A, Oppenheim A, Dauter Z, Wilson KS, Vorgias CE. Nat Struct Biol 3 638-648 (1996)
  43. Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta. Vigers GP, Anderson LJ, Caffes P, Brandhuber BJ. Nature 386 190-194 (1997)
  44. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, de Vos AM. Structure 6 1153-1167 (1998)
  45. Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. Stamos J, Lazarus RA, Yao X, Kirchhofer D, Wiesmann C. EMBO J 23 2325-2335 (2004)
  46. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA. Proc Natl Acad Sci U S A 103 2788-2793 (2006)
  47. Homodimerization and constitutive activation of the erythropoietin receptor. Watowich SS, Yoshimura A, Longmore GD, Hilton DJ, Yoshimura Y, Lodish HF. Proc Natl Acad Sci U S A 89 2140-2144 (1992)
  48. Protein domain movements: detection of rigid domains and visualization of hinges in comparisons of atomic coordinates. Wriggers W, Schulten K. Proteins 29 1-14 (1997)
  49. Electrostatic complementarity at protein/protein interfaces. McCoy AJ, Chandana Epa V, Colman PM. J Mol Biol 268 570-584 (1997)
  50. Protein-protein interaction hotspots carved into sequences. Ofran Y, Rost B. PLoS Comput Biol 3 e119 (2007)
  51. The Erythropoietin Receptor: Structure, Activation and Intracellular Signal Transduction. Constantinescu SN, Ghaffari S, Lodish HF. Trends Endocrinol Metab 10 18-23 (1999)
  52. 1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. Somers W, Stahl M, Seehra JS. EMBO J 16 989-997 (1997)
  53. Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. Clackson T, Ultsch MH, Wells JA, de Vos AM. J Mol Biol 277 1111-1128 (1998)
  54. Proposed acquisition of an animal protein domain by bacteria. Bork P, Doolittle RF. Proc Natl Acad Sci U S A 89 8990-8994 (1992)
  55. Molecular recognition of BMP-2 and BMP receptor IA. Keller S, Nickel J, Zhang JL, Sebald W, Mueller TD. Nat Struct Mol Biol 11 481-488 (2004)
  56. High resolution functional analysis of antibody-antigen interactions. Jin L, Fendly BM, Wells JA. J Mol Biol 226 851-865 (1992)
  57. Isoaspartate in peptides and proteins: formation, significance, and analysis. Aswad DW, Paranandi MV, Schurter BT. J Pharm Biomed Anal 21 1129-1136 (2000)
  58. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Schreuder H, Tardif C, Trump-Kallmeyer S, Soffientini A, Sarubbi E, Akeson A, Bowlin T, Yanofsky S, Barrett RW. Nature 386 194-200 (1997)
  59. A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5. Milburn MV, Hassell AM, Lambert MH, Jordan SR, Proudfoot AE, Graber P, Wells TN. Nature 363 172-176 (1993)
  60. Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma. Zdanov A, Schalk-Hihi C, Gustchina A, Tsang M, Weatherbee J, Wlodawer A. Structure 3 591-601 (1995)
  61. Structural interactions of fibroblast growth factor receptor with its ligands. Stauber DJ, DiGabriele AD, Hendrickson WA. Proc Natl Acad Sci U S A 97 49-54 (2000)
  62. Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography. Radhakrishnan R, Walter LJ, Hruza A, Reichert P, Trotta PP, Nagabhushan TL, Walter MR. Structure 4 1453-1463 (1996)
  63. Crystal structure of chloroplast cytochrome f reveals a novel cytochrome fold and unexpected heme ligation. Martinez SE, Huang D, Szczepaniak A, Cramer WA, Smith JL. Structure 2 95-105 (1994)
  64. Threading analysis suggests that the obese gene product may be a helical cytokine. Madej T, Boguski MS, Bryant SH. FEBS Lett 373 13-18 (1995)
  65. Molecular recognition of human angiogenin by placental ribonuclease inhibitor--an X-ray crystallographic study at 2.0 A resolution. Papageorgiou AC, Shapiro R, Acharya KR. EMBO J 16 5162-5177 (1997)
  66. The crystal structure of human interferon beta at 2.2-A resolution. Karpusas M, Nolte M, Benton CB, Meier W, Lipscomb WN, Goelz S. Proc Natl Acad Sci U S A 94 11813-11818 (1997)
  67. Crystal structure of the tenth type III cell adhesion module of human fibronectin. Dickinson CD, Veerapandian B, Dai XP, Hamlin RC, Xuong NH, Ruoslahti E, Ely KR. J Mol Biol 236 1079-1092 (1994)
  68. Crystal structure of the interleukin-4/receptor alpha chain complex reveals a mosaic binding interface. Hage T, Sebald W, Reinemer P. Cell 97 271-281 (1999)
  69. Structural determinants in the sequences of immunoglobulin variable domain. Chothia C, Gelfand I, Kister A. J Mol Biol 278 457-479 (1998)
  70. A model for insulin binding to the insulin receptor. Schäffer L. Eur J Biochem 221 1127-1132 (1994)
  71. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. Muller YA, Christinger HW, Keyt BA, de Vos AM. Structure 5 1325-1338 (1997)
  72. A receptor for interleukin 10 is related to interferon receptors. Ho AS, Liu Y, Khan TA, Hsu DH, Bazan JF, Moore KW. Proc Natl Acad Sci U S A 90 11267-11271 (1993)
  73. Crystal structure of the extracellular region of human tissue factor. Harlos K, Martin DM, O'Brien DP, Jones EY, Stuart DI, Polikarpov I, Miller A, Tuddenham EG, Boys CW. Nature 370 662-666 (1994)
  74. An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation. Livnah O, Johnson DL, Stura EA, Farrell FX, Barbone FP, You Y, Liu KD, Goldsmith MA, He W, Krause CD, Pestka S, Jolliffe LK, Wilson IA. Nat Struct Biol 5 993-1004 (1998)
  75. Novel fold and assembly of the repetitive B region of the Staphylococcus aureus collagen-binding surface protein. Deivanayagam CC, Rich RL, Carson M, Owens RT, Danthuluri S, Bice T, Höök M, Narayana SV. Structure 8 67-78 (2000)
  76. Structure-function analysis of human IL-6 receptor: dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130. Yawata H, Yasukawa K, Natsuka S, Murakami M, Yamasaki K, Hibi M, Taga T, Kishimoto T. EMBO J 12 1705-1712 (1993)
  77. A physical reference state unifies the structure-derived potential of mean force for protein folding and binding. Liu S, Zhang C, Zhou H, Zhou Y. Proteins 56 93-101 (2004)
  78. Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Gherardi E, Youles ME, Miguel RN, Blundell TL, Iamele L, Gough J, Bandyopadhyay A, Hartmann G, Butler PJ. Proc Natl Acad Sci U S A 100 12039-12044 (2003)
  79. Activation and inhibition of erythropoietin receptor function: role of receptor dimerization. Watowich SS, Hilton DJ, Lodish HF. Mol Cell Biol 14 3535-3549 (1994)
  80. Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group. Goddard AD, Covello R, Luoh SM, Clackson T, Attie KM, Gesundheit N, Rundle AC, Wells JA, Carlsson LM. N Engl J Med 333 1093-1098 (1995)
  81. Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling. Paonessa G, Graziani R, De Serio A, Savino R, Ciapponi L, Lahm A, Salvati AL, Toniatti C, Ciliberto G. EMBO J 14 1942-1951 (1995)
  82. The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. Hill CP, Osslund TD, Eisenberg D. Proc Natl Acad Sci U S A 90 5167-5171 (1993)
  83. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong WJ, Sinha R, Guo F, Fabionar H, Wehrman TS, Krutzik P, Demharter S, Plo I, Weissman IL, Minary P, Majeti R, Constantinescu SN, Piehler J, Garcia KC. Cell 160 1196-1208 (2015)
  84. Activation of JAK2 tyrosine kinase by prolactin receptors in Nb2 cells and mouse mammary gland explants. Campbell GS, Argetsinger LS, Ihle JN, Kelly PA, Rillema JA, Carter-Su C. Proc Natl Acad Sci U S A 91 5232-5236 (1994)
  85. JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone. Winston LA, Hunter T. J Biol Chem 270 30837-30840 (1995)
  86. Optimized clinical performance of growth hormone with an expanded genetic code. Cho H, Daniel T, Buechler YJ, Litzinger DC, Maio Z, Putnam AM, Kraynov VS, Sim BC, Bussell S, Javahishvili T, Kaphle S, Viramontes G, Ong M, Chu S, Becky GC, Lieu R, Knudsen N, Castiglioni P, Norman TC, Axelrod DW, Hoffman AR, Schultz PG, DiMarchi RD, Kimmel BE. Proc Natl Acad Sci U S A 108 9060-9065 (2011)
  87. Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis. Gent J, van Kerkhof P, Roza M, Bu G, Strous GJ. Proc Natl Acad Sci U S A 99 9858-9863 (2002)
  88. Structural comparisons among the short-chain helical cytokines. Rozwarski DA, Gronenborn AM, Clore GM, Bazan JF, Bohm A, Wlodawer A, Hatada M, Karplus PA. Structure 2 159-173 (1994)
  89. Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement. Kruse N, Tony HP, Sebald W. EMBO J 11 3237-3244 (1992)
  90. Crystal structure of the human high-affinity IgE receptor. Garman SC, Kinet JP, Jardetzky TS. Cell 95 951-961 (1998)
  91. Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation. Gurney AL, Wong SC, Henzel WJ, de Sauvage FJ. Proc Natl Acad Sci U S A 92 5292-5296 (1995)
  92. The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody. Malby RL, Tulip WR, Harley VR, McKimm-Breschkin JL, Laver WG, Webster RG, Colman PM. Structure 2 733-746 (1994)
  93. Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3. Radaev S, Rostro B, Brooks AG, Colonna M, Sun PD. Immunity 15 1039-1049 (2001)
  94. The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution. Klaus W, Gsell B, Labhardt AM, Wipf B, Senn H. J Mol Biol 274 661-675 (1997)
  95. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Goodson RJ, Doyle MV, Kaufman SE, Rosenberg S. Proc Natl Acad Sci U S A 91 7129-7133 (1994)
  96. Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor. Skiniotis G, Boulanger MJ, Garcia KC, Walz T. Nat Struct Mol Biol 12 545-551 (2005)
  97. Identification of a nonsense mutation in the granulocyte-colony-stimulating factor receptor in severe congenital neutropenia. Dong F, Hoefsloot LH, Schelen AM, Broeders CA, Meijer Y, Veerman AJ, Touw IP, Löwenberg B. Proc Natl Acad Sci U S A 91 4480-4484 (1994)
  98. The crystal structure of TGF-beta 3 and comparison to TGF-beta 2: implications for receptor binding. Mittl PR, Priestle JP, Cox DA, McMaster G, Cerletti N, Grütter MG. Protein Sci 5 1261-1271 (1996)
  99. Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins. Cytokine receptor-like molecules. Zrihan-Licht S, Baruch A, Elroy-Stein O, Keydar I, Wreschner DH. FEBS Lett 356 130-136 (1994)
  100. An immunophilin that binds M(r) 90,000 heat shock protein: main structural features of a mammalian p59 protein. Callebaut I, Renoir JM, Lebeau MC, Massol N, Burny A, Baulieu EE, Mornon JP. Proc Natl Acad Sci U S A 89 6270-6274 (1992)
  101. Crystal structure and ligand binding properties of the D1D2 region of the inhibitory receptor LIR-1 (ILT2). Chapman TL, Heikema AP, West AP, Bjorkman PJ. Immunity 13 727-736 (2000)
  102. NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Cheetham JC, Smith DM, Aoki KH, Stevenson JL, Hoeffel TJ, Syed RS, Egrie J, Harvey TS. Nat Struct Biol 5 861-866 (1998)
  103. Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand. Raghavan M, Chen MY, Gastinel LN, Bjorkman PJ. Immunity 1 303-315 (1994)
  104. A flexible activin explains the membrane-dependent cooperative assembly of TGF-beta family receptors. Greenwald J, Vega ME, Allendorph GP, Fischer WH, Vale W, Choe S. Mol Cell 15 485-489 (2004)
  105. Outline structure of the human L1 cell adhesion molecule and the sites where mutations cause neurological disorders. Bateman A, Jouet M, MacFarlane J, Du JS, Kenwrick S, Chothia C. EMBO J 15 6050-6059 (1996)
  106. Subtiligase: a tool for semisynthesis of proteins. Chang TK, Jackson DY, Burnier JP, Wells JA. Proc Natl Acad Sci U S A 91 12544-12548 (1994)
  107. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Ball KL, Lain S, Fâhraeus R, Smythe C, Lane DP. Curr Biol 7 71-80 (1997)
  108. Crystal structure of dimeric human ciliary neurotrophic factor determined by MAD phasing. McDonald NQ, Panayotatos N, Hendrickson WA. EMBO J 14 2689-2699 (1995)
  109. The first membrane spanning region of the lamin B receptor is sufficient for sorting to the inner nuclear membrane. Smith S, Blobel G. J Cell Biol 120 631-637 (1993)
  110. Three-dimensional crystal structure of recombinant murine interferon-beta. Senda T, Shimazu T, Matsuda S, Kawano G, Shimizu H, Nakamura KT, Mitsui Y. EMBO J 11 3193-3201 (1992)
  111. High pressure fosters protein refolding from aggregates at high concentrations. St John RJ, Carpenter JF, Randolph TW. Proc Natl Acad Sci U S A 96 13029-13033 (1999)
  112. Identification of an E-selectin region critical for carbohydrate recognition and cell adhesion. Erbe DV, Wolitzky BA, Presta LG, Norton CR, Ramos RJ, Burns DK, Rumberger JM, Rao BN, Foxall C, Brandley BK. J Cell Biol 119 215-227 (1992)
  113. Point mutations within a dimer interface homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity. Alexander WS, Metcalf D, Dunn AR. EMBO J 14 5569-5578 (1995)
  114. Structure of CD94 reveals a novel C-type lectin fold: implications for the NK cell-associated CD94/NKG2 receptors. Boyington JC, Riaz AN, Patamawenu A, Coligan JE, Brooks AG, Sun PD. Immunity 10 75-82 (1999)
  115. Tracing the spread of fibronectin type III domains in bacterial glycohydrolases. Little E, Bork P, Doolittle RF. J Mol Evol 39 631-643 (1994)
  116. Biophysical analysis of the interaction of human ifnar2 expressed in E. coli with IFNalpha2. Piehler J, Schreiber G. J Mol Biol 289 57-67 (1999)
  117. Comprehensive and quantitative mapping of energy landscapes for protein-protein interactions by rapid combinatorial scanning. Pál G, Kouadio JK, Artis DR, Kossiakoff AA, Sidhu SS. J Biol Chem 281 22378-22385 (2006)
  118. Crystal structure of the HLA-Cw3 allotype-specific killer cell inhibitory receptor KIR2DL2. Snyder GA, Brooks AG, Sun PD. Proc Natl Acad Sci U S A 96 3864-3869 (1999)
  119. The structure and binding mode of interleukin-18. Kato Z, Jee J, Shikano H, Mishima M, Ohki I, Ohnishi H, Li A, Hashimoto K, Matsukuma E, Omoya K, Yamamoto Y, Yoneda T, Hara T, Kondo N, Shirakawa M. Nat Struct Biol 10 966-971 (2003)
  120. The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12. Lupardus PJ, Garcia KC. J Mol Biol 382 931-941 (2008)
  121. Topology of the CD2-CD48 cell-adhesion molecule complex: implications for antigen recognition by T cells. van der Merwe PA, McNamee PN, Davies EA, Barclay AN, Davis SJ. Curr Biol 5 74-84 (1995)
  122. Crystallographic insight into collagen recognition by discoidin domain receptor 2. Carafoli F, Bihan D, Stathopoulos S, Konitsiotis AD, Kvansakul M, Farndale RW, Leitinger B, Hohenester E. Structure 17 1573-1581 (2009)
  123. A potent new mode of beta-lactamase inhibition revealed by the 1.7 A X-ray crystallographic structure of the TEM-1-BLIP complex. Strynadka NC, Jensen SE, Alzari PM, James MN. Nat Struct Biol 3 290-297 (1996)
  124. Crystal structure of a cytokine-binding region of gp130. Bravo J, Staunton D, Heath JK, Jones EY. EMBO J 17 1665-1674 (1998)
  125. Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone. Costantino HR, Carrasquillo KG, Cordero RA, Mumenthaler M, Hsu CC, Griebenow K. J Pharm Sci 87 1412-1420 (1998)
  126. Interactive surface in the PapD chaperone cleft is conserved in pilus chaperone superfamily and essential in subunit recognition and assembly. Slonim LN, Pinkner JS, Brändén CI, Hultgren SJ. EMBO J 11 4747-4756 (1992)
  127. The crystal structure of a major allergen from plants. Thorn KS, Christensen HE, Shigeta R, Huddler D, Shalaby L, Lindberg U, Chua NH, Schutt CE. Structure 5 19-32 (1997)
  128. Atomic structure of the GCSF-receptor complex showing a new cytokine-receptor recognition scheme. Aritomi M, Kunishima N, Okamoto T, Kuroki R, Ota Y, Morikawa K. Nature 401 713-717 (1999)
  129. Crystal structure of tandem type III fibronectin domains from Drosophila neuroglian at 2.0 A. Huber AH, Wang YM, Bieber AJ, Bjorkman PJ. Neuron 12 717-731 (1994)
  130. Human epidermal growth factor. High resolution solution structure and comparison with human transforming growth factor alpha. Hommel U, Harvey TS, Driscoll PC, Campbell ID. J Mol Biol 227 271-282 (1992)
  131. Structural basis of chemokine sequestration by a herpesvirus decoy receptor. Alexander JM, Nelson CA, van Berkel V, Lau EK, Studts JM, Brett TJ, Speck SH, Handel TM, Virgin HW, Fremont DH. Cell 111 343-356 (2002)
  132. Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation. Kruse N, Shen BJ, Arnold S, Tony HP, Müller T, Sebald W. EMBO J 12 5121-5129 (1993)
  133. Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency. Tony HP, Shen BJ, Reusch P, Sebald W. Eur J Biochem 225 659-665 (1994)
  134. Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Gadd SL, Clevenger CV. Mol Endocrinol 20 2734-2746 (2006)
  135. Recognition between a bacterial ribonuclease, barnase, and its natural inhibitor, barstar. Guillet V, Lapthorn A, Hartley RW, Mauguen Y. Structure 1 165-176 (1993)
  136. Regulation of signal transducer and activator of transcription (STAT) 5b activation by the temporal pattern of growth hormone stimulation. Gebert CA, Park SH, Waxman DJ. Mol Endocrinol 11 400-414 (1997)
  137. Complex between Peptostreptococcus magnus protein L and a human antibody reveals structural convergence in the interaction modes of Fab binding proteins. Graille M, Stura EA, Housden NG, Beckingham JA, Bottomley SP, Beale D, Taussig MJ, Sutton BJ, Gore MG, Charbonnier JB. Structure 9 679-687 (2001)
  138. Disproportional skeletal growth and markedly decreased bone mineral content in growth hormone receptor -/- mice. Sjögren K, Bohlooly-Y M, Olsson B, Coschigano K, Törnell J, Mohan S, Isaksson OG, Baumann G, Kopchick J, Ohlsson C. Biochem Biophys Res Commun 267 603-608 (2000)
  139. Specificity in Trk receptor:neurotrophin interactions: the crystal structure of TrkB-d5 in complex with neurotrophin-4/5. Banfield MJ, Naylor RL, Robertson AG, Allen SJ, Dawbarn D, Brady RL. Structure 9 1191-1199 (2001)
  140. Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain. Varghese JN, Moritz RL, Lou MZ, Van Donkelaar A, Ji H, Ivancic N, Branson KM, Hall NE, Simpson RJ. Proc Natl Acad Sci U S A 99 15959-15964 (2002)
  141. A critical cytoplasmic domain of the interleukin-5 (IL-5) receptor alpha chain and its function in IL-5-mediated growth signal transduction. Takaki S, Kanazawa H, Shiiba M, Takatsu K. Mol Cell Biol 14 7404-7413 (1994)
  142. Defects in growth hormone receptor signaling. Rosenfeld RG, Belgorosky A, Camacho-Hubner C, Savage MO, Wit JM, Hwa V. Trends Endocrinol Metab 18 134-141 (2007)
  143. Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation. Savino R, Lahm A, Salvati AL, Ciapponi L, Sporeno E, Altamura S, Paonessa G, Toniatti C, Ciliberto G. EMBO J 13 1357-1367 (1994)
  144. Letter Projection structure of a gap junction membrane channel at 7 A resolution. Unger VM, Kumar NM, Gilula NB, Yeager M. Nat Struct Biol 4 39-43 (1997)
  145. A single amino acid substitution in the exoplasmic domain of the human growth hormone (GH) receptor confers familial GH resistance (Laron syndrome) with positive GH-binding activity by abolishing receptor homodimerization. Duquesnoy P, Sobrier ML, Duriez B, Dastot F, Buchanan CR, Savage MO, Preece MA, Craescu CT, Blouquit Y, Goossens M. EMBO J 13 1386-1395 (1994)
  146. Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface. Burke CL, Stern DF. Mol Cell Biol 18 5371-5379 (1998)
  147. Adsorption Kinetics, Conformation, and Mobility of the Growth Hormone and Lysozyme on Solid Surfaces, Studied with TIRF Buijs J, Hlady V. J Colloid Interface Sci 190 171-181 (1997)
  148. Signaling by chimeric erythropoietin-TGF-beta receptors: homodimerization of the cytoplasmic domain of the type I TGF-beta receptor and heterodimerization with the type II receptor are both required for intracellular signal transduction. Luo K, Lodish HF. EMBO J 15 4485-4496 (1996)
  149. Crystal structure of the human p58 killer cell inhibitory receptor (KIR2DL3) specific for HLA-Cw3-related MHC class I. Maenaka K, Juji T, Stuart DI, Jones EY. Structure 7 391-398 (1999)
  150. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Wrighton NC, Balasubramanian P, Barbone FP, Kashyap AK, Farrell FX, Jolliffe LK, Barrett RW, Dower WJ. Nat Biotechnol 15 1261-1265 (1997)
  151. Rational design of a receptor super-antagonist of human interleukin-6. Savino R, Ciapponi L, Lahm A, Demartis A, Cabibbo A, Toniatti C, Delmastro P, Altamura S, Ciliberto G. EMBO J 13 5863-5870 (1994)
  152. Structural organization of a full-length gp130/LIF-R cytokine receptor transmembrane complex. Skiniotis G, Lupardus PJ, Martick M, Walz T, Garcia KC. Mol Cell 31 737-748 (2008)
  153. A mixed-charge pair in human interleukin 4 dominates high-affinity interaction with the receptor alpha chain. Wang Y, Shen BJ, Sebald W. Proc Natl Acad Sci U S A 94 1657-1662 (1997)
  154. Comparison of interleukin-22 and interleukin-10 soluble receptor complexes. Logsdon NJ, Jones BC, Josephson K, Cook J, Walter MR. J Interferon Cytokine Res 22 1099-1112 (2002)
  155. Crystal structure of the extracellular domain of a human Fc gamma RIII. Zhang Y, Boesen CC, Radaev S, Brooks AG, Fridman WH, Sautes-Fridman C, Sun PD. Immunity 13 387-395 (2000)
  156. Expression and binding properties of two isoforms of the human growth hormone receptor. Sobrier ML, Duquesnoy P, Duriez B, Amselem S, Goossens M. FEBS Lett 319 16-20 (1993)
  157. Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor. Kubatzky KF, Ruan W, Gurezka R, Cohen J, Ketteler R, Watowich SS, Neumann D, Langosch D, Klingmüller U. Curr Biol 11 110-115 (2001)
  158. Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases. Liu H, Chen X, Focia PJ, He X. EMBO J 26 891-901 (2007)
  159. Letter X-ray structure of glial cell-derived neurotrophic factor at 1.9 A resolution and implications for receptor binding. Eigenbrot C, Gerber N. Nat Struct Biol 4 435-438 (1997)
  160. Diverse growth hormone receptor gene mutations in Laron syndrome. Berg MA, Argente J, Chernausek S, Gracia R, Guevara-Aguirre J, Hopp M, Pérez-Jurado L, Rosenbloom A, Toledo SP, Francke U. Am J Hum Genet 52 998-1005 (1993)
  161. Structure of the complete extracellular domain of the common beta subunit of the human GM-CSF, IL-3, and IL-5 receptors reveals a novel dimer configuration. Carr PD, Gustin SE, Church AP, Murphy JM, Ford SC, Mann DA, Woltring DM, Walker I, Ollis DL, Young IG. Cell 104 291-300 (2001)
  162. High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. Yanofsky SD, Baldwin DN, Butler JH, Holden FR, Jacobs JW, Balasubramanian P, Chinn JP, Cwirla SE, Peters-Bhatt E, Whitehorn EA, Tate EH, Akeson A, Bowlin TL, Dower WJ, Barrett RW. Proc Natl Acad Sci U S A 93 7381-7386 (1996)
  163. A 16-residue peptide fragment of macrophage migration inhibitory factor, MIF-(50-65), exhibits redox activity and has MIF-like biological functions. Nguyen MT, Beck J, Lue H, Fünfzig H, Kleemann R, Koolwijk P, Kapurniotu A, Bernhagen J. J Biol Chem 278 33654-33671 (2003)
  164. Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2. Piehler J, Schreiber G. J Mol Biol 294 223-237 (1999)
  165. An agonist-induced conformational change in the growth hormone receptor determines the choice of signalling pathway. Rowlinson SW, Yoshizato H, Barclay JL, Brooks AJ, Behncken SN, Kerr LM, Millard K, Palethorpe K, Nielsen K, Clyde-Smith J, Hancock JF, Waters MJ. Nat Cell Biol 10 740-747 (2008)
  166. Crystal Structure of the interleukin-15.interleukin-15 receptor alpha complex: insights into trans and cis presentation. Olsen SK, Ota N, Kishishita S, Kukimoto-Niino M, Murayama K, Uchiyama H, Toyama M, Terada T, Shirouzu M, Kanagawa O, Yokoyama S. J Biol Chem 282 37191-37204 (2007)
  167. Global and local determinants for the kinetics of interleukin-4/interleukin-4 receptor alpha chain interaction. A biosensor study employing recombinant interleukin-4-binding protein. Shen BJ, Hage T, Sebald W. Eur J Biochem 240 252-261 (1996)
  168. Identification of critical IgG binding epitopes on the neonatal Fc receptor. Vaughn DE, Milburn CM, Penny DM, Martin WL, Johnson JL, Bjorkman PJ. J Mol Biol 274 597-607 (1997)
  169. Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist. Tavernier J, Tuypens T, Verhee A, Plaetinck G, Devos R, Van der Heyden J, Guisez Y, Oefner C. Proc Natl Acad Sci U S A 92 5194-5198 (1995)
  170. Interleukin-11 signals through the formation of a hexameric receptor complex. Barton VA, Hall MA, Hudson KR, Heath JK. J Biol Chem 275 36197-36203 (2000)
  171. Shared receptor components but distinct complexes for alpha and beta interferons. Lewerenz M, Mogensen KE, Uzé G. J Mol Biol 282 585-599 (1998)
  172. The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes. Grötzinger J, Kurapkat G, Wollmer A, Kalai M, Rose-John S. Proteins 27 96-109 (1997)
  173. Crystal structure of human interleukin-10 at 1.6 A resolution and a model of a complex with its soluble receptor. Zdanov A, Schalk-Hihi C, Wlodawer A. Protein Sci 5 1955-1962 (1996)
  174. Inhibition of tetrameric Patched1 by Sonic Hedgehog through an asymmetric paradigm. Qian H, Cao P, Hu M, Gao S, Yan N, Gong X. Nat Commun 10 2320 (2019)
  175. 3D-Epitope-Explorer (3DEX): localization of conformational epitopes within three-dimensional structures of proteins. Schreiber A, Humbert M, Benz A, Dietrich U. J Comput Chem 26 879-887 (2005)
  176. An interleukin-2 receptor gamma chain mutation with normal thymus morphology. Sharfe N, Shahar M, Roifman CM. J Clin Invest 100 3036-3043 (1997)
  177. Binding interactions of human interleukin 5 with its receptor alpha subunit. Large scale production, structural, and functional studies of Drosophila-expressed recombinant proteins. Johanson K, Appelbaum E, Doyle M, Hensley P, Zhao B, Abdel-Meguid SS, Young P, Cook R, Carr S, Matico R. J Biol Chem 270 9459-9471 (1995)
  178. Insulin and epidermal growth factor receptors contain the cysteine repeat motif found in the tumor necrosis factor receptor. Ward CW, Hoyne PA, Flegg RH. Proteins 22 141-153 (1995)
  179. Metal-catalyzed oxidation of histidine in human growth hormone. Mechanism, isotope effects, and inhibition by a mild denaturing alcohol. Zhao F, Ghezzo-Schöneich E, Aced GI, Hong J, Milby T, Schöneich C. J Biol Chem 272 9019-9029 (1997)
  180. Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex. Thiel DJ, le Du MH, Walter RL, D'Arcy A, Chène C, Fountoulakis M, Garotta G, Winkler FK, Ealick SE. Structure 8 927-936 (2000)
  181. Solution structure of human prolactin. Teilum K, Hoch JC, Goffin V, Kinet S, Martial JA, Kragelund BB. J Mol Biol 351 810-823 (2005)
  182. Structural basis and kinetics of DsbD-dependent cytochrome c maturation. Stirnimann CU, Rozhkova A, Grauschopf U, Grütter MG, Glockshuber R, Capitani G. Structure 13 985-993 (2005)
  183. Structure and mechanism of receptor sharing by the IL-10R2 common chain. Yoon SI, Jones BC, Logsdon NJ, Harris BD, Deshpande A, Radaeva S, Halloran BA, Gao B, Walter MR. Structure 18 638-648 (2010)
  184. Folding mechanism of the CH2 antibody domain. Feige MJ, Walter S, Buchner J. J Mol Biol 344 107-118 (2004)
  185. The human type I interferon receptor: NMR structure reveals the molecular basis of ligand binding. Chill JH, Quadt SR, Levy R, Schreiber G, Anglister J. Structure 11 791-802 (2003)
  186. Dissecting the energetics of an antibody-antigen interface by alanine shaving and molecular grafting. Jin L, Wells JA. Protein Sci 3 2351-2357 (1994)
  187. Structural basis for receptor sharing and activation by interleukin-20 receptor-2 (IL-20R2) binding cytokines. Logsdon NJ, Deshpande A, Harris BD, Rajashankar KR, Walter MR. Proc Natl Acad Sci U S A 109 12704-12709 (2012)
  188. An unusual cytokine:Ig-domain interaction revealed in the crystal structure of leukemia inhibitory factor (LIF) in complex with the LIF receptor. Huyton T, Zhang JG, Luo CS, Lou MZ, Hilton DJ, Nicola NA, Garrett TP. Proc Natl Acad Sci U S A 104 12737-12742 (2007)
  189. Exploring the potential of the monobody scaffold: effects of loop elongation on the stability of a fibronectin type III domain. Batori V, Koide A, Koide S. Protein Eng 15 1015-1020 (2002)
  190. Correlation of observed fold frequency with the occurrence of local structural motifs. Salem GM, Hutchinson EG, Orengo CA, Thornton JM. J Mol Biol 287 969-981 (1999)
  191. Mapping of an NH2-terminal ligand binding site of the insulin receptor by alanine scanning mutagenesis. Williams PF, Mynarcik DC, Yu GQ, Whittaker J. J Biol Chem 270 3012-3016 (1995)
  192. Molecular cloning of the bovine prolactin receptor and distribution of prolactin and growth hormone receptor transcripts in fetal and utero-placental tissues. Scott P, Kessler MA, Schuler LA. Mol Cell Endocrinol 89 47-58 (1992)
  193. Novel mutations of the growth hormone 1 (GH1) gene disclosed by modulation of the clinical selection criteria for individuals with short stature. Millar DS, Lewis MD, Horan M, Newsway V, Easter TE, Gregory JW, Fryklund L, Norin M, Crowne EC, Davies SJ, Edwards P, Kirk J, Waldron K, Smith PJ, Phillips JA, Scanlon MF, Krawczak M, Cooper DN, Procter AM. Hum Mutat 21 424-440 (2003)
  194. Structural snapshots of full-length Jak1, a transmembrane gp130/IL-6/IL-6Rα cytokine receptor complex, and the receptor-Jak1 holocomplex. Lupardus PJ, Skiniotis G, Rice AJ, Thomas C, Fischer S, Walz T, Garcia KC. Structure 19 45-55 (2011)
  195. Structure-function analysis of human IL-6: identification of two distinct regions that are important for receptor binding. Hammacher A, Ward LD, Weinstock J, Treutlein H, Yasukawa K, Simpson RJ. Protein Sci 3 2280-2293 (1994)
  196. The ciliary neurotrophic factor receptor alpha component induces the secretion of and is required for functional responses to cardiotrophin-like cytokine. Plun-Favreau H, Elson G, Chabbert M, Froger J, deLapeyrière O, Lelièvre E, Guillet C, Hermann J, Gauchat JF, Gascan H, Chevalier S. EMBO J 20 1692-1703 (2001)
  197. Compensatory energetic mechanisms mediating the assembly of signaling complexes between interleukin-2 and its alpha, beta, and gamma(c) receptors. Rickert M, Boulanger MJ, Goriatcheva N, Garcia KC. J Mol Biol 339 1115-1128 (2004)
  198. Kinetic analysis of ligand binding to interleukin-2 receptor complexes created on an optical biosensor surface. Myszka DG, Arulanantham PR, Sana T, Wu Z, Morton TA, Ciardelli TL. Protein Sci 5 2468-2478 (1996)
  199. Leptin signaling and Alzheimer's disease. Marwarha G, Ghribi O. Am J Neurodegener Dis 1 245-265 (2012)
  200. The short form of the prolactin (PRL) receptor silences PRL induction of the beta-casein gene promoter. Berlanga JJ, Garcia-Ruiz JP, Perrot-Applanat M, Kelly PA, Edery M. Mol Endocrinol 11 1449-1457 (1997)
  201. Three residues in the common beta chain of the human GM-CSF, IL-3 and IL-5 receptors are essential for GM-CSF and IL-5 but not IL-3 high affinity binding and interact with Glu21 of GM-CSF. Woodcock JM, Zacharakis B, Plaetinck G, Bagley CJ, Qiyu S, Hercus TR, Tavernier J, Lopez AF. EMBO J 13 5176-5185 (1994)
  202. Variants of somatotropin in cattle: gene frequencies in major dairy breeds and associated milk production. Lucy MC, Hauser SD, Eppard PJ, Krivi GG, Clark JH, Bauman DE, Collier RJ. Domest Anim Endocrinol 10 325-333 (1993)
  203. Biologically inactive growth hormone caused by an amino acid substitution. Takahashi Y, Shirono H, Arisaka O, Takahashi K, Yagi T, Koga J, Kaji H, Okimura Y, Abe H, Tanaka T, Chihara K. J Clin Invest 100 1159-1165 (1997)
  204. Constitutive and impaired signaling of leptin receptors containing the Gln --> Pro extracellular domain fatty mutation. White DW, Wang DW, Chua SC, Morgenstern JP, Leibel RL, Baumann H, Tartaglia LA. Proc Natl Acad Sci U S A 94 10657-10662 (1997)
  205. Specific human granulocyte-macrophage colony-stimulating factor antagonists. Hercus TR, Bagley CJ, Cambareri B, Dottore M, Woodcock JM, Vadas MA, Shannon MF, Lopez AF. Proc Natl Acad Sci U S A 91 5838-5842 (1994)
  206. Structural basis of the activation of c-MET receptor. Uchikawa E, Chen Z, Xiao GY, Zhang X, Bai XC. Nat Commun 12 4074 (2021)
  207. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Feese MD, Tamada T, Kato Y, Maeda Y, Hirose M, Matsukura Y, Shigematsu H, Muto T, Matsumoto A, Watarai H, Ogami K, Tahara T, Kato T, Miyazaki H, Kuroki R. Proc Natl Acad Sci U S A 101 1816-1821 (2004)
  208. The erythropoietin receptor transmembrane region is necessary for activation by the Friend spleen focus-forming virus gp55 glycoprotein. Zon LI, Moreau JF, Koo JW, Mathey-Prevot B, D'Andrea AD. Mol Cell Biol 12 2949-2957 (1992)
  209. Crystal structure of Epstein-Barr virus protein BCRF1, a homolog of cellular interleukin-10. Zdanov A, Schalk-Hihi C, Menon S, Moore KW, Wlodawer A. J Mol Biol 268 460-467 (1997)
  210. Molecular basis for the recognition of two structurally different major histocompatibility complex/peptide complexes by a single T-cell receptor. Brock R, Wiesmüller KH, Jung G, Walden P. Proc Natl Acad Sci U S A 93 13108-13113 (1996)
  211. Novel point mutation in the extracellular domain of the granulocyte colony-stimulating factor (G-CSF) receptor in a case of severe congenital neutropenia hyporesponsive to G-CSF treatment. Ward AC, van Aesch YM, Gits J, Schelen AM, de Koning JP, van Leeuwen D, Freedman MH, Touw IP. J Exp Med 190 497-507 (1999)
  212. Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeric receptor. Zurawski SM, Vega F, Doyle EL, Huyghe B, Flaherty K, McKay DB, Zurawski G. EMBO J 12 5113-5119 (1993)
  213. Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. Samanta A, LeVea CM, Dougall WC, Qian X, Greene MI. Proc Natl Acad Sci U S A 91 1711-1715 (1994)
  214. Mapping of binding site III in the leptin receptor and modeling of a hexameric leptin.leptin receptor complex. Peelman F, Iserentant H, De Smet AS, Vandekerckhove J, Zabeau L, Tavernier J. J Biol Chem 281 15496-15504 (2006)
  215. Solution structure of recombinant human interleukin-6. Xu GY, Yu HA, Hong J, Stahl M, McDonagh T, Kay LE, Cumming DA. J Mol Biol 268 468-481 (1997)
  216. GW domains of the Listeria monocytogenes invasion protein InlB are required for potentiation of Met activation. Banerjee M, Copp J, Vuga D, Marino M, Chapman T, van der Geer P, Ghosh P. Mol Microbiol 52 257-271 (2004)
  217. Ligand-induced activation of chimeric receptors between the erythropoietin receptor and receptor tyrosine kinases. Ohashi H, Maruyama K, Liu YC, Yoshimura A. Proc Natl Acad Sci U S A 91 158-162 (1994)
  218. Evolution of receptors for growth hormone and somatolactin in fish and land vertebrates: lessons from the lungfish and sturgeon orthologues. Fukamachi S, Meyer A. J Mol Evol 65 359-372 (2007)
  219. Molecular cloning of a teleost growth hormone receptor and its functional interaction with human growth hormone. Lee LT, Nong G, Chan YH, Tse DL, Cheng CH. Gene 270 121-129 (2001)
  220. The IL-10R2 binding hot spot on IL-22 is located on the N-terminal helix and is dependent on N-linked glycosylation. Logsdon NJ, Jones BC, Allman JC, Izotova L, Schwartz B, Pestka S, Walter MR. J Mol Biol 342 503-514 (2004)
  221. Recombinant soluble human interleukin-6 receptor. Expression in Escherichia coli, renaturation and purification. Stoyan T, Michaelis U, Schooltink H, Van Dam M, Rudolph R, Heinrich PC, Rose-John S. Eur J Biochem 216 239-245 (1993)
  222. Stoichiometry of interaction between interferon gamma and its receptor. Fountoulakis M, Zulauf M, Lustig A, Garotta G. Eur J Biochem 208 781-787 (1992)
  223. Structural determinants of natriuretic peptide receptor specificity and degeneracy. He XL, Dukkipati A, Garcia KC. J Mol Biol 361 698-714 (2006)
  224. Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation. Matthews EE, Thévenin D, Rogers JM, Gotow L, Lira PD, Reiter LA, Brissette WH, Engelman DM. FASEB J 25 2234-2244 (2011)
  225. Periplasmic production via the pET expression system of soluble, bioactive human growth hormone. Sockolosky JT, Szoka FC. Protein Expr Purif 87 129-135 (2013)
  226. Saturation mutagenesis of the human interleukin 6 receptor-binding site: implications for its three-dimensional structure. Savino R, Lahm A, Giorgio M, Cabibbo A, Tramontano A, Ciliberto G. Proc Natl Acad Sci U S A 90 4067-4071 (1993)
  227. The molecular origins of specificity in the assembly of a multienzyme complex. Frank RA, Pratap JV, Pei XY, Perham RN, Luisi BF. Structure 13 1119-1130 (2005)
  228. A sequential dimerization mechanism for erythropoietin receptor activation. Matthews DJ, Topping RS, Cass RT, Giebel LB. Proc Natl Acad Sci U S A 93 9471-9476 (1996)
  229. Episodic evolution of growth hormone in primates and emergence of the species specificity of human growth hormone receptor. Liu JC, Makova KD, Adkins RM, Gibson S, Li WH. Mol Biol Evol 18 945-953 (2001)
  230. Growth hormone and its receptor in human ovaries from fetuses and adults. Abir R, Garor R, Felz C, Nitke S, Krissi H, Fisch B. Fertil Steril 90 1333-1339 (2008)
  231. Molecular biology of erythropoietin. Ratcliffe PJ. Kidney Int 44 887-904 (1993)
  232. Crystal structure of LIR-2 (ILT4) at 1.8 A: differences from LIR-1 (ILT2) in regions implicated in the binding of the Human Cytomegalovirus class I MHC homolog UL18. Willcox BE, Thomas LM, Chapman TL, Heikema AP, West AP, Bjorkman PJ. BMC Struct Biol 2 6 (2002)
  233. Increased cell surface expression and enhanced folding in the endoplasmic reticulum of a mutant erythropoietin receptor. Hilton DJ, Watowich SS, Murray PJ, Lodish HF. Proc Natl Acad Sci U S A 92 190-194 (1995)
  234. The high-affinity interaction of human IL-4 and the receptor alpha chain is constituted by two independent binding clusters. Zhang JL, Simeonowa I, Wang Y, Sebald W. J Mol Biol 315 399-407 (2002)
  235. Generation of a variant of human interleukin-4 by alternative splicing. Alms WJ, Atamas SP, Yurovsky VV, White B. Mol Immunol 33 361-370 (1996)
  236. Human interleukin-3 (IL-3) induces disulfide-linked IL-3 receptor alpha- and beta-chain heterodimerization, which is required for receptor activation but not high-affinity binding. Stomski FC, Sun Q, Bagley CJ, Woodcock J, Goodall G, Andrews RK, Berndt MC, Lopez AF. Mol Cell Biol 16 3035-3046 (1996)
  237. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex. Xu J, Zhang Y, Berry PA, Jiang J, Lobie PE, Langenheim JF, Chen WY, Frank SJ. Mol Endocrinol 25 597-610 (2011)
  238. High pressure refolding of recombinant human growth hormone from insoluble aggregates. Structural transformations, kinetic barriers, and energetics. St John RJ, Carpenter JF, Balny C, Randolph TW. J Biol Chem 276 46856-46863 (2001)
  239. NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis. Fattorusso R, Pellecchia M, Viti F, Neri P, Neri D, Wüthrich K. Structure 7 381-390 (1999)
  240. The transactivation region of the fis protein that controls site-specific DNA inversion contains extended mobile beta-hairpin arms. Safo MK, Yang WZ, Corselli L, Cramton SE, Yuan HS, Johnson RC. EMBO J 16 6860-6873 (1997)
  241. A single arginine residue determines species specificity of the human growth hormone receptor. Souza SC, Frick GP, Wang X, Kopchick JJ, Lobo RB, Goodman HM. Proc Natl Acad Sci U S A 92 959-963 (1995)
  242. Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly. Mercado M, González B, Sandoval C, Esquenazi Y, Mier F, Vargas G, de los Monteros AL, Sosa E. J Clin Endocrinol Metab 93 3411-3415 (2008)
  243. Receptor binding properties of four-helix-bundle growth factors deduced from electrostatic analysis. Demchuk E, Mueller T, Oschkinat H, Sebald W, Wade RC. Protein Sci 3 920-935 (1994)
  244. Binding of biotin to streptavidin stabilizes intersubunit salt bridges between Asp61 and His87 at low pH. Katz BA. J Mol Biol 274 776-800 (1997)
  245. Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization. Bernat B, Pal G, Sun M, Kossiakoff AA. Proc Natl Acad Sci U S A 100 952-957 (2003)
  246. Dimerization and signal transduction of the growth hormone receptor. Gent J, Van Den Eijnden M, Van Kerkhof P, Strous GJ. Mol Endocrinol 17 967-975 (2003)
  247. Protein fold analysis of the B30.2-like domain. Seto MH, Liu HL, Zajchowski DA, Whitlow M. Proteins 35 235-249 (1999)
  248. The three-dimensional structure of a type I module from titin: a prototype of intracellular fibronectin type III domains. Goll CM, Pastore A, Nilges M. Structure 6 1291-1302 (1998)
  249. Unexpected frameshifts from gene to expressed protein in a phage-displayed peptide library. Cárcamo J, Ravera MW, Brissette R, Dedova O, Beasley JR, Alam-Moghé A, Wan C, Blume A, Mandecki W. Proc Natl Acad Sci U S A 95 11146-11151 (1998)
  250. Characterization of antihuman IFNAR-1 monoclonal antibodies: epitope localization and functional analysis. Goldman LA, Zafari M, Cutrone EC, Dang A, Brickelmeier M, Runkel L, Benjamin CD, Ling LE, Langer JA. J Interferon Cytokine Res 19 15-26 (1999)
  251. Crystal structure of a disulfide-linked "trefoil" motif found in a large family of putative growth factors. De A, Brown DG, Gorman MA, Carr M, Sanderson MR, Freemont PS. Proc Natl Acad Sci U S A 91 1084-1088 (1994)
  252. Human growth hormone expressed in tobacco cells as an arabinogalactan-protein fusion glycoprotein has a prolonged serum life. Xu J, Okada S, Tan L, Goodrum KJ, Kopchick JJ, Kieliszewski MJ. Transgenic Res 19 849-867 (2010)
  253. Immunoglobulin-like domains define the nerve growth factor binding site of the TrkA receptor. Holden PH, Asopa V, Robertson AG, Clarke AR, Tyler S, Bennett GS, Brain SD, Wilcock GK, Allen SJ, Smith SK, Dawbarn D. Nat Biotechnol 15 668-672 (1997)
  254. Oligomeric states and siderophore binding of the ligand-gated FhuA protein that forms channels across Escherichia coli outer membranes. Locher KP, Rosenbusch JP. Eur J Biochem 247 770-775 (1997)
  255. An insulin-like growth factor II (IGF-II) affinity-enhancing domain localized within extracytoplasmic repeat 13 of the IGF-II/mannose 6-phosphate receptor. Devi GR, Byrd JC, Slentz DH, MacDonald RG. Mol Endocrinol 12 1661-1672 (1998)
  256. Phosphoproteomic analysis of the human pituitary. Beranova-Giorgianni S, Zhao Y, Desiderio DM, Giorgianni F. Pituitary 9 109-120 (2006)
  257. Subcloning, expression, purification, and characterization of recombinant human leptin-binding domain. Sandowski Y, Raver N, Gussakovsky EE, Shochat S, Dym O, Livnah O, Rubinstein M, Krishna R, Gertler A. J Biol Chem 277 46304-46309 (2002)
  258. The role of charge and multiple faces of the CD8 alpha/alpha homodimer in binding to major histocompatibility complex class I molecules: support for a bivalent model. Giblin PA, Leahy DJ, Mennone J, Kavathas PB. Proc Natl Acad Sci U S A 91 1716-1720 (1994)
  259. The tertiary structure and backbone dynamics of human prolactin. Keeler C, Dannies PS, Hodsdon ME. J Mol Biol 328 1105-1121 (2003)
  260. Histidine-367 of the human common beta chain of the receptor is critical for high-affinity binding of human granulocyte-macrophage colony-stimulating factor. Lock P, Metcalf D, Nicola NA. Proc Natl Acad Sci U S A 91 252-256 (1994)
  261. Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies. Zhang H, Wang Q, Montone KT, Peavey JE, Drebin JA, Greene MI, Murali R. Exp Mol Pathol 67 15-25 (1999)
  262. The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the complex formation with cell surface hGH receptor and hGH-binding protein circulating in human plasma. Wada M, Uchida H, Ikeda M, Tsunekawa B, Naito N, Banba S, Tanaka E, Hashimoto Y, Honjo M. Mol Endocrinol 12 146-156 (1998)
  263. Aromatic amino acids at the surface of InlB are essential for host cell invasion by Listeria monocytogenes. Machner MP, Frese S, Schubert WD, Orian-Rousseau V, Gherardi E, Wehland J, Niemann HH, Heinz DW. Mol Microbiol 48 1525-1536 (2003)
  264. BiaCore analysis of leptin-leptin receptor interaction: evidence for 1:1 stoichiometry. Mistrík P, Moreau F, Allen JM. Anal Biochem 327 271-277 (2004)
  265. Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody. Broughton SE, Hercus TR, Hardy MP, McClure BJ, Nero TL, Dottore M, Huynh H, Braley H, Barry EF, Kan WL, Dhagat U, Scotney P, Hartman D, Busfield SJ, Owczarek CM, Nash AD, Wilson NJ, Parker MW, Lopez AF. Cell Rep 8 410-419 (2014)
  266. Growth hormone stimulates the tyrosine kinase activity of JAK2 and induces tyrosine phosphorylation of insulin receptor substrates and Shc in rat tissues. Thirone AC, Carvalho CR, Saad MJ. Endocrinology 140 55-62 (1999)
  267. Hematopoietin sub-family classification based on size, gene organization and sequence homology. Boulay JL, Paul WE. Curr Biol 3 573-581 (1993)
  268. Mapping leptin-interacting sites in recombinant leptin-binding domain (LBD) subcloned from chicken leptin receptor. Niv-Spector L, Raver N, Friedman-Einat M, Grosclaude J, Gussakovsky EE, Livnah O, Gertler A. Biochem J 390 475-484 (2005)
  269. Short stature caused by a biologically inactive mutant growth hormone (GH-C53S). Besson A, Salemi S, Deladoëy J, Vuissoz JM, Eblé A, Bidlingmaier M, Bürgi S, Honegger U, Flück C, Mullis PE. J Clin Endocrinol Metab 90 2493-2499 (2005)
  270. Stoichiometry, kinetic and binding analysis of the interaction between epidermal growth factor (EGF) and the extracellular domain of the EGF receptor. Domagala T, Konstantopoulos N, Smyth F, Jorissen RN, Fabri L, Geleick D, Lax I, Schlessinger J, Sawyer W, Howlett GJ, Burgess AW, Nice EC. Growth Factors 18 11-29 (2000)
  271. The interleukin-2 and interleukin-4 receptors studied by molecular modelling. Bamborough P, Hedgecock CJ, Richards WG. Structure 2 839-851 (1994)
  272. Crystal structure of ovine interferon-tau at 2.1 A resolution. Radhakrishnan R, Walter LJ, Subramaniam PS, Johnson HM, Walter MR. J Mol Biol 286 151-162 (1999)
  273. Direct observation of disordered regions in the major histocompatibility complex class II-associated invariant chain. Jasanoff A, Park SJ, Wiley DC. Proc Natl Acad Sci U S A 92 9900-9904 (1995)
  274. Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity. Toniatti C, Cabibbo A, Sporena E, Salvati AL, Cerretani M, Serafini S, Lahm A, Cortese R, Ciliberto G. EMBO J 15 2726-2737 (1996)
  275. Intracellular tyrosine residues of the human growth hormone receptor are not required for the signaling of proliferation or Jak-STAT activation. Wang YD, Wong K, Wood WI. J Biol Chem 270 7021-7024 (1995)
  276. NMR characterization of interleukin-2 in complexes with the IL-2Ralpha receptor component, and with low molecular weight compounds that inhibit the IL-2/IL-Ralpha interaction. Emerson SD, Palermo R, Liu CM, Tilley JW, Chen L, Danho W, Madison VS, Greeley DN, Ju G, Fry DC. Protein Sci 12 811-822 (2003)
  277. Recruitment of the transcriptional machinery through GAL11P: structure and interactions of the GAL4 dimerization domain. Hidalgo P, Ansari AZ, Schmidt P, Hare B, Simkovich N, Farrell S, Shin EJ, Ptashne M, Wagner G. Genes Dev 15 1007-1020 (2001)
  278. The functional binding epitope of a high affinity variant of human growth hormone mapped by shotgun alanine-scanning mutagenesis: insights into the mechanisms responsible for improved affinity. Pal G, Kossiakoff AA, Sidhu SS. J Mol Biol 332 195-204 (2003)
  279. A functional role of the membrane-proximal extracellular domains of the signal transducer gp130 in heterodimerization with the leukemia inhibitory factor receptor. Timmermann A, Küster A, Kurth I, Heinrich PC, Müller-Newen G. Eur J Biochem 269 2716-2726 (2002)
  280. Activation of the erythropoietin receptor by the gp55-P viral envelope protein is determined by a single amino acid in its transmembrane domain. Constantinescu SN, Liu X, Beyer W, Fallon A, Shekar S, Henis YI, Smith SO, Lodish HF. EMBO J 18 3334-3347 (1999)
  281. Artificial Diiron Enzymes with a De Novo Designed Four-Helix Bundle Structure. Chino M, Maglio O, Nastri F, Pavone V, DeGrado WF, Lombardi A. Eur J Inorg Chem 2015 3371-3390 (2015)
  282. Complete solubilization and purification of recombinant human growth hormone produced in Escherichia coli. Kim MJ, Park HS, Seo KH, Yang HJ, Kim SK, Choi JH. PLoS One 8 e56168 (2013)
  283. Detailed analysis of the IL-5-IL-5R alpha interaction: characterization of crucial residues on the ligand and the receptor. Cornelis S, Plaetinck G, Devos R, Van der Heyden J, Tavernier J, Sanderson CJ, Guisez Y, Fiers W. EMBO J 14 3395-3402 (1995)
  284. GDF-5 can act as a context-dependent BMP-2 antagonist. Klammert U, Mueller TD, Hellmann TV, Wuerzler KK, Kotzsch A, Schliermann A, Schmitz W, Kuebler AC, Sebald W, Nickel J. BMC Biol 13 77 (2015)
  285. Hematopoietic cytokines: similarities and differences in the structures, with implications for receptor binding. Wlodawer A, Pavlovsky A, Gustchina A. Protein Sci 2 1373-1382 (1993)
  286. A dominant negative erythropoietin (EPO) receptor inhibits EPO-dependent growth and blocks F-gp55-dependent transformation. Barber DL, DeMartino JC, Showers MO, D'Andrea AD. Mol Cell Biol 14 2257-2265 (1994)
  287. Activating point mutations in the common beta subunit of the human GM-CSF, IL-3 and IL-5 receptors suggest the involvement of beta subunit dimerization and cell type-specific molecules in signalling. Jenkins BJ, D'Andrea R, Gonda TJ. EMBO J 14 4276-4287 (1995)
  288. Bovine leukemia virus SU protein interacts with zinc, and mutations within two interacting regions differently affect viral fusion and infectivity in vivo. Gatot JS, Callebaut I, Van Lint C, Demonté D, Kerkhofs P, Portetelle D, Burny A, Willems L, Kettmann R. J Virol 76 7956-7967 (2002)
  289. Crystal Structure of a Complex of the Intracellular Domain of Interferon λ Receptor 1 (IFNLR1) and the FERM/SH2 Domains of Human JAK1. Zhang D, Wlodawer A, Lubkowski J. J Mol Biol 428 4651-4668 (2016)
  290. Crystal structure and functional dissection of the cytostatic cytokine oncostatin M. Deller MC, Hudson KR, Ikemizu S, Bravo J, Jones EY, Heath JK. Structure 8 863-874 (2000)
  291. IL-27 structural analysis demonstrates similarities with ciliary neurotrophic factor (CNTF) and leads to the identification of antagonistic variants. Rousseau F, Basset L, Froger J, Dinguirard N, Chevalier S, Gascan H. Proc Natl Acad Sci U S A 107 19420-19425 (2010)
  292. Mutations in the WSAWSE and cytosolic domains of the erythropoietin receptor affect signal transduction and ligand binding and internalization. Quelle DE, Quelle FW, Wojchowski DM. Mol Cell Biol 12 4553-4561 (1992)
  293. Refined crystal structure and mutagenesis of human granulocyte-macrophage colony-stimulating factor. Rozwarski DA, Diederichs K, Hecht R, Boone T, Karplus PA. Proteins 26 304-313 (1996)
  294. Signal transduction mediated by growth hormone receptor and its chimeric molecules with the granulocyte colony-stimulating factor receptor. Ishizaka-Ikeda E, Fukunaga R, Wood WI, Goeddel DV, Nagata S. Proc Natl Acad Sci U S A 90 123-127 (1993)
  295. Site-specific chemical modification of proteins with a prelabelled cysteine tag using the artificially split Mxe GyrA intein. Kurpiers T, Mootz HD. Chembiochem 9 2317-2325 (2008)
  296. The Molecular Tweezer CLR01 Stabilizes a Disordered Protein-Protein Interface. Bier D, Mittal S, Bravo-Rodriguez K, Sowislok A, Guillory X, Briels J, Heid C, Bartel M, Wettig B, Brunsveld L, Sanchez-Garcia E, Schrader T, Ottmann C. J Am Chem Soc 139 16256-16263 (2017)
  297. Atomic force microscopy of insulin single crystals: direct visualization of molecules and crystal growth. Yip CM, Ward MD. Biophys J 71 1071-1078 (1996)
  298. Disruption of exon definition produces a dominant-negative growth hormone isoform that causes somatotroph death and IGHD II. Ryther RC, McGuinness LM, Phillips JA, Moseley CT, Magoulas CB, Robinson IC, Patton JG. Hum Genet 113 140-148 (2003)
  299. Insulin receptor activation with transmembrane domain ligands. Lee J, Miyazaki M, Romeo GR, Shoelson SE. J Biol Chem 289 19769-19777 (2014)
  300. Role of the growth hormone (GH) receptor transmembrane domain in receptor predimerization and GH-induced activation. Yang N, Wang X, Jiang J, Frank SJ. Mol Endocrinol 21 1642-1655 (2007)
  301. Scanning mutagenesis of the Arc repressor as a functional probe of operator recognition. Brown BM, Milla ME, Smith TL, Sauer RT. Nat Struct Biol 1 164-168 (1994)
  302. The membrane distal half of gp130 is responsible for the formation of a ternary complex with IL-6 and the IL-6 receptor. Horsten U, Schmitz-Van de Leur H, Müllberg J, Heinrich PC, Rose-John S. FEBS Lett 360 43-46 (1995)
  303. The molecular role of the common gamma c subunit in signal transduction reveals functional asymmetry within multimeric cytokine receptor complexes. Lai SY, Xu W, Gaffen SL, Liu KD, Longmore GD, Greene WC, Goldsmith MA. Proc Natl Acad Sci U S A 93 231-235 (1996)
  304. The structure and activity of a monomeric interferon-gamma:alpha-chain receptor signaling complex. Randal M, Kossiakoff AA. Structure 9 155-163 (2001)
  305. Characterization of critical residues in the cytoplasmic domain of the human interleukin-5 receptor alpha chain required for growth signal transduction. Cornelis S, Fache I, Van der Heyden J, Guisez Y, Tavernier J, Devos R, Fiers W, Plaetinck G. Eur J Immunol 25 1857-1864 (1995)
  306. Comparison of R128Q mutations in human, ovine, and chicken leptins. Raver N, Vardy E, Livnah O, Devos R, Gertler A. Gen Comp Endocrinol 126 52-58 (2002)
  307. Molecular modelling and experimental studies of mutation and cell-adhesion sites in the fibronectin type III and whey acidic protein domains of human anosmin-1. Robertson A, MacColl GS, Nash JA, Boehm MK, Perkins SJ, Bouloux PM. Biochem J 357 647-659 (2001)
  308. Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor. Underwood DJ, Strader CD, Rivero R, Patchett AA, Greenlee W, Prendergast K. Chem Biol 1 211-221 (1994)
  309. A fusion protein of interleukin-11 and soluble interleukin-11 receptor acts as a superagonist on cells expressing gp130. Pflanz S, Tacken I, Grötzinger J, Jacques Y, Minvielle S, Dahmen H, Heinrich PC, Müller-Newen G. FEBS Lett 450 117-122 (1999)
  310. Alternative views of functional protein binding epitopes obtained by combinatorial shotgun scanning mutagenesis. Pál G, Fong SY, Kossiakoff AA, Sidhu SS. Protein Sci 14 2405-2413 (2005)
  311. An automated method for modeling proteins on known templates using distance geometry. Srinivasan S, March CJ, Sudarsanam S. Protein Sci 2 277-289 (1993)
  312. Characterization of anti-anti-idiotypic antibodies that bind antigen and an anti-idiotype. Goldbaum FA, Velikovsky CA, Dall'Acqua W, Fossati CA, Fields BA, Braden BC, Poljak RJ, Mariuzza RA. Proc Natl Acad Sci U S A 94 8697-8701 (1997)
  313. Crystal structure of the human monocyte-activating receptor, "Group 2" leukocyte Ig-like receptor A5 (LILRA5/LIR9/ILT11). Shiroishi M, Kajikawa M, Kuroki K, Ose T, Kohda D, Maenaka K. J Biol Chem 281 19536-19544 (2006)
  314. Increased insulin-like growth factor 1 production by human osteoarthritic chondrocytes is not dependent on growth hormone action. Doré S, Abribat T, Rousseau N, Brazeau P, Tardif G, DiBattista JA, Cloutier JM, Pelletier JP, Martel-Pelletier J. Arthritis Rheum 38 413-419 (1995)
  315. Quantitative FRET imaging of leptin receptor oligomerization kinetics in single cells. Biener E, Charlier M, Ramanujan VK, Daniel N, Eisenberg A, Bjørbaek C, Herman B, Gertler A, Djiane J. Biol Cell 97 905-919 (2005)
  316. Two different epitopes of the signal transducer gp130 sequentially cooperate on IL-6-induced receptor activation. Pflanz S, Kurth I, Grötzinger J, Heinrich PC, Müller-Newen G. J Immunol 165 7042-7049 (2000)
  317. A long-acting, mono-PEGylated human growth hormone analog is a potent stimulator of weight gain and bone growth in hypophysectomized rats. Cox GN, Rosendahl MS, Chlipala EA, Smith DJ, Carlson SJ, Doherty DH. Endocrinology 148 1590-1597 (2007)
  318. Characterization of the receptor binding determinants of granulocyte colony stimulating factor. Young DC, Zhan H, Cheng QL, Hou J, Matthews DJ. Protein Sci 6 1228-1236 (1997)
  319. Expression of human growth hormone in transgenic rice cell suspension culture. Kim TG, Baek MY, Lee EK, Kwon TH, Yang MS. Plant Cell Rep 27 885-891 (2008)
  320. Glycosylation of human prolactin regulates hormone bioactivity and metabolic clearance. Hoffmann T, Penel C, Ronin C. J Endocrinol Invest 16 807-816 (1993)
  321. Identification of CD4 and major histocompatibility complex functional peptide sites and their homology with oligopeptides from human immunodeficiency virus type 1 glycoprotein gp120: role in AIDS pathogenesis. Zagury JF, Bernard J, Achour A, Astgen A, Lachgar A, Fall L, Carelli C, Issing W, Mbika JP, Picard O. Proc Natl Acad Sci U S A 90 7573-7577 (1993)
  322. Multiple cis-trans conformers of the prolactin receptor proline-rich motif (PRM) peptide detected by reverse-phase HPLC, CD and NMR spectroscopy. O'Neal KD, Chari MV, Mcdonald CH, Cook RG, Yu-Lee LY, Morrisett JD, Shearer WT. Biochem J 315 ( Pt 3) 833-844 (1996)
  323. Natriuretic peptide receptor A activation stabilizes a membrane-distal dimer interface. De Léan A, McNicoll N, Labrecque J. J Biol Chem 278 11159-11166 (2003)
  324. Predictive recognition of native proteins by cucurbit[7]uril in a complex mixture. Li W, Bockus AT, Vinciguerra B, Isaacs L, Urbach AR. Chem Commun (Camb) 52 8537-8540 (2016)
  325. Signaling cross talk between growth hormone (GH) and insulin-like growth factor-I (IGF-I) in pancreatic islet β-cells. Ma F, Wei Z, Shi C, Gan Y, Lu J, Frank SJ, Balducci J, Huang Y. Mol Endocrinol 25 2119-2133 (2011)
  326. Site2 binding energetics of the regulatory step of growth hormone-induced receptor homodimerization. Walsh ST, Jevitts LM, Sylvester JE, Kossiakoff AA. Protein Sci 12 1960-1970 (2003)
  327. Structural analysis and localization of the carbohydrate moieties of a soluble human interferon gamma receptor produced in baculovirus-infected insect cells. Manneberg M, Friedlein A, Kurth H, Lahm HW, Fountoulakis M. Protein Sci 3 30-38 (1994)
  328. A cytokine-cytokine interaction in the assembly of higher-order structure and activation of the interleukine-3:receptor complex. Dey R, Ji K, Liu Z, Chen L. PLoS One 4 e5188 (2009)
  329. Apo structure of the ligand-binding domain of aspartate receptor from Escherichia coli and its comparison with ligand-bound or pseudoligand-bound structures. Chi YI, Yokota H, Kim SH. FEBS Lett 414 327-332 (1997)
  330. Different forms of the prolactin receptor: insights into the mechanism of prolactin action. Kelly PA, Djiane J, Edery M. Trends Endocrinol Metab 3 54-59 (1992)
  331. Electrostatic stabilization in four-helix bundle proteins. Robinson CR, Sligar SG. Protein Sci 2 826-837 (1993)
  332. Fibronectin type III modules in the receptor phosphatase CD45 and tapeworm antigens. Bork P, Doolittle RF. Protein Sci 2 1185-1187 (1993)
  333. Heterozygous nonsense mutation in exon 3 of the growth hormone receptor (GHR) in severe GH insensitivity (Laron syndrome) and the issue of the origin and function of the GHRd3 isoform. Pantel J, Grulich-Henn J, Bettendorf M, Strasburger CJ, Heinrich U, Amselem S. J Clin Endocrinol Metab 88 1705-1710 (2003)
  334. Production of human growth hormone in transgenic rice seeds: co-introduction of RNA interference cassette for suppressing the gene expression of endogenous storage proteins. Shigemitsu T, Ozaki S, Saito Y, Kuroda M, Morita S, Satoh S, Masumura T. Plant Cell Rep 31 539-549 (2012)
  335. Small glutamine-rich tetratricopeptide repeat-containing protein (SGT) interacts with the ubiquitin-dependent endocytosis (UbE) motif of the growth hormone receptor. Schantl JA, Roza M, De Jong AP, Strous GJ. Biochem J 373 855-863 (2003)
  336. The 2.5 A resolution structure of the jel42 Fab fragment/HPr complex. Prasad L, Waygood EB, Lee JS, Delbaere LT. J Mol Biol 280 829-845 (1998)
  337. The rabbit mammary gland prolactin receptor is tyrosine-phosphorylated in response to prolactin in vivo and in vitro. Waters MJ, Daniel N, Bignon C, Djiane J. J Biol Chem 270 5136-5143 (1995)
  338. Duplication of accelerated evolution and growth hormone gene in passerine birds. Yuri T, Kimball RT, Braun EL, Braun MJ. Mol Biol Evol 25 352-361 (2008)
  339. Evidence for the formation of a heterotrimeric complex of leukaemia inhibitory factor with its receptor subunits in solution. Zhang JG, Owczarek CM, Ward LD, Howlett GJ, Fabri LJ, Roberts BA, Nicola NA. Biochem J 325 ( Pt 3) 693-700 (1997)
  340. Functional epitope of common gamma chain for interleukin-4 binding. Zhang JL, Buehner M, Sebald W. Eur J Biochem 269 1490-1499 (2002)
  341. Functional human antibody CDR fusions as long-acting therapeutic endocrine agonists. Liu T, Zhang Y, Liu Y, Wang Y, Jia H, Kang M, Luo X, Caballero D, Gonzalez J, Sherwood L, Nunez V, Wang D, Woods A, Schultz PG, Wang F. Proc Natl Acad Sci U S A 112 1356-1361 (2015)
  342. Mutagenesis in the C-terminal region of human interleukin 5 reveals a central patch for receptor alpha chain recognition. Morton T, Li J, Cook R, Chaiken I. Proc Natl Acad Sci U S A 92 10879-10883 (1995)
  343. Structural characterization of the stem-stem dimerization interface between prolactin receptor chains complexed with the natural hormone. van Agthoven J, Zhang C, Tallet E, Raynal B, Hoos S, Baron B, England P, Goffin V, Broutin I. J Mol Biol 404 112-126 (2010)
  344. The role of prolactin receptor in GH signaling in breast cancer cells. Xu J, Sun D, Jiang J, Deng L, Zhang Y, Yu H, Bahl D, Langenheim JF, Chen WY, Fuchs SY, Frank SJ. Mol Endocrinol 27 266-279 (2013)
  345. Transmembrane signalling and the aspartate receptor. Scott WG, Stoddard BL. Structure 2 877-887 (1994)
  346. Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. Giustina A, Ambrosio MR, Beck Peccoz P, Bogazzi F, Cannavo' S, De Marinis L, De Menis E, Grottoli S, Pivonello R. J Endocrinol Invest 37 1017-1030 (2014)
  347. A human interleukin 3 analog with increased biological and binding activities. Lopez AF, Shannon MF, Barry S, Phillips JA, Cambareri B, Dottore M, Simmons P, Vadas MA. Proc Natl Acad Sci U S A 89 11842-11846 (1992)
  348. Characterization of a soluble ternary complex formed between human interferon-beta-1a and its receptor chains. Arduini RM, Strauch KL, Runkel LA, Carlson MM, Hronowski X, Foley SF, Young CN, Cheng W, Hochman PS, Baker DP. Protein Sci 8 1867-1877 (1999)
  349. Genetic variation at the growth hormone (GH1) and growth hormone receptor (GHR) loci as a risk factor for hypertension and stroke. Horan M, Newsway V, Yasmin, Lewis MD, Easter TE, Rees DA, Mahto A, Millar DS, Procter AM, Scanlon MF, Wilkinson IB, Hall IP, Wheatley A, Blakey J, Bath PM, Cockcroft JR, Krawczak M, Cooper DN. Hum Genet 119 527-540 (2006)
  350. Human IL-21 and IL-4 bind to partially overlapping epitopes of common gamma-chain. Zhang JL, Foster D, Sebald W. Biochem Biophys Res Commun 300 291-296 (2003)
  351. In vitro mutagenesis of growth hormone receptor Asn-linked glycosylation sites. Harding PA, Wang XZ, Kelder B, Souza S, Okada S, Kopchick JJ. Mol Cell Endocrinol 106 171-180 (1994)
  352. Inter-species chimeras of leukaemia inhibitory factor define a major human receptor-binding determinant. Owczarek CM, Layton MJ, Metcalf D, Lock P, Willson TA, Gough NM, Nicola NA. EMBO J 12 3487-3495 (1993)
  353. Mass spectrometrical analysis of recombinant human growth hormone (Genotropin(R)) reveals amino acid substitutions in 2% of the expressed protein. Hepner F, Cszasar E, Roitinger E, Lubec G. Proteome Sci 3 1 (2005)
  354. Specific antiviral activities of the human alpha interferons are determined at the level of receptor (IFNAR) structure. Mouchel-Vielh E, Lutfalla G, Mogensen KE, Uzé G. FEBS Lett 313 255-259 (1992)
  355. The Src-like tyrosine kinase Hck is activated by granulocyte colony-stimulating factor (G-CSF) and docks to the activated G-CSF receptor. Ward AC, Monkhouse JL, Csar XF, Touw IP, Bello PA. Biochem Biophys Res Commun 251 117-123 (1998)
  356. The full agonistic effect of recombinant 20 kDa human growth hormone (hGH) on CHO cells stably transfected with hGH receptor cDNA. Wada M, Ikeda M, Takahashi Y, Asada N, Chang KT, Takahashi M, Honjo M. Mol Cell Endocrinol 133 99-107 (1997)
  357. Topology, sequence evolution and folding dynamics of an immunoglobulin domain. Parker MJ, Dempsey CE, Hosszu LL, Waltho JP, Clarke AR. Nat Struct Biol 5 194-198 (1998)
  358. Functional homodimeric glycoprotein hormones: implications for hormone action and evolution Moyle WR, Myers RV, Wang Y, Han Y, Lin W, Kelley GL, Ehrlich PH, Rao SV, Bernard MP. Chem Biol 5 241-254 (1998)
  359. G120R, a human growth hormone antagonist, shows zinc-dependent agonist and antagonist activity on Nb2 cells. Dattani MT, Hindmarsh PC, Brook CG, Robinson IC, Kopchick JJ, Marshall NJ. J Biol Chem 270 9222-9226 (1995)
  360. High-level production of human growth hormone in Escherichia coli by a simple recombinant process. Shin NK, Kim DY, Shin CS, Hong MS, Lee J, Shin HC. J Biotechnol 62 143-151 (1998)
  361. Homology model of human interferon-alpha 8 and its receptor complex. Seto MH, Harkins RN, Adler M, Whitlow M, Church WB, Croze E. Protein Sci 4 655-670 (1995)
  362. Identification of critical residues in the colicin E9 DNase binding region of the Im9 protein. Osborne MJ, Wallis R, Leung KY, Williams G, Lian LY, James R, Kleanthous C, Moore GR. Biochem J 323 ( Pt 3) 823-831 (1997)
  363. Insulin receptor-deficient cells as a new tool for dissecting complex interplay in insulin and insulin-like growth factors. Lamothe B, Baudry A, Christoffersen CT, De Meyts P, Jami J, Bucchini D, Joshi RL. FEBS Lett 426 381-385 (1998)
  364. Interleukin-5 receptor subunit oligomerization and rearrangement revealed by fluorescence resonance energy transfer imaging. Zaks-Zilberman M, Harrington AE, Ishino T, Chaiken IM. J Biol Chem 283 13398-13406 (2008)
  365. Saturation mutagenesis of human interleukin-3. Olins PO, Bauer SC, Braford-Goldberg S, Sterbenz K, Polazzi JO, Caparon MH, Klein BK, Easton AM, Paik K, Klover JA. J Biol Chem 270 23754-23760 (1995)
  366. The beta subunit of human granulocyte-macrophage colony-stimulating factor receptor forms a homodimer and is activated via association with the alpha subunit. Muto A, Watanabe S, Miyajima A, Yokota T, Arai K. J Exp Med 183 1911-1916 (1996)
  367. Analysis of human/mouse interleukin-6 hybrid proteins: both amino and carboxy termini of human interleukin-6 are required for in vitro receptor binding. Fiorillo MT, Cabibbo A, Iacopetti P, Fattori E, Ciliberto G. Eur J Immunol 22 2609-2615 (1992)
  368. Chimeric tumor necrosis factor receptors with constitutive signaling activity. Bazzoni F, Alejos E, Beutler B. Proc Natl Acad Sci U S A 92 5376-5380 (1995)
  369. Definition of receptor binding sites on human interleukin-11 by molecular modeling-guided mutagenesis. Tacken I, Dahmen H, Boisteau O, Minvielle S, Jacques Y, Grötzinger J, Küster A, Horsten U, Blanc C, Montero-Julian FA, Heinrich PC, Müller-Newen G. Eur J Biochem 265 645-655 (1999)
  370. Effect of three elution buffers on the recovery and structure of monoclonal antibodies. Narhi LO, Caughey DJ, Horan T, Kita Y, Chang D, Arakawa T. Anal Biochem 253 236-245 (1997)
  371. Helical fold prediction for the cyclin box. Bazan JF. Proteins 24 1-17 (1996)
  372. Human type I interferon receptor, IFNAR, is a heavily glycosylated 120-130 kD membrane protein. Ling LE, Zafari M, Reardon D, Brickelmeier M, Goelz SE, Benjamin CD. J Interferon Cytokine Res 15 55-61 (1995)
  373. Intramolecular cooperativity in a protein binding site assessed by combinatorial shotgun scanning mutagenesis. Pál G, Ultsch MH, Clark KP, Currell B, Kossiakoff AA, Sidhu SS. J Mol Biol 347 489-494 (2005)
  374. Novel CalphaNN structural motif for protein recognition of phosphate ions. Denessiouk KA, Johnson MS, Denesyuk AI. J Mol Biol 345 611-629 (2005)
  375. Post-genomic science: converting primary structure into physiological function. Benner SA, Trabesinger N, Schreiber D. Adv Enzyme Regul 38 155-180 (1998)
  376. Solution structure of an extracellular domain containing the WSxWS motif of the granulocyte colony-stimulating factor receptor and its interaction with ligand. Yamasaki K, Naito S, Anaguchi H, Ohkubo T, Ota Y. Nat Struct Biol 4 498-504 (1997)
  377. A growth hormone agonist produced by targeted mutagenesis at binding site 1. Evidence that site 1 regulates bioactivity. Rowlinson SW, Barnard R, Bastiras S, Robins AJ, Brinkworth R, Waters MJ. J Biol Chem 270 16833-16839 (1995)
  378. A model of the complex between interleukin-4 and its receptors. Gustchina A, Zdanov A, Schalk-Hihi C, Wlodawer A. Proteins 21 140-148 (1995)
  379. BIAcore: a microchip-based system for analyzing the formation of macromolecular complexes. Raghavan M, Bjorkman PJ. Structure 3 331-333 (1995)
  380. Characterization of a potent human interleukin-11 agonist. Harmegnies D, Wang XM, Vandenbussche P, Leon A, Vusio P, Grötzinger J, Jacques Y, Goormaghtigh E, Devreese B, Content J. Biochem J 375 23-32 (2003)
  381. Definition of a composite binding site for gp130 in human interleukin-6. Ciapponi L, Graziani R, Paonessa G, Lahm A, Ciliberto G, Savino R. J Biol Chem 270 31249-31254 (1995)
  382. Ligand-specific utilization of the extracellular membrane-proximal region of the gp130-related signalling receptors. Hammacher A, Wijdenes J, Hilton DJ, Nicola NA, Simpson RJ, Layton JE. Biochem J 345 Pt 1 25-32 (2000)
  383. Molecular evolution of growth hormone (GH) in Cetartiodactyla: cloning and characterization of the gene encoding GH from a primitive ruminant, the chevrotain (Tragulus javanicus). Wallis OC, Wallis M. Gen Comp Endocrinol 123 62-72 (2001)
  384. Neutralizing epitopes on the extracellular interferon gamma receptor (IFNgammaR) alpha-chain characterized by homolog scanning mutagenesis and X-ray crystal structure of the A6 fab-IFNgammaR1-108 complex. Sogabe S, Stuart F, Henke C, Bridges A, Williams G, Birch A, Winkler FK, Robinson JA. J Mol Biol 273 882-897 (1997)
  385. Secretin receptor oligomers form intracellularly during maturation through receptor core domains. Lisenbee CS, Miller LJ. Biochemistry 45 8216-8226 (2006)
  386. Structure of a phage display-derived variant of human growth hormone complexed to two copies of the extracellular domain of its receptor: evidence for strong structural coupling between receptor binding sites. Schiffer C, Ultsch M, Walsh S, Somers W, de Vos AM, Kossiakoff A. J Mol Biol 316 277-289 (2002)
  387. The membrane proximal region of the cytoplasmic domain of the growth hormone receptor is involved in the activation of Stat 3. Sotiropoulos A, Moutoussamy S, Binart N, Kelly PA, Finidori J. FEBS Lett 369 169-172 (1995)
  388. The resonant recognition model (RRM) predicts amino acid residues in highly conserved regions of the hormone prolactin (PRL). Hejase de Trad C, Fang Q, Cosic I. Biophys Chem 84 149-157 (2000)
  389. Use of immobilized synthetic peptides for the identification of contact sites between human interleukin-6 and its receptor. Weiergräber O, Schneider-Mergener J, Grötzinger J, Wollmer A, Küster A, Exner M, Heinrich PC. FEBS Lett 379 122-126 (1996)
  390. A generic method for expression and use of "tagged" soluble versions of cell surface receptors. Whitehorn EA, Tate E, Yanofsky SD, Kochersperger L, Davis A, Mortensen RB, Yonkovich S, Bell K, Dower WJ, Barrett RW. Biotechnology (N Y) 13 1215-1219 (1995)
  391. A third fibronectin type III domain in the extracellular region of the insulin receptor family. Marino-Buslje C, Mizuguchi K, Siddle K, Blundell TL. FEBS Lett 441 331-336 (1998)
  392. Activation of erythropoietin receptor in the absence of hormone by a peptide that binds to a domain different from the hormone binding site. Naranda T, Wong K, Kaufman RI, Goldstein A, Olsson L. Proc Natl Acad Sci U S A 96 7569-7574 (1999)
  393. Assessment of the aggregation state of integral membrane proteins in reconstituted phospholipid vesicles using small angle neutron scattering. Hunt JF, McCrea PD, Zaccaï G, Engelman DM. J Mol Biol 273 1004-1019 (1997)
  394. Identification of single amino acid residues of human IL-6 involved in receptor binding and signal initiation. Ehlers M, Grötzinger J, Fischer M, Bos HK, Brakenhoff JP, Rose-John S. J Interferon Cytokine Res 16 569-576 (1996)
  395. Inadequacy of the Janus kinase 2/signal transducer and activator of transcription signal transduction pathway to mediate episodic growth hormone-dependent regulation of hepatic CYP2C11. Verma AS, Dhir RN, Shapiro BH. Mol Pharmacol 67 891-901 (2005)
  396. Isolation of erythropoietin receptor agonist peptides using evolved phage libraries. McConnell SJ, Dinh T, Le MH, Brown SJ, Becherer K, Blumeyer K, Kautzer C, Axelrod F, Spinella DG. Biol Chem 379 1279-1286 (1998)
  397. Participation of two Ser-Ser-Phe-Tyr repeats in interleukin-6 (IL-6)-binding sites of the human IL-6 receptor. Kalai M, Montero-Julian FA, Grötzinger J, Wollmer A, Morelle D, Brochier J, Rose-John S, Heinrich PC, Brailly H, Content J. Eur J Biochem 238 714-723 (1996)
  398. Preparation and characterization of recombinant prolactin receptor extracellular domain from rat. Sandowski Y, Nagano M, Bignon C, Djiane J, Kelly PA, Gertler A. Mol Cell Endocrinol 115 1-11 (1995)
  399. Structural basis for binding multiple ligands by the common cytokine receptor gamma-chain. Olosz F, Malek TR. J Biol Chem 277 12047-12052 (2002)
  400. Structure analysis of the IL-5 ligand-receptor complex reveals a wrench-like architecture for IL-5Rα. Patino E, Kotzsch A, Saremba S, Nickel J, Schmitz W, Sebald W, Mueller TD. Structure 19 1864-1875 (2011)
  401. The activation and differential signalling of the growth hormone receptor induced by pGH or anti-idiotypic monoclonal antibodies in primary rat hepatocytes. Li W, Lan H, Liu H, Fu Z, Yang Y, Han W, Guo F, Liu Y, Zhang H, Liu J, Zheng X. Mol Cell Endocrinol 376 51-59 (2013)
  402. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists. Langenheim JF, Tan D, Walker AM, Chen WY. Mol Endocrinol 20 661-674 (2006)
  403. A dual role for the N-terminal domain of the IL-3 receptor in cell signalling. Broughton SE, Hercus TR, Nero TL, Kan WL, Barry EF, Dottore M, Cheung Tung Shing KS, Morton CJ, Dhagat U, Hardy MP, Wilson NJ, Downton MT, Schieber C, Hughes TP, Lopez AF, Parker MW. Nat Commun 9 386 (2018)
  404. Crucial role of the residue R280 at the F'-G' loop of the human granulocyte/macrophage colony-stimulating factor receptor alpha chain for ligand recognition. Rajotte D, Cadieux C, Haman A, Wilkes BC, Clark SC, Hercus T, Woodcock JA, Lopez A, Hoang T. J Exp Med 185 1939-1950 (1997)
  405. E-cadherin: a distant member of the immunoglobulin superfamily. Wagner G. Science 267 342 (1995)
  406. Evaluation of different primary recovery methods for E. coli-derived recombinant human growth hormone and compatibility with further down-stream purification. Persson J, Andersen DC, Lester PM. Biotechnol Bioeng 90 442-451 (2005)
  407. Expression and localization of growth hormone and its receptors in the chicken ovary during sexual maturation. Hrabia A, Paczoska-Eliasiewicz HE, Berghman LR, Harvey S, Rzasa J. Cell Tissue Res 332 317-328 (2008)
  408. Identification of a ligand-binding site on the granulocyte colony-stimulating factor receptor by molecular modeling and mutagenesis. Layton JE, Iaria J, Smith DK, Treutlein HR. J Biol Chem 272 29735-29741 (1997)
  409. Influence of methionine oxidation on the aggregation of recombinant human growth hormone. Mulinacci F, Poirier E, Capelle MA, Gurny R, Arvinte T. Eur J Pharm Biopharm 85 42-52 (2013)
  410. Integrin receptor specificity for human red cell ICAM-4 ligand. Critical residues for alphaIIbeta3 binding. Hermand P, Gane P, Callebaut I, Kieffer N, Cartron JP, Bailly P. Eur J Biochem 271 3729-3740 (2004)
  411. Interaction of granulocyte colony-stimulating factor (G-CSF) with its receptor. Evidence that Glu19 of G-CSF interacts with Arg288 of the receptor. Layton JE, Shimamoto G, Osslund T, Hammacher A, Smith DK, Treutlein HR, Boone T. J Biol Chem 274 17445-17451 (1999)
  412. Lutropins appear to contact two independent sites in the extracellular domain of their receptors. Bernard MP, Myers RV, Moyle WR. Biochem J 335 ( Pt 3) 611-617 (1998)
  413. Multiple conformations of a human interleukin-3 variant. Feng Y, Hood WF, Forgey RW, Abegg AL, Caparon MH, Thiele BR, Leimgruber RM, McWherter CA. Protein Sci 6 1777-1782 (1997)
  414. Neurotrophin-3 acquires NGF-like activity after exchange to five NGF amino acid residues: molecular analysis of the sites in NGF mediating the specific interaction with the NGF high affinity receptor. Kullander K, Ebendal T. J Neurosci Res 39 195-210 (1994)
  415. Pierced Lasso Bundles are a new class of knot-like motifs. Haglund E, Sulkowska JI, Noel JK, Lammert H, Onuchic JN, Jennings PA. PLoS Comput Biol 10 e1003613 (2014)
  416. Polymorphic structural features of modelled HLA-DQ molecules segregate according to susceptibility or resistance to IDDM. Routsias J, Papadopoulos GK. Diabetologia 38 1251-1261 (1995)
  417. Precise and combinatorial PEGylation generates a low-immunogenic and stable form of human growth hormone. Wu L, Chen J, Wu Y, Zhang B, Cai X, Zhang Z, Wang Y, Si L, Xu H, Zheng Y, Zhang C, Liang C, Li J, Zhang L, Zhang Q, Zhou D. J Control Release 249 84-93 (2017)
  418. Radiation inactivation of human gamma-interferon: cellular activation requires two dimers. Langer JA, Rashidbaigi A, Garotta G, Kempner E. Proc Natl Acad Sci U S A 91 5818-5822 (1994)
  419. Rare inborn errors associated with chronic hepatitis B virus infection. Zhao Q, Peng L, Huang W, Li Q, Pei Y, Yuan P, Zheng L, Zhang Y, Deng J, Zhong C, Hu B, Ding H, Fang W, Li R, Liao Q, Lin C, Deng W, Yan H, Hou J, Wu Q, Xu T, Liu J, Hu L, Peng T, Chen S, Lai KN, Yuen MF, Wang Y, Maini MK, Li C, Li M, Wang J, Zhang X, Sham PC, Wang J, Gao ZL, Wang Y. Hepatology 56 1661-1670 (2012)
  420. Rationalizing 5000-fold differences in receptor-binding rate constants of four cytokines. Pang X, Qin S, Zhou HX. Biophys J 101 1175-1183 (2011)
  421. The solution structure of the cytokine-binding domain of the common beta-chain of the receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3 and interleukin-5. Mulhern TD, Lopez AF, D'Andrea RJ, Gaunt C, Vandeleur L, Vadas MA, Booker GW, Bagley CJ. J Mol Biol 297 989-1001 (2000)
  422. A hydrophobic segment within the 81-amino-acid domain of TFIIIA from Saccharomyces cerevisiae is essential for its transcription factor activity. Rowland O, Segall J. Mol Cell Biol 18 420-432 (1998)
  423. A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist. Wilkinson IR, Ferrandis E, Artymiuk PJ, Teillot M, Soulard C, Touvay C, Pradhananga SL, Justice S, Wu Z, Leung KC, Strasburger CJ, Sayers JR, Ross RJ. Nat Med 13 1108-1113 (2007)
  424. Bushbaby growth hormone is much more similar to nonprimate growth hormones than to rhesus monkey and human growth hormones. Adkins RM, Nekrutenko A, Li WH. Mol Biol Evol 18 55-60 (2001)
  425. Differential intracellular signalling properties of the growth hormone receptor induced by the activation of an anti-GHR antibody. Lan H, Li W, Fu Z, Yang Y, Wu T, Liu Y, Zhang H, Cui H, Li Y, Hong P, Liu J, Zheng X. Mol Cell Endocrinol 390 54-64 (2014)
  426. Erythropoietin receptor (EpoR)-dependent mitogenicity of spleen focus-forming virus correlates with viral pathogenicity and processing of env protein but not with formation of gp52-EpoR complexes in the endoplasmic reticulum. Wang Y, Kayman SC, Li JP, Pinter A. J Virol 67 1322-1327 (1993)
  427. Evidence for the ligand-induced conversion from a dimer to a tetramer of the granulocyte colony-stimulating factor receptor. Hiraoka O, Anaguchi H, Ota Y. FEBS Lett 356 255-260 (1994)
  428. Growth hormone receptor targeting to lipid rafts requires extracellular subdomain 2. Yang N, Jiang J, Deng L, Waters MJ, Wang X, Frank SJ. Biochem Biophys Res Commun 391 414-418 (2010)
  429. His499 Regulates Dimerization and Prevents Oncogenic Activation by Asparagine Mutations of the Human Thrombopoietin Receptor. Leroy E, Defour JP, Sato T, Dass S, Gryshkova V, Shwe MM, Staerk J, Constantinescu SN, Smith SO. J Biol Chem 291 2974-2987 (2016)
  430. Identification of a ligand-binding site in an immunoglobulin fold domain of the Saccharomyces cerevisiae adhesion protein alpha-agglutinin. de Nobel H, Lipke PN, Kurjan J. Mol Biol Cell 7 143-153 (1996)
  431. Identification of functional sites on bovine leukemia virus envelope glycoproteins using structural and immunological data. Callebaut I, Portetelle D, Burny A, Mornon JP. Eur J Biochem 222 405-414 (1994)
  432. Identification of the domain in the human interleukin-11 receptor that mediates ligand binding. Schleinkofer K, Dingley A, Tacken I, Federwisch M, Müller-Newen G, Heinrich PC, Vusio P, Jacques Y, Grötzinger J. J Mol Biol 306 263-274 (2001)
  433. Interleukin-3 binding to the murine betaIL-3 and human betac receptors involves functional epitopes formed by domains 1 and 4 of different protein chains. Murphy JM, Ford SC, Olsen JE, Gustin SE, Jeffrey PD, Ollis DL, Young IG. J Biol Chem 279 26500-26508 (2004)
  434. Isolation and characterization of a trisulfide variant of recombinant human growth hormone formed during expression in Escherichia coli. Andersson C, Edlund PO, Gellerfors P, Hansson Y, Holmberg E, Hult C, Johansson S, Kördel J, Lundin R, Mendel-Hartvig IB, Norén B, Wehler T, Widmalm G, Ohman J. Int J Pept Protein Res 47 311-321 (1996)
  435. Separation of oxidized and deamidated human growth hormone variants by isocratic reversed-phase high-performance liquid chromatography. Karlsson G, Gellerfors P, Persson A, Norén B, Edlund PO, Sandberg C, Birnbaum S. J Chromatogr A 855 147-155 (1999)
  436. The N-terminus of gp130 is critical for the formation of the high-affinity interleukin-6 receptor complex. Moritz RL, Ward LD, Tu GF, Fabri LJ, Ji H, Yasukawa K, Simpson RJ. Growth Factors 16 265-278 (1999)
  437. Analytically defined surfaces to analyze molecular interaction properties. Gabdoulline RR, Wade RC. J Mol Graph 14 341-53, 374-5 (1996)
  438. Computational detection of the binding-site hot spot at the remodeled human growth hormone-receptor interface. Verkhivker GM, Bouzida D, Gehlhaar DK, Rejto PA, Freer ST, Rose PW. Proteins 53 201-219 (2003)
  439. Crystal structure and site 1 binding energetics of human placental lactogen. Walsh ST, Kossiakoff AA. J Mol Biol 358 773-784 (2006)
  440. Effects of triacontanol on ascorbate-glutathione cycle in Brassica napus L. exposed to cadmium-induced oxidative stress. Asadi Karam E, Maresca V, Sorbo S, Keramat B, Basile A. Ecotoxicol Environ Saf 144 268-274 (2017)
  441. Functional promiscuity of squirrel monkey growth hormone receptor toward both primate and nonprimate growth hormones. Yi S, Bernat B, Pál G, Kossiakoff A, Li WH. Mol Biol Evol 19 1083-1092 (2002)
  442. Grouper interleukin-12, linked by an ancient disulfide-bond architecture, exhibits cytokine and chemokine activities. Tsai JL, Priya TA, Hu KY, Yan HY, Shen ST, Song YL. Fish Shellfish Immunol 36 27-37 (2014)
  443. Identification of amino acid residues of gp130 signal transducer and gp80 alpha receptor subunit that are involved in ligand binding and signaling by human herpesvirus 8-encoded interleukin-6. Li H, Nicholas J. J Virol 76 5627-5636 (2002)
  444. Identification, isolation, and cloning of growth hormone (GH)-inducible interscapular brown adipose complementary deoxyribonucleic acid from GH antagonist mice. Li Y, Kelder B, Kopchick JJ. Endocrinology 142 2937-2945 (2001)
  445. Members of the insulin receptor family contain three fibronectin type III domains. Ward CW. Growth Factors 16 315-322 (1999)
  446. Molecular modeling of the GM-CSF and IL-3 receptor complexes. Lyne PD, Bamborough P, Duncan D, Richards WG. Protein Sci 4 2223-2233 (1995)
  447. The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the effect on the human prolactin receptor. Tsunekawa B, Wada M, Ikeda M, Uchida H, Naito N, Honjo M. Endocrinology 140 3909-3918 (1999)
  448. Three-dimensional structural model of the serine receptor ligand-binding domain. Jeffery CJ, Koshland DE. Protein Sci 2 559-566 (1993)
  449. A dimeric ternary complex of FGFR [correction of FGFR1], heparin and FGF-1 leads to an 'electrostatic sandwich' model for heparin binding. Huhtala MT, Pentikäinen OT, Johnson MS. Structure 7 699-709 (1999)
  450. Direct binding of Shc, Grb2, SHP-2 and p40 to the murine granulocyte colony-stimulating factor receptor. Ward AC, Monkhouse JL, Hamilton JA, Csar XF. Biochim Biophys Acta 1448 70-76 (1998)
  451. Effect of maternal dexamethasone treatment and ambient temperature on prolactin receptor abundance in Brown adipose and hepatic tissue in the foetus and new-born lamb. Bispham J, Heasman L, Clarke L, Ingleton PM, Stephenson T, Symonds ME. J Neuroendocrinol 11 849-856 (1999)
  452. Evolution of growth hormone in primates: the GH gene clusters of the New World monkeys marmoset (Callithrix jacchus) and white-fronted capuchin (Cebus albifrons). Wallis OC, Wallis M. J Mol Evol 63 591-601 (2006)
  453. Functional characterization of c-Mpl ectodomain mutations that underlie congenital amegakaryocytic thrombocytopenia. Varghese LN, Zhang JG, Young SN, Willson TA, Alexander WS, Nicola NA, Babon JJ, Murphy JM. Growth Factors 32 18-26 (2014)
  454. Increased site 1 affinity improves biopotency of porcine growth hormone. Evidence against diffusion dependent receptor dimerization. Wan Y, McDevitt A, Shen B, Smythe ML, Waters MJ. J Biol Chem 279 44775-44784 (2004)
  455. Induction of anchorage independent growth by heparin-binding EGF-like growth factor (HB-EGF). Harding PA, Davis-Fleischer KM, Crissman-Combs MA, Miller MT, Brigstock DR, Besner GE. Growth Factors 17 49-61 (1999)
  456. Interaction of lactogenic hormones with purified recombinant extracellular domain of rabbit prolactin receptor expressed in insect cells. Gertler A, Petridou B, Kriwi GG, Djiane J. FEBS Lett 319 277-281 (1993)
  457. Modeling and experimental validation of the binary complex of the plectin actin-binding domain and the first pair of fibronectin type III (FNIII) domains of the beta4 integrin. Litjens SH, Wilhelmsen K, de Pereda JM, Perrakis A, Sonnenberg A. J Biol Chem 280 22270-22277 (2005)
  458. Probing the structure of human growth hormone by limited proteolysis. Polverino de Laureto P, Toma S, Tonon G, Fontana A. Int J Pept Protein Res 45 200-208 (1995)
  459. The upper cytokine-binding module and the Ig-like domain of the leukaemia inhibitory factor (LIF) receptor are sufficient for a functional LIF receptor complex. Aasland D, Oppmann B, Grötzinger J, Rose-John S, Kallen KJ. J Mol Biol 315 637-646 (2002)
  460. Turning the growth hormone receptor on: evidence that hormone binding induces subunit rotation. Poger D, Mark AE. Proteins 78 1163-1174 (2010)
  461. A rapid, quantitative functional assay for measuring leptin. Rosenblum CI, Vongs A, Tota MR, Varnerin JP, Frazier E, Cully DF, Morsy MA, Van der Ploeg LH. Mol Cell Endocrinol 143 117-123 (1998)
  462. Allosteric effects of monoclonal antibodies on human growth hormone. Aguilar RC, Retegui LA, Postel-Vinay MC, Roguin LP. Mol Cell Biochem 136 35-42 (1994)
  463. Computational analysis of ligand binding dynamics at the intermolecular hot spots with the aid of simulated tempering and binding free energy calculations. Verkhivker GM. J Mol Graph Model 22 335-348 (2004)
  464. High-level expression and purification of recombinant human growth hormone produced in soluble form in Escherichia coli. Levarski Z, Šoltýsová A, Krahulec J, Stuchlík S, Turňa J. Protein Expr Purif 100 40-47 (2014)
  465. Resonance assignments for Oncostatin M, a 24-kDa alpha-helical protein. Hoffman RC, Moy FJ, Price V, Richardson J, Kaubisch D, Frieden EA, Krakover JD, Castner BJ, King J, March CJ, Powers R. J Biomol NMR 7 273-282 (1996)
  466. Selective complexation of N-alkylpyridinium salts: binding of NAD+ in water. Fokkens M, Jasper C, Schrader T, Koziol F, Ochsenfeld C, Polkowska J, Lobert M, Kahlert B, Klärner FG. Chemistry 11 477-494 (2005)
  467. The growth hormone receptor associates with Jak1, Jak2 and Tyk2 in human liver. Hellgren G, Jansson JO, Carlsson LM, Carlsson B. Growth Horm IGF Res 9 212-218 (1999)
  468. The signal transducer gp130: solution structure of the carboxy-terminal domain of the cytokine receptor homology region. Kernebeck T, Pflanz S, Müller-Newen G, Kurapkat G, Scheek RM, Dijkstra K, Heinrich PC, Wollmer A, Grzesiek S, Grötzinger J. Protein Sci 8 5-12 (1999)
  469. The therapeutic potential of interleukin-6 hyperagonists and antagonists. Kallen KJ, zum Büschenfelde KH, Rose-John S. Expert Opin Investig Drugs 6 237-266 (1997)
  470. Thermodynamic characterization of an intermediate state of human growth hormone. Gomez-Orellana I, Variano B, Miura-Fraboni J, Milstein S, Paton DR. Protein Sci 7 1352-1358 (1998)
  471. A computer model of the interleukin-4/receptor complex. Bamborough P, Grant GH, Hedgecock CJ, West SP, Richards WG. Proteins 17 11-19 (1993)
  472. A homology model of human interferon alpha-2. Murgolo NJ, Windsor WT, Hruza A, Reichert P, Tsarbopoulos A, Baldwin S, Huang E, Pramanik B, Ealick S, Trotta PP. Proteins 17 62-74 (1993)
  473. Letter A third fibronectin-type-III domain in the insulin-family receptors. Mulhern TD, Booker GW, Cosgrove L. Trends Biochem Sci 23 465-466 (1998)
  474. Activation of membrane receptors. Ji TH, Murdoch WJ, Ji I. Endocrine 3 187-194 (1995)
  475. An immobilised peptide array identifies antibodies to a discontinuous epitope in the extracellular domain of the bovine growth hormone receptor. Beattie J, Shand JH, Flint DJ. Eur J Biochem 239 479-486 (1996)
  476. Ciliary neurotrophic factor, cardiotrophin-like cytokine, and neuropoietin share a conserved binding site on the ciliary neurotrophic factor receptor alpha chain. Rousseau F, Chevalier S, Guillet C, Ravon E, Diveu C, Froger J, Barbier F, Grimaud L, Gascan H. J Biol Chem 283 30341-30350 (2008)
  477. Comparative model building of interleukin-7 using interleukin-4 as a template: a structural hypothesis that displays atypical surface chemistry in helix D important for receptor activation. Cosenza L, Rosenbach A, White JV, Murphy JR, Smith T. Protein Sci 9 916-926 (2000)
  478. D1 cap region involved in the receptor recognition and neural cell survival activity of human ciliary neurotrophic factor. Inoue M, Nakayama C, Kikuchi K, Kimura T, Ishige Y, Ito A, Kanaoka M, Noguchi H. Proc Natl Acad Sci U S A 92 8579-8583 (1995)
  479. Growth hormone receptor interaction with Jak proteins differs between tissues. Hellgren G, Albertsson-Wikland K, Billig H, Carlsson LM, Carlsson B. J Interferon Cytokine Res 21 75-83 (2001)
  480. Neutralizing monoclonal antibodies define two different functional sites in human interleukin-4. Reusch P, Arnold S, Heusser C, Wagner K, Weston B, Sebald W. Eur J Biochem 222 491-499 (1994)
  481. Role of the C-terminus in the activity, conformation, and stability of interleukin-6. Ward LD, Hammacher A, Zhang JG, Weinstock J, Yasukawa K, Morton CJ, Norton RS, Simpson RJ. Protein Sci 2 1472-1481 (1993)
  482. Selective complexation of N-alkylpyridinium salts: recognition of NAD+ in water. Jasper C, Schrader T, Panitzky J, Klärner FG. Angew Chem Int Ed Engl 41 1355-1358 (2002)
  483. Signaling by the cytokine receptor superfamily just another kinase story. Ihle JN. Trends Endocrinol Metab 5 137-143 (1994)
  484. Structural Mimicry of Receptor Interaction by Antagonistic Interleukin-6 (IL-6) Antibodies. Blanchetot C, De Jonge N, Desmyter A, Ongenae N, Hofman E, Klarenbeek A, Sadi A, Hultberg A, Kretz-Rommel A, Spinelli S, Loris R, Cambillau C, de Haard H. J Biol Chem 291 13846-13854 (2016)
  485. A 40-amino acid segment of the growth hormone receptor cytoplasmic domain is essential for GH-induced tyrosine-phosphorylated cytosolic proteins. Wang X, Souza SC, Kelder B, Cioffi JA, Kopchick JJ. J Biol Chem 270 6261-6266 (1995)
  486. Brazilian multicenter study on pegvisomant treatment in acromegaly. Boguszewski CL, Huayllas MKP, Vilar L, Naves LA, Ribeiro-Oliveira Junior A, Soares BS, Czepielewski MA, Abucham J, Correa-Silva SR, Bronstein MD, Jallad RS, Duarte FG, Musolino NR, Kasuki L, Gadelha MR. Arch Endocrinol Metab 63 328-336 (2019)
  487. Cysteine induces longitudinal bone growth in mice by upregulating IGF-I. Moon PD, Kim MH, Oh HA, Nam SY, Han NR, Jeong HJ, Kim HM. Int J Mol Med 36 571-576 (2015)
  488. Development of a long acting human growth hormone analog suitable for once a week dosing. Palanki MS, Bhat A, Bolanos B, Brunel F, Del Rosario J, Dettling D, Horn M, Lappe R, Preston R, Sievers A, Stankovic N, Woodnut G, Chen G. Bioorg Med Chem Lett 23 402-406 (2013)
  489. Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development. Haque A, Sahu V, Lombardo JL, Xiao L, George B, Wolff RA, Morris JS, Rashid A, Kopchick JJ, Kaseb AO, Amin HM. J Hepatocell Carcinoma 9 823-837 (2022)
  490. Evidence for positive selection on the leptin gene in Cetacea and Pinnipedia. Yu L, Jin W, Zhang X, Wang D, Zheng JS, Yang G, Xu SX, Cho S, Zhang YP. PLoS One 6 e26579 (2011)
  491. Expression, crystallization and derivatization of the complete extracellular domain of the beta(c) subunit of the human IL-5, IL-3 and GM-CSF receptors. Gustin SE, Church AP, Ford SC, Mann DA, Carr PD, Ollis DL, Young IG. Eur J Biochem 268 2905-2911 (2001)
  492. Human Growth Hormone Adsorption Kinetics and Conformation on Self-Assembled Monolayers. Buijs J, Britt DW, Hlady V. Langmuir 14 335-341 (1998)
  493. Human thrombopoietin structure-function relationships: identification of functionally important residues. Jagerschmidt A, Fleury V, Anger-Leroy M, Thomas C, Agnel M, O'brien DP. Biochem J 333 ( Pt 3) 729-734 (1998)
  494. Ligand-induced distortion of an active site in thymidylate synthase upon binding anticancer drug 1843U89. Weichsel A, Montfort WR. Nat Struct Biol 2 1095-1101 (1995)
  495. Multimeric cytokine receptors. Kitamura T, Ogorochi T, Miyajima A. Trends Endocrinol Metab 5 8-14 (1994)
  496. O-Glycosylated 24 kDa human growth hormone has a mucin-like biantennary disialylated tetrasaccharide attached at Thr-60. Bustamante JJ, Gonzalez L, Carroll CA, Weintraub ST, Aguilar RM, Muñoz J, Martinez AO, Haro LS. Proteomics 9 3474-3488 (2009)
  497. Production of a biologically active recombinant teleostean growth hormone in E. coli cells. Cheng CM, Lin CM, Shamblott M, Gonzalez-Villasenor LI, Powers DA, Woods C, Chen TT. Mol Cell Endocrinol 108 75-85 (1995)
  498. RGD sequences in several receptor proteins: novel cell adhesion function of receptors? Papadopoulos GK, Ouzounis C, Eliopoulos E. Int J Biol Macromol 22 51-57 (1998)
  499. Severe growth hormone insensitivity (Laron syndrome) due to nonsense mutation of the GH receptor in brothers from Russia. Rosenbloom AL, Berg MA, Kasatkina EP, Volkova TN, Skorobogatova VF, Sokolovskaya VN, Francke U. J Pediatr Endocrinol Metab 8 159-165 (1995)
  500. 16 kDa vasoinhibin binds to integrin alpha5 beta1 on endothelial cells to induce apoptosis. Morohoshi K, Mochinaga R, Watanabe T, Nakajima R, Harigaya T. Endocr Connect 7 630-636 (2018)
  501. Acute effects of rat growth hormone (GH), human GH and prolactin on proliferating rat liver cells in vitro: a study of mitotic behaviour and ultrastructural alterations. Vergani G, Mayerhofer A, Bartke A. Tissue Cell 26 457-465 (1994)
  502. Clarifying the role of cryo- and lyo-protectants in the biopreservation of proteins. Arsiccio A, Pisano R. Phys Chem Chem Phys 20 8267-8277 (2018)
  503. Deletions in one domain of the Friend virus-encoded membrane glycoprotein overcome host range restrictions for erythroleukemia. Hoatlin ME, Ferro FE, Geib RW, Fox MT, Kozak SL, Kabat D. J Virol 69 856-863 (1995)
  504. Diabetes-associated mutations in a beta-cell transcription factor destabilize an antiparallel "mini-zipper" in a dimerization interface. Hua QX, Zhao M, Narayana N, Nakagawa SH, Jia W, Weiss MA. Proc Natl Acad Sci U S A 97 1999-2004 (2000)
  505. Direct evidence that lactogenic hormones induce homodimerization of membrane-anchored prolactin receptor in intact Nb2-11C rat lymphoma cells. Sakal E, Elberg G, Gertler A. FEBS Lett 410 289-292 (1997)
  506. Dynamic analysis of GH receptor conformational changes by split luciferase complementation. Liu Y, Berry PA, Zhang Y, Jiang J, Lobie PE, Paulmurugan R, Langenheim JF, Chen WY, Zinn KR, Frank SJ. Mol Endocrinol 28 1807-1819 (2014)
  507. Episodic molecular evolution of pituitary growth hormone in Cetartiodactyla. Maniou Z, Wallis OC, Wallis M. J Mol Evol 58 743-753 (2004)
  508. Escherichia coli periplasmic chaperone FaeE is a homodimer and the chaperone-K88 subunit complex is a heterotrimer. Mol O, Visschers RW, de Graff FK, Oudega B. Mol Microbiol 11 391-402 (1994)
  509. Homology modelling and 1H NMR studies of human leukaemia inhibitory factor. Smith DK, Treutlein HR, Maurer T, Owczarek CM, Layton MJ, Nicola NA, Norton RS. FEBS Lett 350 275-280 (1994)
  510. Identification of a region critical for proteolysis of the human growth hormone receptor. Conte F, Salles JP, Raynal P, Fernandez L, Molinas C, Tauber M, Bieth E. Biochem Biophys Res Commun 290 851-857 (2002)
  511. Interferon gamma receptor extracellular domain expressed as IgG fusion protein in Chinese hamster ovary cells. Purification, biochemical characterization, and stoichiometry of binding. Fountoulakis M, Mesa C, Schmid G, Gentz R, Manneberg M, Zulauf M, Dembic Z, Garotta G. J Biol Chem 270 3958-3964 (1995)
  512. Leucine-58 in the putative 5th helical region of human interleukin (IL)-6 is important for activation of the IL-6 signal transducer, gp130. de Hon FD, Klaasse Bos HK, Ebeling SB, Grötzinger J, Kurapkat G, Rose-John S, Aarden LA, Brakenhoff JP. FEBS Lett 369 187-191 (1995)
  513. Long-distance conformational changes in a protein engineered by modulated sequence duplication. Sagermann M, Gay L, Matthews BW. Proc Natl Acad Sci U S A 100 9191-9195 (2003)
  514. Mechanisms of Signal Transduction from Receptors of Type I and Type II Cytokines. Fujii H. J Immunotoxicol 4 69-76 (2007)
  515. Mode of receptor binding and activation by plasminogen-related growth factors. Miller M, Leonard EJ. FEBS Lett 429 1-3 (1998)
  516. Molecular and structural advances in tissue factor-dependent coagulation. Kirchhofer D, Banner DW. Trends Cardiovasc Med 7 316-324 (1997)
  517. Obligate ordered binding of human lactogenic cytokines. Voorhees JL, Brooks CL. J Biol Chem 285 20022-20030 (2010)
  518. Pharmacological characterization of a biosynthetic trisulfide-containing hydrophobic derivative of human growth hormone: comparison with standard 22 K growth hormone. Thomsen MK, Hansen BS, Nilsson P, Nowak J, Johansen PB, Thomsen PD, Christiansen J. Pharmacol Toxicol 74 351-358 (1994)
  519. Proteasome and thiol involvement in quality control of glycosylphosphatidylinositol anchor addition. Wilbourn B, Nesbeth DN, Wainwright LJ, Field MC. Biochem J 332 ( Pt 1) 111-118 (1998)
  520. Protein-protein alternative binding modes do not overlap. Kundrotas PJ, Vakser IA. Protein Sci 22 1141-1145 (2013)
  521. Selective binding and oligomerization of the murine granulocyte colony-stimulating factor receptor by a low molecular weight, nonpeptidyl ligand. Doyle ML, Tian SS, Miller SG, Kessler L, Baker AE, Brigham-Burke MR, Dillon SB, Duffy KJ, Keenan RM, Lehr R, Rosen J, Schneeweis LA, Trill J, Young PR, Luengo JI, Lamb P. J Biol Chem 278 9426-9434 (2003)
  522. Structural features of Escherichia coli heat-stable enterotoxin that activates membrane-associated guanylyl cyclase. Sato T, Shimonishi Y. J Pept Res 63 200-206 (2004)
  523. Subdomain 2, Not the Transmembrane Domain, Determines the Dimerization Partner of Growth Hormone Receptor and Prolactin Receptor. Liu Y, Jiang J, Lepik B, Zhang Y, Zinn KR, Frank SJ. Endocrinology 158 3235-3248 (2017)
  524. The Interleukin-4-Receptor: From Recognition Mechanism to Pharmacological Target Structure. Reinemer P, Sebald W, Duschl A. Angew Chem Int Ed Engl 39 2834-2846 (2000)
  525. The effect of bovine somatotropin and diet on somatotropin binding sites in hepatic tissue of lactating dairy cows. Newbold JA, Heap RB, Prosser CG, Phipps RH, Adriaens F, Hard DL. J Dairy Sci 80 1085-1091 (1997)
  526. A structural model of the human thrombopoietin receptor complex. Deane CM, Kroemer RT, Richards WG. J Mol Graph Model 15 170-8, 185-8 (1997)
  527. Binding and signalling properties of a growth hormone enhancing monoclonal antibody. Beattie J, Bramani S, Secchi C, Mockridge J. Mol Cell Biochem 198 61-67 (1999)
  528. Biological activity of bovine placental lactogen in 3T3-F442A preadipocytes is mediated through a somatogenic receptor. Vashdi D, Elberg G, Sakal E, Gertler A. FEBS Lett 305 101-104 (1992)
  529. Direct evidence of a heterotrimeric complex of human interleukin-4 with its receptors. Hoffman RC, Castner BJ, Gerhart M, Gibson MG, Rasmussen BD, March CJ, Weatherbee J, Tsang M, Gustchina A, Schalk-Hihi C. Protein Sci 4 382-386 (1995)
  530. Engineering an interfacial zinc site to increase hormone-receptor affinity. Matthews DJ, Wells JA. Chem Biol 1 25-30 (1994)
  531. Generation of growth hormone binding protein by avian growth plate chondrocytes is dependent on cell differentiation. Monsonego E, Baumbach WR, Lavelin I, Gertler A, Hurwitz S, Pines M. Mol Cell Endocrinol 135 1-10 (1997)
  532. Growth hormone-induced JAK2 signaling and GH receptor down-regulation: role of GH receptor intracellular domain tyrosine residues. Deng L, Jiang J, Frank SJ. Endocrinology 153 2311-2322 (2012)
  533. Heterozygous mutation in the WSXWS equivalaent motif of the growth hormone receptor in a child with poor response to growth hormone therapy. Tauber MT, Porra V, Dastot F, Molinas C, Amselem S, Cholin S, Rochiccioli P, Bieth E. Growth Horm IGF Res 8 211-216 (1998)
  534. Human growth hormone fragment (hGH44-91) produces insulin resistance and hyperinsulinemia but is less potent than 22 kDa hGH in the rat. Hettiarachchi M, Watkinson A, Leung KC, Sinha YN, Ho KK, Kraegen EW. Endocrine 6 47-52 (1997)
  535. Ligand-induced internalization and phosphorylation-dependent degradation of growth hormone receptor in human IM-9 cells. Saito Y, Teshima R, Yamazaki T, Ikebuchi H, Sawada J. Mol Cell Endocrinol 106 67-74 (1994)
  536. Mammalian genome projects reveal new growth hormone (GH) sequences. Characterization of the GH-encoding genes of armadillo (Dasypus novemcinctus), hedgehog (Erinaceus europaeus), bat (Myotis lucifugus), hyrax (Procavia capensis), shrew (Sorex araneus), ground squirrel (Spermophilus tridecemlineatus), elephant (Loxodonta africana), cat (Felis catus) and opossum (Monodelphis domestica). Wallis M. Gen Comp Endocrinol 155 271-279 (2008)
  537. Molecular model of interleukin 12 that highlights amino acid sequence homologies with adhesion domains and gastrointestinal peptides. Dwyer DS. J Mol Graph 14 148-57, 143-4 (1996)
  538. Non-native intermediate conformational states of human growth hormone in the presence of organic solvents. Sukumar M, Storms SM, De Felippis MR. Pharm Res 22 789-796 (2005)
  539. On the use of structural templates for high-resolution docking. Movshovitz-Attias D, London N, Schueler-Furman O. Proteins 78 1939-1949 (2010)
  540. Postreceptor signaling mechanisms for Growth Hormone. Roupas P, Herington AC. Trends Endocrinol Metab 5 154-158 (1994)
  541. Editorial Protein engineering. Freedman RB, Wetzel R. Curr Opin Biotechnol 3 323-325 (1992)
  542. Comment Protein-protein interactions. Postmodern complexes. Bazan JF. Nature 376 217-218 (1995)
  543. Recombinant human erythropoietin (rHuEPO): cross-linking with disuccinimidyl esters and identification of the interfacing domains in EPO. Haniu M, Narhi LO, Arakawa T, Elliott S, Rohde MF. Protein Sci 2 1441-1451 (1993)
  544. Selective modification at the N-terminal region of human growth hormone that shows antagonistic activity. Tchelet A, Vogel T, Helman D, Guy R, Neospouolus C, Goffin V, Djiane J, Gertler A. Mol Cell Endocrinol 130 141-152 (1997)
  545. Structural requirements for the interaction between tissue factor and factor VII: characterization of chymotrypsin-derived tissue factor polypeptides. O'Brien DP, Anderson JS, Martin DM, Byfield PG, Tuddenham EG. Biochem J 292 ( Pt 1) 7-12 (1993)
  546. Structure from function: screening structural models with functional data. Jin L, Cohen FE, Wells JA. Proc Natl Acad Sci U S A 91 113-117 (1994)
  547. The exon 3-retaining and the exon 3-deleted forms of the growth hormone-binding protein (GHBP) in human serum are regulated differently. Kratzsch J, Wu Z, Kiess W, Dehmel B, Bosse-Henck A, Reuter W, Pflaum CD, Strasburger CJ. Clin Endocrinol (Oxf) 54 61-68 (2001)
  548. The three-dimensional structure of human interleukin-5 at 2.4-angstroms resolution: implication for the structures of other cytokines. Wells TN, Graber P, Proudfoot AE, Arod CY, Jordan SR, Lambert MH, Hassel AM, Milburn MV. Ann N Y Acad Sci 725 118-127 (1994)
  549. UV resonance Raman study of cation-π interactions in an indole crown ether. Schlamadinger DE, Daschbach MM, Gokel GW, Kim JE. J Raman Spectrosc 42 633-638 (2011)
  550. Water entrapment and structure ordering as protection mechanisms for protein structural preservation. Arsiccio A, Pisano R. J Chem Phys 148 055102 (2018)
  551. A novel peptide antagonist of the human growth hormone receptor. Basu R, Nahar K, Kulkarni P, Kerekes O, Sattler M, Hall Z, Neggers S, Holub JM, Kopchick JJ. J Biol Chem 296 100588 (2021)
  552. A thermodynamic study on the interaction between magnesium ion and human growth hormone. Saboury AA, Atri MS, Sanati MH, Moosavi-Movahedi AA, Hakimelahi GH, Sadeghi M. Biopolymers 81 120-126 (2006)
  553. Alanine-scanning mutagenesis reveals residues involved in binding of pap-3-encoded pili. Klann AG, Hull RA, Palzkill T, Hull SI. J Bacteriol 176 2312-2317 (1994)
  554. Analyses of insulin-potentiating fragments of human growth hormone by computative simulation; essential unit for insulin-involved biological responses. Ohkura K, Hori H. Bioorg Med Chem 8 1733-1740 (2000)
  555. Anti-idiotypic antibody: A new strategy for the development of a growth hormone receptor antagonist. Lan H, Zheng X, Khan MA, Li S. Int J Biochem Cell Biol 68 101-108 (2015)
  556. Cloning and characterisation of the GH gene from the common dolphin (Delphinus delphis). Maniou Z, Caryl Wallis O, Wallis M. Gen Comp Endocrinol 127 300-306 (2002)
  557. Detection and characterization of an ovine placental lactogen stable intermediate in the urea-induced unfolding process. Cymes GD, Grosman C, Delfino JM, Wolfenstein-Todel C. Protein Sci 5 2074-2079 (1996)
  558. Development of a novel ligand that activates JAK2/STAT5 signaling through a heterodimer of prolactin receptor and growth hormone receptor. Langenheim JF, Chen WY. J Recept Signal Transduct Res 29 107-112 (2009)
  559. Effects of calcium binding on the structure and stability of human growth hormone. Saboury AA, Atri MS, Sanati MH, Moosavi-Movahedi AA, Haghbeen K. Int J Biol Macromol 36 305-309 (2005)
  560. Expression of mutant bovine growth hormone genes in mice perturbs age-related nutrient utilization patterns. Turner ND, Knapp JR, Byers FM, Kopchick JJ. J Nutr 128 520-524 (1998)
  561. Growth hormone stimulates the secretion of insulin-like growth factor binding protein-2 (IGFBP-2) by monolayer cultures of sheep costal growth plate chondrocytes. Borromeo V, Bramani S, Holder AT, Carter C, Secchi C, Beattie J. Mol Cell Biochem 162 145-151 (1996)
  562. Human growth hormone site 2 lactogenic activity requires a distant tyrosine164. Duda KM, Brooks CL. FEBS Lett 449 120-124 (1999)
  563. Influence of the d orbital occupation on the nature and strength of copper cation-pi interactions: threshold collision-induced dissociation and theoretical studies. Ruan C, Yang Z, Rodgers MT. Phys Chem Chem Phys 9 5902-5918 (2007)
  564. Kinetic analysis of cytokine-mediated receptor assembly using engineered FC heterodimers. Deshpande A, Putcha BD, Kuruganti S, Walter MR. Protein Sci 22 1100-1108 (2013)
  565. LIF receptor-gp130 interaction investigated by homology modeling: implications for LIF binding. Smith DK, Treutlein HR. Protein Sci 7 886-896 (1998)
  566. Ligand-induced receptor dimerization may be critical for signal transduction by choriogonadotropin. Grewal N, Nagpal S, Chavali GB, Majumdar SS, Pal R, Salunke DM. Biophys J 73 1190-1197 (1997)
  567. Molecular dynamics simulations to determine the optimal loop length in the helix-loop-helix motif. Liu HL, Shu YC, Wu YH. J Biomol Struct Dyn 20 741-745 (2003)
  568. Molecular models of two competitive inhibitors, IL-2delta2 and IL-2delta3, generated by alternative splicing of human interleukin-2. Denesyuk AI, Zav'yalov VP, Denessiouk KA, Korpela T. Immunol Lett 60 61-66 (1998)
  569. Neutralising antibodies to the granulocyte colony-stimulating factor receptor recognise both the immunoglobulin-like domain and the cytokine receptor homologous domain. Layton JE, Iaria J, Nicholson SE. Growth Factors 14 117-130 (1997)
  570. Oxidized recombinant human growth hormone that maintains conformational integrity. Mulinacci F, Bell SE, Capelle MA, Gurny R, Arvinte T. J Pharm Sci 100 110-122 (2011)
  571. Production and structural characterization of amino terminally histidine tagged human oncostatin M in E. coli. Sporeno E, Barbato G, Graziani R, Pucci P, Nitti G, Paonessa G. Cytokine 6 255-264 (1994)
  572. Stoichiometry of the complex of human interleukin-4 with its receptor. Hoffman RC, Schalk-Hihi C, Castner BJ, Gibson MG, Rasmussen BD, Zdanov A, Gustchina A, March CJ, Wlodawer A. FEBS Lett 347 17-21 (1994)
  573. Synthesis and conformation of constrained peptides with hypoglycaemic activity derived from human growth hormone. Ede NJ, Rae ID, Hearn MT. Int J Pept Protein Res 44 568-581 (1994)
  574. The GH receptor exon 3 deleted/full-length polymorphism is associated with central adiposity in the general population. Glad CA, Carlsson LM, Melander O, Almgren P, Sjöström L, Nilsson S, Larsson I, Svensson PA, Johannsson G. Eur J Endocrinol 172 123-128 (2015)
  575. The interaction of heparin/polyanions with bovine, porcine, and human growth hormone. Joshi SB, Kamerzell TJ, McNown C, Middaugh CR. J Pharm Sci 97 1368-1385 (2008)
  576. A miniature condition in Brahman cattle is associated with a single nucleotide mutation within the growth hormone gene. McCormack BL, Chase CC, Olson TA, Elsasser TH, Hammond AC, Welsh TH, Jiang H, Randel RD, Okamura CA, Lucy MC. Domest Anim Endocrinol 37 104-111 (2009)
  577. Addition of an N-terminal dimerization domain promotes assembly of hCG analogs: implications for subunit combination and structure-function analysis. Lin W, Ransom MX, Myers RV, Bernard MP, Moyle WR. Mol Cell Endocrinol 152 91-98 (1999)
  578. An unusual member of the human growth hormone/placental lactogen (GH/PL) family, the testicular alternative splicing variant hPL-A2: recombinant expression revealed a membrane-associated growth factor molecule. Untergasser G, Hermann M, Rumpold H, Pfister G, Berger P. Mol Cell Endocrinol 167 117-125 (2000)
  579. Functional relationship of serine 90 phosphorylation and the surrounding putative salt bridge in bovine prolactin. Schenck EJ, Canfield JM, Brooks CL. Mol Cell Endocrinol 204 117-125 (2003)
  580. GHR/PRLR Heteromultimer Is Composed of GHR Homodimers and PRLR Homodimers. Liu Y, Zhang Y, Jiang J, Lobie PE, Paulmurugan R, Langenheim JF, Chen WY, Zinn KR, Frank SJ. Mol Endocrinol 30 504-517 (2016)
  581. Generation and characterization of anti-idiotypic antibodies recognizing the interferon-alpha receptor: implications for ligand-receptor interactions. Lim JK, Langer JA. J Interferon Res 13 295-301 (1993)
  582. Growth hormone (GH) receptor (GHR)-specific inhibition of GH-Induced signaling by soluble IGF-1 receptor (sol IGF-1R). Zhang Y, Gc S, Patel SB, Liu Y, Paterson AJ, Kappes JC, Jiang J, Frank SJ. Mol Cell Endocrinol 492 110445 (2019)
  583. Mapping mouse IL-13 binding regions using structure modeling, molecular docking, and high-density peptide microarray analysis. Madala SK, Dolan MA, Sharma D, Ramalingam TR, Wilson MS, Mentink-Kane MM, Masison DC, Wynn TA. Proteins 79 282-293 (2011)
  584. Modeling the alpha IIb beta 3 integrin solution conformation. Rocco M, Spotorno B, Hantgan RR. Protein Sci 2 2154-2166 (1993)
  585. Modes of transduction. Hendrickson WA. Curr Biol 2 57-59 (1992)
  586. Molecular evolution of growth hormone and receptor in the guinea-pig, a mammal unresponsive to growth hormone. Adkins RM, Vandeberg J, Li WH. Gene 246 357-363 (2000)
  587. Molecular evolution of the avian growth hormone gene and comparison with its mammalian counterpart. Buggiotti L, Primmer CR. J Evol Biol 19 844-854 (2006)
  588. Physiological and metabolic characteristics of novel double-mutant female mice with targeted disruption of both growth hormone-releasing hormone and growth hormone receptor. Icyuz M, Zhang F, Fitch MP, Joyner MR, Challa AK, Sun LY. Aging Cell 20 e13339 (2021)
  589. Predicted common structural features of DNA-binding domains from Ets, Myb and HMG transcription factors. Laget MP, Callebaut I, de Launoit Y, Stehelin D, Mornon JP. Nucleic Acids Res 21 5987-5996 (1993)
  590. Recombinant goldfish growth hormones (gfGH-I and -II) expressed in Escherichia coli have similar biological activities. Chan YH, Cheng CH, Chan KM. Comp Biochem Physiol A Mol Integr Physiol 135 613-624 (2003)
  591. Small chicken growth hormone (scGH) variant in the neural retina. Baudet ML, Harvey S. J Mol Neurosci 31 261-271 (2007)
  592. Spatio-temporal kinetics of growth hormone receptor signaling in single cells using FRET microscopy. Biener-Ramanujan E, Ramanujan VK, Herman B, Gertler A. Growth Horm IGF Res 16 247-257 (2006)
  593. Structural insight into how an anti-idiotypic antibody against D3H44 (anti-tissue factor antibody) restores normal coagulation. Eigenbrot C, Meng YG, Krishnamurthy R, Lipari MT, Presta L, Devaux B, Wong T, Moran P, Bullens S, Kirchhofer D. J Mol Biol 331 433-446 (2003)
  594. Structural restoration of inactive recombinant fish growth hormones by chemical chaperonin and solvent restraint approaches. Chang CC, Tsai CT, Chang CY. Protein Eng 15 437-441 (2002)
  595. Theoretical investigation of IL-6 multiprotein receptor assembly. Menziani MC, Fanelli F, De Benedetti PG. Proteins 29 528-544 (1997)
  596. Topochemistry for preparing ligands that dimerize receptors. Katz BA, Stroud RM, Collins N, Liu B, Arze R. Chem Biol 2 591-600 (1995)
  597. A Friend virus mutant encodes a small glycoprotein that causes erythroleukemia. Hoatlin ME, Ferro FE, Kozak SL, Kabat D. J Virol 68 4053-4056 (1994)
  598. A method for preparing chelate-cytokine conjugates with retention of protein structure, biological activity, and pharmacokinetic properties. Litzinger DC, Ransone CM, Ralph LD, Laderach W, Whitcomb KL, Woodward MA, Niven RW, Treuheit MJ. J Immunol Methods 187 151-161 (1995)
  599. Bovine pancreatic trypsin inhibitor-trypsin complex as a detection system for recombinant proteins. Borjigin J, Nathans J. Proc Natl Acad Sci U S A 90 337-341 (1993)
  600. Changes in conformation and stability upon formation of complexes of erythropoietin (EPO) and soluble EPO receptor. Narhi LO, Aoki KH, Philo JS, Arakawa T. J Protein Chem 16 213-225 (1997)
  601. Characterization of the human Y1 neuropeptide Y receptor expressed in insect cells. Munoz M, Sautel M, Martinez R, Sheikh SP, Walker P. Mol Cell Endocrinol 107 77-86 (1995)
  602. Determinants of oligomeric structure in the chicken liver glycoprotein receptor. Verrey F, Drickamer K. Biochem J 292 ( Pt 1) 149-155 (1993)
  603. Development of a receptor peptide antagonist to human gamma-interferon and characterization of its ligand-bound conformation using transferred nuclear Overhauser effect spectroscopy. Seelig GF, Prosise WW, Hawkins JC, Senior MM. J Biol Chem 270 9241-9249 (1995)
  604. Discovery of cytokine mimics using cell-based systems. Miller SG. Drug Discov Today 5 77-83 (2000)
  605. Dynamic character of human growth hormone and its receptor: normal mode analysis. Kurihara Y, Watanabe T, Nojima H, Takeda-Shitaka M, Sumikawa H, Kamiya K, Umeyama H. Chem Pharm Bull (Tokyo) 51 754-758 (2003)
  606. GH mutant (R77C) in a pedigree presenting with the delay of growth and pubertal development: structural analysis of the mutant and evaluation of the biological activity. Petkovic V, Thevis M, Lochmatter D, Besson A, Eblé A, Flück CE, Mullis PE. Eur J Endocrinol 157 Suppl 1 S67-74 (2007)
  607. Generation of 5 and 17 kDa human growth hormone fragments through limited proteolysis. Such-Sanmartín G, Bosch J, Segura J, Gutiérrez-Gallego R. Growth Factors 27 255-264 (2009)
  608. Growth hormone-related genes from baboon (Papio hamadryas): Characterization, placental expression and evolutionary aspects. Rodríguez-Sánchez IP, Tejero ME, Cole SA, Comuzzie AG, Nathanielsz PW, Wallis M, Barrera-Saldaña HA. Gene 450 1-7 (2010)
  609. High thermal stability imparted by a designed tandem Arg-Trp stretch in an alpha-helical coiled coil. Sakurai Y, Mizuno T, Hiroaki H, Gohda K, Oku J, Tanaka T. Angew Chem Int Ed Engl 44 6180-6183 (2005)
  610. Identification of novel sites in the ovine growth hormone receptor involved in binding hormone and conferring species specificity. Allan GJ, Shand JH, Beattie J, Flint DJ. Eur J Biochem 261 555-562 (1999)
  611. Intracellular signaling transduction pathways triggered by a well-known anti-GHR monoclonal antibody, Mab263, in vitro and in vivo. Lan H, Li W, Jiang H, Yang Y, Zheng X. Int J Mol Sci 15 20538-20554 (2014)
  612. Molecular design of small organic molecules based on structural information for a conformationally constrained peptide that binds to G-CSF receptor. El-Haggar R, Kamikawa K, Machi K, Ye Z, Ishino Y, Tsumuraya T, Fujii I. Bioorg Med Chem Lett 20 1169-1172 (2010)
  613. Phage display mutagenesis of the chimeric dual cytokine receptor agonist myelopoietin. Lee SC, Ibdah R, Van Valkenburgh C, Rowold E, Abegg A, Donnelly A, Klover J, Merlin S, McKearn JP. Leukemia 15 1277-1285 (2001)
  614. Protodomains: Symmetry-Related Supersecondary Structures in Proteins and Self-Complementarity. Youkharibache P. Methods Mol Biol 1958 187-219 (2019)
  615. Residue 146 regulates prolactin receptor folding, basal activity and ligand-responsiveness: potential implications in breast tumorigenesis. Zhang C, Cherifi I, Nygaard M, Haxholm GW, Bogorad RL, Bernadet M, England P, Broutin I, Kragelund BB, Guidotti JE, Goffin V. Mol Cell Endocrinol 401 173-188 (2015)
  616. Sequence comparison and predicted structure for the four exon-encoded regions of human insulin-like growth factor binding protein 4. Landale EC, Strong DD, Mohan S, Baylink DJ. Growth Factors 12 245-250 (1995)
  617. Solution structure of synthetic peptides corresponding to the C-terminal helix of interleukin-6. Morton CJ, Simpson RJ, Norton RS. Eur J Biochem 219 97-107 (1994)
  618. Structural analysis of natriuretic peptide receptor-C by truncation and site-directed mutagenesis. Itakura M, Suzuki H, Hirose S. Biochem J 322 ( Pt 2) 585-590 (1997)
  619. Structural and functional epitopes in the growth hormone receptor complex. Wells JA. Biotechnology (N Y) 13 647-651 (1995)
  620. Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis. Tsutsumi N, Masoumi Z, James SC, Tucker JA, Winkelmann H, Grey W, Picton LK, Moss L, Wilson SC, Caveney NA, Jude KM, Gati C, Piehler J, Hitchcock IS, Garcia KC. Cell 186 4189-4203.e22 (2023)
  621. Study of goldfish (Carassius auratus) growth hormone structure-function relationship by domain swapping. Chan YH, Cheng CH, Chan KM. Comp Biochem Physiol B Biochem Mol Biol 146 384-394 (2007)
  622. The chimpanzee GH locus: composition, organization, and evolution. Pérez-Maya AA, Rodríguez-Sánchez IP, de Jong P, Wallis M, Barrera-Saldaña HA. Mamm Genome 23 387-398 (2012)
  623. Wrapping mimicking in drug-like small molecules disruptive of protein-protein interfaces. Accordino SR, Morini MA, Sierra MB, Fris JA, Appignanesi GA, Fernández A. Proteins 80 1755-1765 (2012)
  624. 1H and 15N NMR resonance assignments and secondary structure of titin type I domains. Muhle-Goll C, Nilges M, Pastore A. J Biomol NMR 9 2-10 (1997)
  625. A first-order-like state transition for recombinant protein folding. Chang CC, Cheng MS, Su YC, Kan LS. J Biomol Struct Dyn 21 247-256 (2003)
  626. A large-scale expression strategy for multimeric extracellular protein complexes using Drosophila S2 cells and its application to the recombinant expression of heterodimeric ligand-binding domains of taste receptor. Yamashita A, Nango E, Ashikawa Y. Protein Sci 26 2291-2301 (2017)
  627. Letter Antagonist design through forced electrostatic mismatch. Müller T, Sebald W, Oschkinat H. Nat Struct Biol 1 674-676 (1994)
  628. Characterization of pituitary growth hormone and its receptor in the green iguana (Iguana iguana). Ávila-Mendoza J, Carranza M, Pérez-Rueda E, Luna M, Arámburo C. Gen Comp Endocrinol 203 281-295 (2014)
  629. Constitutive activation of a variant of the env-mpl oncogene product by disulfide-linked homodimerization. Courtois G, Bénit L, Mikaeloff Y, Pauchard M, Charon M, Varlet P, Gisselbrecht S. J Virol 69 2794-2800 (1995)
  630. Crystal structure of the mouse interleukin-3 β-receptor: insights into interleukin-3 binding and receptor activation. Carr PD, Ewens CL, Dai J, Ollis DL, Murphy JM, Jackson CJ, Young IG. Biochem J 463 393-403 (2014)
  631. Cys 786 and Cys 776 in the posttranslational processing of the insulin and IGF-I receptors. Maggi D, Cordera R. Biochem Biophys Res Commun 280 836-841 (2001)
  632. ELISA for Determination of Human Growth Hormone: Recognition of Helix 4 Epitopes. Moura JF, DeLacerda L, Sandrini R, Borba FM, Castelo DN, Sade ER, Sella S, Minozzo JC, Callefe LG, Figueiredo BC. J Biomed Biotechnol 2004 143-149 (2004)
  633. Effect of protamine on the solubility and deamidation of human growth hormone. Ablinger E, Wegscheider S, Keller W, Prassl R, Zimmer A. Int J Pharm 427 209-216 (2012)
  634. Expression and purification of a mutant human growth hormone that is resistant to proteolytic cleavage by thrombin, plasmin and human plasma in vitro. Alam KS, Morimoto M, Yoshizato H, Fujikawa T, Furukawa K, Tanaka M, Nakashima K. J Biotechnol 65 183-190 (1998)
  635. Expression of a functional porcine growth hormone receptor cDNA in mouse L cells. Wang X, Cioffi JA, Kelder B, Harding PA, Chen WY, Kopchick JJ. Mol Cell Endocrinol 94 89-96 (1993)
  636. Expression of a recombinant human growth hormone binding protein in baculovirus/insect cell system. Cholin S, Bieth E, Molinas C, Cahoreau C, Perals C, Cerruti M, Devauchelle G, Rochiccioli P, Tauber M. Biochimie 78 882-886 (1996)
  637. Impact of del32-71-GH (exon 3 skipped GH) on intracellular GH distribution, secretion and cell viability: a quantitative confocal microscopy analysis. Salemi S, Yousefi S, Eblé A, Deladoëy J, Mullis PE. Horm Res 65 132-141 (2006)
  638. Macromolecular docking of a three-body system: the recognition of human growth hormone by its receptor. Hendrix DK, Klein TE, Kuntz ID. Protein Sci 8 1010-1022 (1999)
  639. Mink growth hormone structural-functional relationships: effects of renaturing and storage conditions. Borromeo V, Sereikaite J, Bumelis VA, Secchi C, Scirè A, Ausili A, D'Auria S, Tanfani F. Protein J 27 170-180 (2008)
  640. Molecular Cloning, Expression, Sequence Characterization and Structural Insight of Bubalus bubalis Growth Hormone-Receptor. Gul R, Hanif MU, Gul F, Rehman HM, Saleem M, Ahmad MS, Mirza MU. Mol Biotechnol 65 1062-1075 (2023)
  641. Mutant and misfolded human growth hormone is rapidly degraded through the proteasomal degradation pathway in a cellular model for isolated growth hormone deficiency type II. Kannenberg K, Wittekindt NE, Tippmann S, Wolburg H, Ranke MB, Binder G. J Neuroendocrinol 19 882-890 (2007)
  642. Ovine placental lactogen and human growth hormone bind to different regions of the same receptors. Longhi SA, Wolfenstein-Todel C, Gómez KA, Miranda ME, Retegui LA. Growth Horm IGF Res 9 157-164 (1999)
  643. Rational design of cytotoxic T-cell inhibitors. Tretiakova AP, Little CS, Blank KJ, Jameson BA. Nat Biotechnol 18 984-988 (2000)
  644. Receptor binding dependent structural changes in human choriogonadotropin: photochemical inter-subunit crosslinking. Ji I, Pan YN, Lee YM, Phang T, Ji TH. Endocrine 3 907-911 (1995)
  645. Relative localization of the prolactin receptor binding sites for lactogenic hormones. Longhi SA, Blank VC, Roguin LP, Cristodero M, Retegui LA. Growth Horm IGF Res 11 324-328 (2001)
  646. Revisiting the putative TCR Cα dimerization model through structural analysis. Wang JH, Reinherz EL. Front Immunol 4 16 (2013)
  647. Role of extracellular domain dimerization in agonist-induced activation of natriuretic peptide receptor A. Parat M, McNicoll N, Wilkes B, Fournier A, De Léan A. Mol Pharmacol 73 431-440 (2008)
  648. Secretion of eukaryotic growth hormones in Escherichia coli is influenced by the sequence of the mature proteins. Cheah KC, Harrison S, King R, Crocker L, Wells JR, Robins A. Gene 138 9-15 (1994)
  649. Comment Signal transduction. Fishing in Src-infested waters. Petsko GA. Nature 358 625-626 (1992)
  650. Specific covalent modification of the tryptophan residues in murine interleukin-6. Effect on biological activity and conformational stability. Zhang JG, Reid GE, Moritz RL, Ward LD, Simpson RJ. Eur J Biochem 217 53-59 (1993)
  651. Structural basis of activation and antagonism of receptor signaling mediated by interleukin-27. Składanowska K, Bloch Y, Strand J, White KF, Hua J, Aldridge D, Welin M, Logan DT, Soete A, Merceron R, Murphy C, Provost M, Bazan JF, Hunter CA, Hill JA, Savvides SN. Cell Rep 41 111490 (2022)
  652. The Preservation of Lyophilized Human Growth Hormone Activity: how Do Buffers and Sugars Interact? Arsiccio A, Pisano R. Pharm Res 35 131 (2018)
  653. The addition of nine residues at the C-terminus of human prolactin drastically alters its biological properties. Goffin V, Struman I, Goormaghtigh E, Martial JA. Eur J Biochem 214 483-490 (1993)
  654. cDNA cloning and functional expression of growth hormone receptor from soft-shelled turtle (Pelodiscus sinensis japonicus). Zhang X, Lu X, Jing N, Zhu S. Gen Comp Endocrinol 119 265-275 (2000)
  655. A new look at cytokine signaling. Zdanov A, Wlodawer A. Cell 132 179-181 (2008)
  656. A protein engineering approach differentiates the functional importance of carbohydrate moieties of interleukin-5 receptor α. Ishino T, Economou NJ, McFadden K, Zaks-Zilberman M, Jost M, Baxter S, Contarino MR, Harrington AE, Loll PJ, Pasut G, Lievens S, Tavernier J, Chaiken I. Biochemistry 50 7546-7556 (2011)
  657. Activity of growth hormone peptides bGH 96-133 and hGH 95-133 in 3T3-F442A cells. Sonenberg M, Guller S, Wu KY, Corin RE, Allen DL. Mol Cell Endocrinol 99 193-199 (1994)
  658. An integrative toolbox to unlock the structure and dynamics of protein-surfactant complexes. Sanchez-Fernandez A, Diehl C, Houston JE, Leung AE, Tellam JP, Rogers SE, Prevost S, Ulvenlund S, Sjögren H, Wahlgren M. Nanoscale Adv 2 4011-4023 (2020)
  659. Computational Investigation of Growth Hormone Receptor Trp169Arg Heterozygous Mutation in a Child With Short Stature. Porto WF, Marques FA, Pogue HB, de Oliveira Cardoso MT, do Vale MGR, da Silva Pires Á, Franco OL, de Alencar SA, Pogue R. J Cell Biochem 118 4762-4771 (2017)
  660. Conformational analysis of alkali metal complexes of anionic species of aspartic acid, their interconversion and deprotonation: a DFT investigation. Sang-Aroon W, Ruangpornvisuti V. J Mol Graph Model 26 982-990 (2008)
  661. Crystals of soluble interleukin-1 receptor complexed with its natural antagonist reveal a 1:1 receptor-ligand complex. Schreuder H, Tardif C, Soffientini A, Sarubbi E, Akeson A, Bowlin T, Yanofsky S, Barrett RW. FEBS Lett 373 39-40 (1995)
  662. Development and characterization of a novel GHR antibody antagonist, GF185. Sun F, Liu Y, Sun H, Tian B. Int J Biol Macromol 79 864-870 (2015)
  663. G120K-PEG, a human GH antagonist, decreases GH signal transduction in the liver of mice. Thirone AC, Carvalho CR, Saad MJ. Mol Cell Endocrinol 192 65-74 (2002)
  664. Homology modeling of rabbit prolactin hormone complexed with its receptor. Halaby D, Thoreau E, Djiane J, Mornon JP. Proteins 27 459-468 (1997)
  665. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Habibullah MM, Mohan S, Syed NK, Makeen HA, Jamal QMS, Alothaid H, Bantun F, Alhazmi A, Hakamy A, Kaabi YA, Samlan G, Lohani M, Thangavel N, Al-Kasim MA. Drug Des Devel Ther 16 1963-1974 (2022)
  666. Immunogenicity, toxicology, pharmacokinetics and pharmacodynamics of growth hormone ligand-receptor fusions. Ferrandis E, Pradhananga SL, Touvay C, Kinoshita C, Wilkinson IR, Stafford K, Wu Z, Strasburger CJ, Sayers JR, Artymiuk PJ, Ross RJ. Clin Sci (Lond) 119 483-491 (2010)
  667. MALDI-TOF characterization of hGH1 produced by hairy root cultures of Brassica oleracea var. italica grown in an airlift with mesh bioreactor. López EG, Ramírez EG, Gúzman OG, Calva GC, Ariza-Castolo A, Pérez-Vargas J, Rodríguez HG. Biotechnol Prog 30 161-171 (2014)
  668. Mapping of human granulocyte-macrophage-colony-stimulating-factor domains interacting with the human granulocyte-macrophage-colony-stimulating-factor-receptor alpha-subunit. Brown CB, Pihl CE, Kaushansky K. Eur J Biochem 225 873-880 (1994)
  669. Lecture Molecular basis of cytokine signalling--theme and variations. Sebald W, Nickel J, Zhang JL, Mueller TD. FEBS J 277 106-118 (2010)
  670. Molecular matchmakers. Binge D. Curr Biol 2 545-547 (1992)
  671. Multiple conformational states of a new hematopoietic cytokine (megakaryocyte growth and development factor): pH- and urea-induced denaturation. Hamburger JB, Chen E, Narhi LO, Wu GM, Brems DN. Proteins 32 495-503 (1998)
  672. Recombinant extracellular domain of rabbit growth hormone receptor and biological activity of somatogenic hormones. Sakal E, Chapnik-Cohen N, Belair L, Djiane J, Gertler A. Prep Biochem Biotechnol 30 107-123 (2000)
  673. Editorial Rewriting the mechanism of JAK2 activation. Brooks AJ, Waters MJ. Cell Cycle 14 285-286 (2015)
  674. Short stature in two siblings heterozygous for a novel bioinactive GH mutant (GH-P59S) suggesting that the mutant also affects secretion of the wild-type GH. Petkovic V, Miletta MC, Boot AM, Losekoot M, Flück CE, Pandey AV, Eblé A, Wit JM, Mullis PE. Eur J Endocrinol 168 K35-43 (2013)
  675. Structure and function of a new class of human prolactin antagonists. DePalatis L, Almgren CM, Patmastan J, Troyer M, Woodrich T, Brooks CL. Protein Expr Purif 66 121-130 (2009)
  676. The biochemical and physiological characteristics of receptors. King GL, Feener EP. Adv Drug Deliv Rev 29 197-213 (1998)
  677. The design of antagonist peptide of hIL-6 based on the binding epitope of hIL-6 by computer-aided molecular modeling. Feng J, Li Y, Shen B. Peptides 25 1123-1131 (2004)
  678. The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms. Svensson J, Boguszewski CL, Shibata F, Carlsson B, Carlsson LM, Bengtsson BA. Growth Horm IGF Res 13 1-7 (2003)
  679. The history of parathyroid hormone and its receptor: structure-based design of parathyroid hormone analogues. Potts JT, Gardella TJ, Jüppner H, Kronenberg H. Osteoporos Int 7 Suppl 3 S169-73 (1997)
  680. The prolactin receptor scaffolds Janus kinase 2 via co-structure formation with phosphoinositide-4,5-bisphosphate. Araya-Secchi R, Bugge K, Seiffert P, Petry A, Haxholm GW, Lindorff-Larsen K, Pedersen SF, Arleth L, Kragelund BB. Elife 12 e84645 (2023)
  681. Actions of monoclonal antibodies on the activity of human growth hormone (GH) in an in vitro bioassay. Burbridge D, Wallis M. Mol Cell Endocrinol 174 11-19 (2001)
  682. Activation of the growth hormone receptor. Pelekanos RA, Waters MJ. Expert Rev Endocrinol Metab 1 189-198 (2006)
  683. Antibodies as molecular mimics of biomolecules: roles in understanding physiological functions and mechanisms. Hill RA, Flint DJ, Pell JM. Adv Physiol Educ 32 261-273 (2008)
  684. Biochemistry and pharmacology of rabbit cardiac growth hormone (GH) receptors. Haro LS, Bustamante J, Hernandez P, Flores R, Aguilar R, Lopez-Guajardo C, Martinez AO. Mol Cell Endocrinol 152 179-187 (1999)
  685. Cell biology. New tricks for an old dimer. Wells JA, Kossiakoff AA. Science 344 703-704 (2014)
  686. Characterization of free alpha- and beta-chains of recombinant macrophage-stimulating protein. Yoshikawa W, Hara H, Takehara T, Shimonishi M, Sakai H, Shimizu N, Shimizu S, Wang MH, Hagiya M, Skeel A, Leonard EJ. Arch Biochem Biophys 363 356-360 (1999)
  687. Cloning and characterization of the gene encoding growth hormone in finback whale (Balaenoptera physalus). Wallis OC, Maniou Z, Wallis M. Gen Comp Endocrinol 143 92-97 (2005)
  688. Conformational analysis of alkali metal complexes of aspartate dianion and their interactions in gas phase. Sang-Aroon W, Ruangpornvisuti V. J Mol Graph Model 26 342-351 (2007)
  689. Conformational flexibility and crystallization of tandemly linked type III modules of human fibronectin. Lombardo A, Wang Y, Ni CZ, Dai X, Dickinson CD, Kodandapani R, Chiang S, White CA, Pio F, Xuong NH, Hamlin RC, Ruoslahti E, Ely KR. Protein Sci 5 1934-1938 (1996)
  690. Design, synthesis and conformational analysis of hGM-CSF(13-31)-Gly-Pro-Gly-(103-116). Noli N, Gurrath M, Rovero P, Pegoraro S, Revoltella RP, Schievano E, Mammi S, Peggion E. J Pept Sci 3 323-335 (1997)
  691. Expression, purification, and lipolytic activity of recombinant human serum albumin fusion proteins with one domain of human growth hormone in Pichia pastoris. Wang F, Wu M, Liu W, Shen Q, Sun H, Chen S. Biotechnol Appl Biochem 60 405-411 (2013)
  692. High affinity cross-reacting mAb generated by minimal mimicry: implications for the pathogenesis of anti-nuclear autoantibodies and immunosuppression. Rothermel AL, Altieri DC. Proc Natl Acad Sci U S A 95 3816-3820 (1998)
  693. Identification, synthesis and properties of a consensus peptide recognized by a monoclonal antibody directed to various type I cytokine receptors. Belloc CG, Longhi SA, Peña C, Blank VA, Miranda ME, Retegui LA. Life Sci 81 553-559 (2007)
  694. Isolated growth hormone deficiency in a Chihuahua with a GH1 mutation. Iio A, Maeda S, Yonezawa T, Momoi Y, Motegi T. J Vet Diagn Invest 32 733-736 (2020)
  695. Molecular cloning of growth hormone encoding cDNA of Indian major carps by a modified rapid amplification of cDNA ends strategy. Venugopal T, Mathavan S, Pandian TJ. J Biosci 27 261-272 (2002)
  696. Mutagenesis of immunoglobulin-like domains from the extracellular human interferon-gamma receptor alpha chain and their recognition by neutralizing antibodies monitored by surface plasmon resonance technology. Ruegg N, Williams G, Birch A, Robinson JA, Schlatter D, Huber W. J Immunol Methods 183 95-101 (1995)
  697. Comment Protein-protein interaction. Complex flexibility. Jurnak F. Nature 372 409-410 (1994)
  698. Recognition of porcine growth hormone by a panel of monoclonal antibodies. Cahill CM, Holder AT, Lawton TL, Butcher GW, Taussig MJ. Hybridoma 16 371-379 (1997)
  699. Sensitivity of hybrid ovine/rat GH receptors to oGH and rat GH in transfected FDC-P1 mouse myeloid cells in vitro. Beattie J, Phillips K, Shand JH, Brocklehurst S, Flint DJ, Allan GJ. Mol Cell Biochem 238 137-143 (2002)
  700. Structural modeling of the complex between an acetylcholine receptor-mimicking antibody and its snake toxin antigen. Tenette-Souaille C, Smith JC. Proteins 30 249-263 (1998)
  701. The role of protein "Stability patches" in molecular recognition: A case study of the human growth hormone-receptor complex. Osman R, Mezei M, Engel S. J Comput Chem 37 913-919 (2016)
  702. The separation of recombinant human growth hormone variants by UHPLC. Karlsson G, Eriksson K, Persson A, Månsson H, Söderholm S. J Chromatogr Sci 51 943-949 (2013)
  703. The species specificity of growth hormone requires the cooperative interaction of two motifs. Peterson FC, Brooks CL. FEBS Lett 472 276-282 (2000)
  704. Variable region cDNA sequences and characterization of murine anti-human interferon gamma receptor monoclonal antibodies that inhibit receptor binding by interferon gamma. Bridges A, Birch A, Williams G, Aguet M, Schlatter D, Huber W, Garotta G, Robinson JA. Mol Immunol 32 1329-1338 (1995)
  705. Letter 1H and 15N chemical shift assignments for domain 4 of the common beta-chain of the IL-3, IL-5 and GM-CSF receptors. Mulhern TD, Bagley CJ, Gaunt C, Lopez AF, Vadas MA, D'Andrea RJ, Booker GW. J Biomol NMR 14 281-282 (1999)
  706. Analytical characterization of NOTA-modified somatropins. Bracke N, Wynendaele E, D'Hondt M, Haselberg R, Somsen GW, Pauwels E, Van de Wiele C, De Spiegeleer B. J Pharm Biomed Anal 96 1-9 (2014)
  707. Binding of human GM-CSF to synthetic peptides of the alpha subunit of its receptor. Di Bartolo V, Danè A, Cassano E, Viganò S, Chiello E, Verniani D, Beffy P, Pegoraro S, Hamdan M, Rovero P, Revoltella RP. J Recept Signal Transduct Res 16 77-92 (1996)
  708. Chemical modification of ovine prolactin with N-acetylimidazole. Cymes GD, Iglesias MM, Wolfenstein-Todel C. Int J Pept Protein Res 42 33-38 (1993)
  709. Computational simulations of stem-cell factor/c-kit receptor interaction. Menziani MC, Fanelli F, De Benedetti PG. Proteins 26 42-54 (1996)
  710. Computational study of elements of stability of a four-helix bundle protein biosurfactant. Schaller A, Connors NK, Dwyer MD, Oelmeier SA, Hubbuch J, Middelberg AP. J Comput Aided Mol Des 29 47-58 (2015)
  711. Conformational analysis of cyclo(2,9)-Ac-QCRSVEGSCG-OH from the C-terminal loop of human growth hormone. Jois DS, Conrad MW, Chakrabarti S, Siahaan TJ. J Pept Res 49 15-22 (1997)
  712. Cryo-EM structure of the extracellular domain of murine Thrombopoietin Receptor in complex with Thrombopoietin. Sarson-Lawrence KTG, Hardy JM, Iaria J, Stockwell D, Behrens K, Saiyed T, Tan C, Jebeli L, Scott NE, Dite TA, Nicola NA, Leis AP, Babon JJ, Kershaw NJ. Nat Commun 15 1135 (2024)
  713. Effect of N-terminal modified analogs of growth hormone on collagen synthesis in avian skin fibroblasts. Granot I, Halevy O, Tchelet A, Sakal E, Gertler A, Vogel T, Hurwitz S, Pines M. Mol Cell Endocrinol 92 241-246 (1993)
  714. Endoplasmic reticulum calcium storage and release in cells expressing misfolded growth hormone. Graves TK, Hinkle PM. Growth Horm IGF Res 13 36-43 (2003)
  715. Exploring protein domain organization by recognition of secondary structure packing interfaces. Deng L, Wu A, Dai W, Song T, Cui Y, Jiang T. Bioinformatics 30 2440-2446 (2014)
  716. Function of a conserved residue in the amino terminal alpha-helix of four helical bundle cytokines. Oshima Y, Fujimura A. Cytokine 24 36-45 (2003)
  717. GH kinase activity in bovine anterior pituitary subcellular fractions. Wicks JR, Brooks CL. Endocrine 10 77-82 (1999)
  718. Generation of epitope-specific antibodies to rat GHBP in the sheep using an interspecies switching strategy involving site-directed mutagenesis of ovine GHBP. Shand JH, Allan GJ, Beattie J, Flint DJ. Eur J Biochem 266 917-923 (1999)
  719. Granulocyte-macrophage colony-stimulating factor mimicry and receptor interactions. Von Feldt JM, Monfardini C, Kieber-Emmons T, Voet D, Weiner DB, Williams WV. Immunol Res 13 96-109 (1994)
  720. News Hormone peptidomimetics: seeing double. Braisted A. Nat Biotechnol 15 1244-1245 (1997)
  721. Identification of regions within the third FnIII-like domain of the IL-5Ralpha involved in IL-5 interaction. Czabotar PE, Holland J, Sanderson CJ. Cytokine 12 867-873 (2000)
  722. Interpretation of Seemingly Contradictory Data: Low NMR S2 Order Parameters Observed in Helices and High NMR S2 Order Parameters in Disordered Loops of the Protein hGH at Low pH. Smith LJ, Athill R, van Gunsteren WF, Hansen N. Chemistry 23 9585-9591 (2017)
  723. Local GHR roles in regulation of mitochondrial function through mitochondrial biogenesis during myoblast differentiation. Hu B, Zhao C, Pan X, Wei H, Mo G, Xian M, Luo W, Nie Q, Li H, Zhang X. Cell Commun Signal 21 148 (2023)
  724. Nuclear magnetic resonance studies of the C-terminal human growth hormone fragment I179-C182-[SS]-C189-P191 and the related trisulfide peptide I179-C182-[SSS]-C189-P191. Strandberg E, Kördel J, Lundin R, Wehler T, Widmalm G. J Pept Res 49 254-260 (1997)
  725. Congress Recent advances in the design and synthesis of small-molecule mimetic drugs. Kazmierski WM. Trends Biotechnol 12 216-218 (1994)
  726. Reflections on growth hormone. Deghenghi R. J Endocrinol Invest 23 480-481 (2000)
  727. Refolding of soluble leukemia inhibitory factor receptor fusion protein (gp 190 sol DAF) from urea. Liu H, Moreau JF, Gualde N, Fu J. Mol Cell Biochem 169 43-50 (1997)
  728. Resonance assignments, secondary structure and topology of leukaemia inhibitory factor in solution. Hinds MG, Maurer T, Zhang JG, Nicola NA, Norton RS. J Biomol NMR 9 113-126 (1997)
  729. Short stature explained by dimerization of human growth hormone induced by a p.C53S point mutation. Sander M, Wu Z, Strasburger CJ. J Biol Chem 295 4893-4901 (2020)
  730. Site-directed mutagenesis of hGH at the 54-74 loop selectively modifies its lactogenic receptor-mediated biological activity. Sakal E, Tchelet A, Uchida E, Shimokawa S, Nishikawa S, Hayakawa T, Krivi GG, Gertler A. Mol Cell Endocrinol 97 129-134 (1993)
  731. Editorial Software engineering in health informatics. Möhr JR, Blum BI. Methods Inf Med 30 165-166 (1991)
  732. Structure and evolution of the gorilla and orangutan growth hormone loci. Pérez-Maya AA, Wallis M, Barrera-Saldaña HA. Mamm Genome 27 511-523 (2016)
  733. Synthetic peptides as putative therapeutic agents in transplantation medicine: application of PEPSCAN to the identification of functional sequences in the extracellular domain of the interleukin-2 receptor beta chain (IL-2Rbeta). Dionyssopoulou H, Mouzaki A, Slootstra J, Puijk W, Meloen R, Cordopatis P, Sotiropoulou G. J Immunol Methods 241 83-95 (2000)
  734. A novel GH-1 gene mutation (GH-P59L) causes partial GH deficiency type II combined with bioinactive GH syndrome. Petkovic V, Eblé A, Pandey AV, Betta M, Mella P, Flück CE, Buzi F, Mullis PE. Growth Horm IGF Res 21 160-166 (2011)
  735. A two-step selection approach for the identification of ligand-binding determinants in cytokine receptors. Friedrich K, Wietek S, Lischke A, Wellbrock C, Kreitman RJ, Pastan I, Sebald W. Anal Biochem 268 179-186 (1999)
  736. An immuno-dominant sequential epitope recognized by mouse anti-recombinant bovine growth hormone antisera. Beattie J, Borromeo V, Fawcett HA, Secchi C. Immunol Lett 38 41-45 (1993)
  737. Analysis of antibody-antigen and antibody-anti-(idiotypic antibody) cross-reactivity using synthetic peptide probes. McInerney TL, Brown LE, Sutton VR, Jackson DC. Mol Immunol 31 289-299 (1994)
  738. Architecture of the two metal-binding sites in prolactin. Vang J, Pustovalova Y, Korzhnev DM, Gorbatyuk O, Keeler C, Hodsdon ME, Hoch JC. Biophys J 121 1312-1321 (2022)
  739. CHEM-PATH-TRACKER: An automated tool to analyze chemical motifs in molecular structures. Ribeiro JV, Cerqueira NM, Fernandes PA, Ramos MJ. Chem Biol Drug Des 84 44-53 (2014)
  740. Defining the regions of human interleukin-5 important in receptor binding and cellular activation. Wells TN, Graber P, McKinnon M, Banks M, Fattah D, Solari R, Peitsch MC, Proudfoot AE. Ann N Y Acad Sci 796 226-234 (1996)
  741. Distinct or Overlapping Areas of Mitochondrial Thioredoxin 2 May Be Used for Its Covalent and Strong Non-Covalent Interactions with Protein Ligands. Ntallis C, Tzoupis H, Tselios T, Chasapis CT, Vlamis-Gardikas A. Antioxidants (Basel) 13 15 (2023)
  742. Enhancement of the receptor binding and Nb2 proliferation activities of rat prolactin by site-directed mutagenesis. Kato Y, Tomizawa K, Kato T. Zoolog Sci 14 147-152 (1997)
  743. Evidence for two distinct classes of high affinity growth hormone binding proteins in pregnant rat serum. Ymer SI, Stevenson JL, Herington AC. Growth Horm IGF Res 10 275-289 (2000)
  744. Evolution of the Growth Hormone Gene Duplication in Passerine Birds. Rasband SA, Bolton PE, Fang Q, Johnson PLF, Braun MJ. Genome Biol Evol 15 evad033 (2023)
  745. Homology modeling of the receptor binding domain of human thrombopoietin. Song JS, Park H, Hong HJ, Yu MH, Ryu SE. J Comput Aided Mol Des 12 419-424 (1998)
  746. Hydrophobic neighboring homology (HNH) dotplot: an approach for assessing structurally similar motifs in proteins. Semertzidis MT, Hazout S, Etchebest C, Mornon JP. Comput Methods Programs Biomed 45 265-282 (1994)
  747. Immunological manipulation of body composition. Beattie J, Flint DJ. Expert Opin Investig Drugs 8 19-27 (1999)
  748. Increased thermo-stability of rat prolactin after replacing glutamic acid at position 118 by lysine. Chung HO, Tomizawa K, Kato T, Wakabayashi K, Kato Y. Zoolog Sci 13 915-919 (1996)
  749. Integrated analysis of RNA-seq in hepatocellular carcinoma reveals competing endogenous RNA network composed of circRNA, lncRNA, and mRNA. Zhou F, Kang Q, Ma J, Cai J, Chen Y, Qu K, Li F. Medicine (Baltimore) 102 e32915 (2023)
  750. Inter-species chimeras of leukemia inhibitory factor define a human receptor binding site. Owczarek CM, Layton MJ, Metcalf D, Clark R, Gough NM, Nicola NA. Ann N Y Acad Sci 762 165-178 (1995)
  751. Comment Keeping signaling in check. Kossiakoff AA, Rizk S. Structure 18 275-276 (2010)
  752. Modification of arginine residues in ovine prolactin by 1,2-cyclohexanedione. Effect on binding capacity to lactogenic receptors. Cymes GD, Atlasovich FM, Caridad JJ, Iglesias MM, Wolfenstein-Todel C. Int J Pept Protein Res 44 31-35 (1994)
  753. Pegvisomant therapy for acromegaly. Freda PU. Expert Rev Endocrinol Metab 1 489-498 (2006)
  754. Peptide insertions in domain 4 of hbeta(c), the shared signalling receptor subunit for GM-CSF, IL3 and IL5, induce ligand-independent activation. Jones KL, Bagley CJ, Butcher C, Barry SC, Vadas MA, D'Andrea RJ. Cytokine 14 303-315 (2001)
  755. Preparation and Characterization of an Antibody Antagonist That Targets the Porcine Growth Hormone Receptor. Cui H, Wang Y, Song M, Zhang H. Asian-Australas J Anim Sci 29 1508-1514 (2016)
  756. Structural insights into IL-11-mediated signalling and human IL6ST variant-associated immunodeficiency. Gardner S, Jin Y, Fyfe PK, Voisin TB, Bellón JS, Pohler E, Piehler J, Moraga I, Bubeck D. Nat Commun 15 2071 (2024)
  757. Superfamily structure and biotech drug development. Edgington SM. Biotechnology (N Y) 10 1529-1534 (1992)
  758. Template-based docking of a prolactin receptor proline-rich motif octapeptide to FKBP12: implications for cytokine receptor signaling. Soman KV, Hanks BA, Tien H, Chari MV, O'Neal KD, Morrisett JD. Protein Sci 6 999-1008 (1997)
  759. The acute insulin-like effects of growth hormone in primary adipocyte-signaling mechanisms. Tornqvist H, Ridderstråle M, Eriksson H, Degerman E. Ann N Y Acad Sci 766 469-471 (1995)
  760. The crystal structure of murine leukemia inhibitory factor. Robinson RC, Grey LM, Staunton D, Stuart DI, Heath JK, Jones EY. Ann N Y Acad Sci 762 179-87; discussion 187-8 (1995)
  761. The enhancement of the extracellular carboxyl-terminal domain of human growth hormone receptor on growth hormone dependent responses of 3T3-F442A cells. Asakura A, Kikuchi M, Uchida E, Hayakawa T, Ota Y. Biomed Pharmacother 48 35-39 (1994)
  762. Tyrosine 462 of the membrane-proximal F'-G' loop of murine Mpl is not essential for high-affinity binding of thrombopoietin. Sabath DF, Lin N, Sabath DE, Kaushansky K, Broudy VC. Cytokine 12 127-133 (2000)


Related citations provided by authors (2)

  1. Crystals of the Complex between Human Growth Hormone and the Extracellular Domain of its Receptor. Ultsch M, De Vos AM, Kossiakoff AA J. Mol. Biol. 222 865- (1991)
  2. Dimerization of the Extracellular Domain of the Human Growth Hormone Receptor by a Single Hormone Molecule. Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clauser KR, Wells JA Science 254 821- (1991)

Quick links